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ABSTRACT 
 
Dysregulation of the tumor suppressor thyroid hormone receptor beta (TRβ) is a 
frequent event in a number of solid tumors. As a nuclear hormone receptor, the primary 
function of TRβ is to regulate transcriptional activity in a ligand-dependent manner. 
However, TRβ activity is not well-defined and the pathways it regulates are not yet fully 
delineated. The two cancer types where TRβ is best studied are thyroid cancer and breast 
cancer. Interestingly, thyroid cancer is a risk factor for breast cancer and breast cancer is 
a risk factor for thyroid cancer, suggestive of an etiological link. Determining the 
molecular mechanisms of a tumor suppressor shared by both diseases may reveal critical 
tumor suppressive pathways. 
First, in order to discover novel pathways that are regulated by TRβ, TRβ was 
stably overexpressed in an anaplastic thyroid cancer (ATC) cell line through lentiviral 
transduction. TRβ has not previously been overexpressed in ATC and, through 
triiodothyronine (T3) stimulation, TRβ repressed pro-malignant phenotypes including 
cellular growth, migration, and stemness. Additionally, TRβ and T3 promoted apoptosis. 
RNA-sequencing and subsequent analysis revealed novel TRβ-mediated STAT1 
stimulation. Additionally, unmodified anaplastic thyroid cancer cells were sensitive to 
treatment with a STAT1 agonist.  
Next, to determine if there is common transcriptional signaling between different 
types of solid tumors, the TRβ-RUNX2 pathway was examined in breast cell lines. In 
thyroid cancer, TRβ represses expression of the pro-metastatic transcription factor 
RUNX2. In addition to promoting thyroid cancer, aberrant overexpression of RUNX2 is a 
driver of breast carcinogenesis. This informed the hypothesis that TRβ-mediated 
repression of RUNX2 and resultant signaling is common to thyroid and breast cancers. T3 
treatment reduced RUNX2 expression in breast cell lines. Additionally, TRβ bound to 
thyroid hormone response elements in the RUNX2 promoter, the same mechanism of 
action for T3-mediated repression as in thyroid cells. 
Lastly, to more broadly address mechanisms mediated by TRβ, TRβ was stably 
overexpressed in a basal-like aggressive breast cancer cell line. TRβ is already known to 
be able to repress tumor growth and metastasis in this type of cancer. However, the 
specific molecular mechanisms driving the anti-tumor phenotype are not well delineated. 
In order to determine which molecular signaling pathways are regulated by TRβ, RNA-
sequencing was performed. TRβ induced a more epithelial profile of these cells, in 
contrast to the typically mesenchymal nature of basal-like breast cancer. Novel TRβ-
mediated repression of pro-invasive cytokeratins was found. The genes regulated by TRβ 
in these cells were also compared to the findings in ATC. The set of common genes 
included chromatin remodelers and enzymes involved in stearate biosynthesis; the latter 
is known to have anti-cancer properties and may be an important driver of TRβ-mediated 
tumor suppression in both breast and thyroid cancers. 
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CHAPTER 1: Comprehensive Literature Review 
 
1.1. Thyroid Hormone Receptor Signaling 
 The human genome encodes for two nuclear thyroid hormone receptors (TR), 
which are member of the nuclear hormone receptor (NR) superfamily of genes. TRs are 
encoded by the genes THRA, which produces the protein TRα, and THRB, which codes 
for TRβ. TRs serve as receptors to the hormones produced by the thyroid gland, 
thyroxine (T4) and triiodothyronine (T3). Both proteins exhibit greater binding affinity to 
T3 over T4. As a result, T4 functions as a pro-hormone for TRs. Although the thyroid does 
produce some T3, most T3 is the result of deiodinases cleaving the 5’ iodine atom from T4 
in peripheral tissues (1). Nuclear TRs are ubiquitously expressed throughout the body, 
however different tissues exhibit different concentrations of each TR. Expression of TRα 
is greater in muscle and fat tissue, whereas TRβ is the predominate TR expressed in the 
brain and liver (1). TRs, unlike steroid NRs, are predominately nuclear even in the 
absence of endogenous ligand. As a consequence, TRs are able to exert transcriptional 
effects in the presence and the absence of ligand. Additionally, the integrin αvβ3 is 
preferentially responsive to T4, rendering the pro-hormone status of T4 dependent upon 
the context of the signaling that occurs within a given cellular system (2). As a cell 
membrane bound receptor, αvβ3 triggers a kinase cascade, primarily through stimulation 
of the mitogen activated protein kinase (MAPK) pathway (3).  
 The different modes of signaling from thyroid hormones have recently been 
codified based upon broad mechanisms of action (4). Type 1 signaling reflects the 
canonical model of thyroid hormone action, transcriptional regulation. In this model, 
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nuclear TRs bind to chromatin directly, either as a monomer, a homodimer, or a 
heterodimer, and recruit protein complexes to alter transcription of a gene. Type 2 
signaling is where TRs bind to other DNA-bound proteins to modulate their activity. This 
mechanism has been demonstrated to occur with AP1 where TRs blocks AP1 signaling 
(5-7). Type 3 signaling is the last to occur with nuclear TRs, however the mechanism is 
entirely non-genomic. TR binds to a cytoplasmic protein in order to regulation signaling. 
An example of this is that both TRα and TRβ are able to bind to the phosphoinositide 3-
kinase (PI3K) complex in the cytoplasm in order to alter downstream AKT 
phosphorylation (8). Lastly, type 4 thyroid hormone signaling is through receptors other 
than nuclear TRs. This is primarily through the αvβ3 integrin. 
1.1.1. Thyroid Hormone Receptor Regulation of Gene Expression 
 The primary method by which TRs act in a cell is through type 1 signaling. The 
canonical model by which TRs exert regulatory effects is through cofactor switching (1). 
In the absence of hormone, TR is bound to DNA at a thyroid hormone response element 
(TRE) and recruits proteins that repress gene expression. The census element upon which 
TRs bind is AGGTCA, which forms a half-site. A full TRE contains two direct binding 
sites, typically separated by 0, 4, or 6 nucleotides (9). These binding sets may be direct 
repeats, palindromic, or inverted palindromes. Depending upon the nature of the TRE, 
TR may bind to a single half site, as a dimer to two consensus elements, or as a 
heterodimer with another transcription factor, most commonly retinoid x receptor (RXR). 
Notable co-repressors of gene expression are nuclear receptor co-repressor (NCOR) and 
silencing mediator for retinoid or thyroid-hormone receptors (SMRT) (10,11). These co-
repressors aid in the further recruitment of histone methyltransferases (12) and histone 
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deacetylases (13), which leads to the modification of chromatin in order to compact DNA 
and inhibit the ability of polymerases to synthesize RNA. Upon binding of cognate 
ligand, a conformation change in TR occurs and the association between TR and co-
repressor complexes dissociates. Co-activator proteins including nuclear receptor 
coactivator 1 (NCOA1), p300, and the vitamin D receptor interacting protein/thyroid 
hormone receptor-associated protein  (DRIP/TRAP) complex (14,15). Importantly, 
NCOA1 and p300 have each been shown to exert histone acetyltransferase (HAT) 
activity, thereby modifying chromatin to induce an open structure and promote gene 
transcription (15). Although, the DRIP/TRAP complex does not demonstrate HAT 
activity and does not require histones to be present to promote transcriptional activity, 
demonstrating that varied mechanisms of gene induction are utilized on TREs (16). 
 In addition to positively inducing the expression of genes, a minority of TREs 
are responsible for repressing gene expression in the presence of T3. These negative 
TREs are not as well characterized as positive TREs, although many of the same co-
regulatory proteins are involved. In the absence of hormone, TRs can stimulate 
expression of a gene regulated by a negative TRE while the addition of T3 drives gene 
repression (17). This hormone-null stimulation is blocked in a mutant TR which cannot 
interact with co-repressor proteins NCOR and SMRT (18). Additionally, T3 treatment 
initiated the dissociation of NCOR and SMRT from a negative TRE, however there was 
no accumulation of coactivator proteins (19). These results suggest that corepressor 
proteins act in a stimulatory manner in the context of a negative TRE, although the 
molecular mechanism is not yet understood. 
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 Cistrome wide data of TRβ binding demonstrates the inadequacy of the 
canonical type 1 model. A key concept of this model is that, on absence of cognate 
ligand, TRs bind to TREs and that addition of T3 is not required to initiate a protein-DNA 
interaction. However, chromatin immunoprecipitation (ChIP)-sequencing of TRβ in 
mouse liver shows that there is minimal overlap between peaks in hypothyroid and 
hyperthyroid animals (20). This is contrary to the canonical model discussed above where 
TRs bind to TREs independent of hormonal control. Additionally, evidence from 
glucocorticoid receptor (GR), another member of the NR superfamily, show that 
interaction between a NR and chromatin are transient (21). Residence times on the 
chromatin for GR varied significantly, depending upon the response element, ranging 
from 0.2 to 47 seconds. If TRs act in a similar fashion it would mean that the current 
model is insufficient to explain how unliganded TRs repress the expression of positive 
TREs. 
1.1.2. Thyroid Hormone Signaling in Cancer 
 Thyroid hormones have been investigated in tumor biology since the 19th 
century when thyroid extract was used in conjunction with an ovariectomy for 
management of surgically unresectable breast cancer (22). Due to there being three 
receptors that respond to thyroid hormones in the body, it has been difficult to determine 
whether thyroid hormone activity is of a net positive or negative with regard to cancer 
risk. There is epidemiological evidence of a pro-oncogenic role of high levels of thyroid 
hormones (23) as well as evidence of hypothyroidism protecting against breast cancer 
(24). However, the type of tissue matters as hypothyroidism is deleterious in 
hepatocellular carcinoma (HCC), where low levels of thyroid hormones are associated 
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with increased risk of HCC (25,26). Importantly, hypothyroidism is associated with 
reduced survival following liver transplantation for HCC patients (27). There is also 
evidence that hypothyroidism impairs the efficacy of tyrosine kinase inhibitors in cancer 
patients (28). Additionally, patients treated with T3 after being rendered hypothyroid 
showed improved outcomes in a small, multicancer clinical study (29). These data are 
consistent with the different thyroid hormone receptors playing different roles in tumor 
biology and further demonstrate the anti-tumor potential of T3 signaling while 
highlighting how T4-mediated pathways can promote oncogenesis. 
 As mentioned previously, the T4 responsive αvβ3 integrin exerts activity through 
stimulation of the MAPK pathway. The MAPK pathway is well-characterized to be pro-
tumorigenic and drives the survival of a multitude of types of cancers (Figure 1). Briefly, 
following stimulation of a receptor tyrosine kinase (RTK) and subsequent 
autophosphorylation the phosphotyrosine residues serve as a docking site for a scaffold 
complex. Through this complex a Ras protein is activated by replacement of bound 
guanidine diphosphate (GDP) with guanidine triphosphate (GTP). This allows for 
binding, and subsequent activation, of a rapidly accelerated fibrosarcoma (RAF) family 
protein. In turn, RAF phosphorylates MEK, which activates ERK (also known as MAPK) 
by phosphorylation (30). ERK acts upon an array of proteins to promote pro-tumorigenic 
signaling to induce unchecked cell proliferation and evade apoptosis. As a result of 
MAPK stimulation, The T4-αvβ3 axis promotes tumor cell proliferation and anti-
apoptotic activity (31). Additionally, αvβ3 is a driver of migration and invasiveness in 
cancer cell lines (32,33). This activity can result in pro-tumorigenic signaling from T4 
when expression of αvβ3 is high. 
 6 
 
Figure 1: The Thyroid Hormone Modulated Pathways MAPK and PI3K are Drivers of 
Tumorigenesis 
 The nuclear TRs also have a role in tumor biology. The viral oncogene v-erbA is 
homologous to TRα (34,35). In chicken embryonic fibroblasts, v-erbA induced 
anchorage-independent growth and tumor formation (36). This viral gene lacks functional 
hormone receptor binding, and so can act antagonistically to endogenous thyroid 
hormone signaling ((37). However, it has also been demonstrated that the majority of 
genes regulated by v-erbA are not regulated by TRα, suggesting that the competition 
model is incomplete (38). TRα itself has a putative oncogenic role. High levels of TRα 
expressed in intestinal tissue increase tumor formation (39). This is likely due to the 
known proliferative role of TRα in the colon, primarily through stimulation of the WNT 
pathway effector β-catenin (40). TRα is also a putative oncogene in breast tissue; high 
levels of the ligand-responsive splice variant TRα1 are associated with reduced survival 
odds in breast tumors (41). Additionally, high levels of TRα is linked with worse 
outcomes in patients diagnosed with BRCA-associated breast cancer (42). This is in 
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contrast to TRβ, which was reported to have a protective role in the same study (42). 
Heightened TRβ expression has also been demonstrated to increase survival odds in 
triple-negative breast cancer (43). Some of the protective role of TRβ expression may be 
a result of sensitizing tumor cells to chemotherapeutic agents (43). 
 There are a multitude of studies which highlight the functional significance of 
TRβ in tumor biology. Some of the earliest evidence demonstrating that TRβ could have 
a tumor suppressing function was the observation that TRβ was frequently mutated in 
hepatocellular carcinoma (44) and PTC (45). The tumor suppressive functionality of TRβ 
was validated with the discovery that a N-terminal mutation which causes resistance to 
thyroid hormone (designated TRβ-PV) can spur the development of FTC in mice (46,47). 
When homozygous TRβ-PV mice were crosses with Pten+/- mice, the resulting 
THRBPV/PV Pten+/- animals developed more aggressive thyroid cancer, including tumors 
with increased anaplasia and metastasis (48). WT TRβ abrogates the tumorigenicity of 
FTC cells, as demonstrated by xenograft experiments (49). Further investigation of TRβ 
in cancer models showed that overexpression can inhibit the progression of 
hepatocellular carcinoma and both luminal and basal breast cancers (50,51). Additionally, 
in a breast cancer xenograft, TRβ-PV fails to inhibit tumorigenesis (52). 
 The cancer studies on TRβ have revealed important anti-tumorigenic signaling. 
TRβ-PV exhibits strong binding to the PI3K complex, specifically to the regulatory p85α 
subunit in a classic type 3 mechanism (53,54). In the class model of the PI3K pathway 
(Figure 1), PI3K is stimulated by an RTK to promote cell growth. PI3K catalyzes the 
production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) from phosphatidylinositol 
4,5-bisphosphate (PIP2). PIP3 serves as a docking site for the enzymes 3-
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phosphoinositide dependent protein kinase-1 (PDK1) and mammalian target of 
rapamycin complex 2 (mTORC2). Both PDK1 and mTORC2 phosphorylate the kinase 
AKT, also known in the literature as protein kinase B, on threonine 308 and serine 473, 
respectively, in order to induce the activity of AKT (55-57). Once activated, AKT 
phosphorylates a variety of proteins to promote cell growth, migration, and suppress 
apoptosis. TRβ and T3 act to increase PI3K activity in non-cancerous models (58,59), 
however in tumor studies WT TRβ consistently reduces AKT phosphorylation, 
demonstrating a role in abrogating this pro-tumorigenic pathway (49,52,60).  
 TRβ anti-tumor activity has been demonstrated through regulation of other 
pathways implicated in tumorigenesis. TRβ reduces expression of the oncogenes β-
Catenin (61,62) and RUNX2 (63) in thyroid cancer. Additionally in thyroid cancer, TRβ 
represses NF-κβ signaling (64) and modulates inflammatory processes (64). Studies in 
breast cancer models demonstrate that TRβ inhibits pro-tumorigenic signaling from 
STAT3 (51), the Ras/MAPK pathway (65), and lowers expression of epithelial to 
mesenchymal transition (EMT) markers (50). 
 In addition to the evidence from epidemiological association studies, the TRβ-
PV mutant, and delineation of anti-oncogenic signaling, it has also been demonstrated 
that TRβ prevents tumorigenesis from initiating. Hyperthyroid mice are less likely to 
develop liver tumors than euthyroid animals, whereas hypothyroid mice are the most 
likely to develop hepatocellular carcinoma (66). As TRβ is the predominant thyroid 
hormone receptor in liver cells, this action is likely through TRβ signaling. Additionally, 
knockout of TRs in mice drive the development of thyroid tumors (67). Collectively, 
these data show that TRβ is a potent tumor suppressor of multiple types of solid tumors 
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and further investigation into the molecular activity of TRβ is merited. 
1.1.3. Structural Biology of Thyroid Hormone Receptor Beta 
 The structural features of TRβ drive the molecular role of the protein. TRβ is 
comprised of four domains. These are the N-terminal A/B transactivation domain, the 
DNA-binding domain (DBD), a hinge domain, and a C-terminal ligand-binding domain 
(LBD) (Figure 2) (68). Although not required for binding to DNA ,the A/B domain is 
essential for induction of transcriptional activity (69). The LBD is comprised of 12 alpha 
helices that, in addition to stabilizing the interaction between receptor and T3, act as 
interaction sites for dimerization, co-activators, and co-repressors (70). Additionally, TRβ 
contains a nuclear localization signal (NLS) within the hinge domain starting at amino 
acid 184 and nuclear export signals (NES) are present in the ligand binding domain of 
TRβ (71) (Figure 1). Most NRs are predominately cytoplasmic until binding to ligand, 
however, TRs are unique in that they are constrictively nuclear, which does allow for 
ligand-independent transcriptional regulation (72). 
 
Figure 2: Functional Domains of TRβ. 
Like many proteins within the body, TRβ is a phosphoprotein. Phosphorylation of 
TRβ has been shown to enhance transcriptional activity (73). Additionally, kinase 
inhibitors can block T3 induced transcription of lipogenic enzymes (74). Inhibition of 
serine/threonine kinases have also been shown to reduce the stability of TRβ as well as 
reduce the level of THRB mRNA expressed in cells and dimerization with retinoid x 
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receptor (75,76). Additionally, T3 appears to be able a key signal to induce 
serine/threonine phosphorylation of TRβ (77). Identified sites of phosphorylation are 
T134 and S142 in the DBD and Y406 in the LBD (78-80). T134 is phosphorylated by 
protein kinase C and has a role in protein localization, keeping the receptor in the 
cytoplasm. Phosphorylation of S142 is trigged by the MAPK pathway and disrupts 
interactions between TRβ and SMRT. Src phosphorylates TRβ on the residue Y406 and 
phospho-ablative mutants of TRβ are unable to suppress xenograft tumor growth (80,81). 
Additional putative phosphorylation of DBD residues Y147 and Y171 was observed in 
the hippocampus, and although mutation of the residues blocked TRβ driven induction of 
the PI3K pathway direct phosphorylation of Y147 and Y171 was not empirically 
confirmed when TRβ was subjected to mass spectroscopy (59).  
Other post-translational modifications to TRβ has also been demonstrated to be 
important in regulating TRβ activity. Ubiquitin in a small protein that is linked to lysine 
residues by a ligase; polyubiquitination serves as a signal for proteasomal degradation. 
This process serves to rapidly degrade TRs upon T3 binding, thereby modulating the 
transcriptional activity of TR (82). Interestingly, inhibition of ubiquitin-mediated 
degradation reduced the transcriptional activity of TRβ in vitro (82). This phenomenon is 
similar to what has been observed in estrogen receptor (ER) α and progesterone receptor 
(PR) and may be a common feature in the regulation of NRs (83). TRβ is also regulated 
by SUMOylation, that is, the addition of small ubiquitin-like modifier (SUMO) to a 
lysine residue. SUMOylation enhances the transcriptional activity of TRβ on both 
positive and negative TREs and alters affinity for co-regulator interactions (84). These 
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modifications add an additional layer of nuance to regulation of gene expression by TRβ 
beyond activation by ligand binding. 
 
1.2. Thyroid Cancer 
Thyroid cancer is the most commonly diagnosed cancer in the United States. 
Incidence of the disease is increasing rapidly and has been for multiple decades (85). 
Thyroid cancer is projected to be the 4th most commonly diagnosed cancer in the 
United States by 2030 (86), although in the last few years the increase in thyroid cancer 
incidence has started to stabilize (87). This stabilization may be due, in part, to 
reclassification of the thyroid cancer subtype “noninvasive encapsulated follicular 
variant of papillary thyroid cancer” to “noninvasive follicular thyroid neoplasm with 
papillary-like nuclear features” (88). This variant has been estimated to make up 
approximately 9% of papillary thyroid cancer diagnoses (89).  Regardless, the increase 
in incidence is unlikely to be simply the result of improvements in diagnostics due to 
the increase in incidence of both relatively benign and more aggressive cancers (90).  
The majority of thyroid tumors develop from the epithelial follicular cells, 
which are responsible for production of thyroid hormones T4 and T3. This includes the 
major subtypes of papillary (PTC), follicular (FTC), poorly differentiated (PDTC), and 
anaplastic thyroid cancer (ATC) (91). PTC and FTC are differentiated tumors with 
overall positive prognosis, whereas PDTC and ATC are dedifferentiated tumors with 
poor prognosis. These subtypes of thyroid cancer are distinguished by differences in 
their morphology and genetic drivers. Additionally, different subtypes of thyroid cancer 
vary in their prognoses and treatment options. 
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1.2.1. Differentiated Thyroid Cancer  
The primary subtypes of differentiated thyroid cancer are PTC and FTC. Over 
80% of thyroid cancers are diagnosed as PTC and approximately 10% are FTC (92). Both 
subtypes typically exhibit an overall good prognosis, although FTC is the more 
aggressive of the two. The primary cytopathological difference is FTC nodules are 
typically encapsulated by fibrous connective tissues and PTC is unencapsulated (93). 
Additionally, FTC typically presents with larger tumors at time of diagnosis. 
The genetic alterations and signaling pathways that induce differentiated thyroid 
cancers are well-established. Mutations to the BRAF gene are common, 45% of PTC 
cases exhibit the constitutively active BRAFV600E variant (94). The other primary 
molecular subtype of PTC are Ras-like carcinomas (95). BRAF and Ras proteins are 
effectors within the mitogen activated MAPK pathway (Figure 1), which promotes cell 
growth. Increased MAPK signaling is the primary molecular alteration driving PTC 
development and malignancy (91). Mutations to RAF proteins and effectors of the 
MAPK pathway are common in an array of cancers and inhibitors of the pathway have 
demonstrable utility in treating tumors, including thyroid tumors (96). Mutation of the 
RAF gene BRAF is predictive of a worse prognosis in thyroid cancer patients (97). 
Additionally, ~5% of PTCs have been reported to harbor mutations to EGFR, an 
upstream RTK and itself a recognized oncogene (98). The second major driver of thyroid 
cancer is the phosphoinositide 3-kinase (PI3K) pathway (Figure 1). Mutations to the 
PI3K pathway are common in FTC, which includes mutations to the catalytic subunit of 
PI3K, PIK3CA, and mutations or deletions to the phosphatase PTEN (91), which reverses 
PI3K driven phosphorylation of PIP2. The PI3K pathway is recognized to be the primary 
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molecular pathway driving FTC malignancy (91).  
Differentiated thyroid cancer is treated primarily through surgery and 
radioactive iodide (RAI) treatment (99). Depending upon overall risk of the lesion, 
surgical options include partial or a complete thyroidectomy. RAI is the first example 
of precision medicine applied to cancer, with reports dating back to the 1940s (100). 
RAI is effective and selective because thyroid glands express a sodium-iodide 
symporter (NIS), unlike most other cells in the body, due to the necessity of iodine for 
the synthesis of thyroid hormones. This allows for systemic RAI to preferentially target 
the cancerous thyroid tissue if the tumor robustly expresses NIS and if the cells retain 
iodide. Without NIS activity, the iodide anion cannot cross through the cell membrane 
and, as a result, these cells are not subjected to radiotoxicity. However, during the 
process of tumorigenesis resistance to RAI can develop through loss of NIS expression 
and activity. The MAPK pathway has been implicated in this process as inhibition of 
the MAPK effector MEK1 increases expression of NIS and restores the ability of a 
thyroid tumor cell to retain iodide (101). In clinical trials MEK1 inhibition restored NIS 
functionality sufficiently to allow formerly RAI retractive patients to be successfully 
treated with RAI (102,103). 
1.2.2. Dedifferentiated Thyroid Cancer  
Dedifferentiated thyroid tumors include both PDTC and ATC. These subtypes 
of thyroid cancer are rare; PDTC makes up approximately 3% of thyroid tumors (104) 
and ATC comprises 1-2% of thyroid tumors (105). Both tumor types are highly 
invasive and exhibit low expression of thyroid markers including NIS. ATC is 
distinguished from PDTC pathologically by exhibiting greater necrosis, increased 
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heterogeneity of cellular morphology, and atypical nuclei (105). Additionally, ATC is 
definitionally a stage IV neoplasm (106). Both of these subtypes of cancer have a worse 
prognosis than differentiated thyroid cancers. Five year survival in PDTC is 
approximately 60% (107) and less than 15% of ATC patients survive two years after 
diagnosis (105). 
In recent years, the genetic markers defining these two thyroid cancer subtypes 
have been delineated. These alterations provide insights into the molecular drivers of 
the most aggressive variants of thyroid cancer. Both dedifferentiated subtypes exhibit 
mutations in the MAPK signaling pathway; mutations to BRAF are particularly 
prominent being found in a third of PDTC and nearly half of ATC cases (108). 
Mutations to TERT are also common in both subtypes, with 40% of PDTC and over 
70% of ATC tumors exhibiting a TERT mutation. Almost three quarters of ATC tumors 
exhibit mutations to the transcriptional regulator TP53, which is rarely mutated in other 
thyroid cancer subtypes (108,109). Additionally, mutations to SWI/SNF components, 
PI3K effectors, and histone methyl transferases are more common in ATC than in 
PDTC (108). There was also a difference in the thyroid differentiation score (TDS), a 
value derived from the expression of 16 genes (95) (now 13 genes (110)) that defines 
thyroid cells. These are primarily genes that are necessary for the synthesis of thyroid 
hormones. PDTC tumors had a higher TDS than ATC tumors, additionally, Ras-like 
PDTC tumors exhibit an even greater TDS (108). 
Due to low expression and activity of NIS in dedifferentiated thyroid cancers, 
RAI is not an effective treatment option. Conventional treatment of ATC is largely 
palliative, with the goal being to improve quality of life at the expense of life extension 
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(105). Conventional treatments include the use of surgery, beam radiotherapy, and 
broad-spectrum chemotherapy. Inhibitors of both MAPK and PI3K signaling are 
actively being investigated for use in advanced thyroid cancers, including PDTC and 
ATC (111). In 2018, the FDA approved a combinational therapy of a BRAF and MEK 
inhibitor for ATC, with a response rate of over 60% in trials (112). In one trial, 80% of 
patients with BRAF mutant ATC were alive after 12 months (113). Immunotherapies 
have also shown promise, with antibodies against PD-1 exhibiting a 20% response rate 
(112). 
As in treatment resistant differentiated thyroid cancer, there is an interest in 
inducing expression of NIS in dedifferentiated thyroid tumors. Transfection of wild 
type p53 into cultured ATC cells restored NIS expression and rendered the cells 
sensitive to RAI (114). PI3K inhibition also increased NIS expression in ATC stem 
cells (115). An inverse agonist to estrogen-related receptor gamma, GSK5182, 
increased expression of NIS and other thyroid markers (116). In ATC xenografts 
GSK5182 also restored sensitive to RAI, where co-treatment with the GSK5182 and 
131I reduced tumor burden (116).  
 
1.3. Breast Cancer 
 Breast cancer is the most common cancer diagnosed in women in the United 
States with over 250,000 cases per year (87). Additionally, breast cancer is the second 
leading cause of cancer mortality in American women (87). Globally, breast cancer is 
the most common cancer in women and also responsible for the greatest number of 
cancer deaths (117). Breast cancer has also been revealed to be a risk factor for thyroid 
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cancer, similarly a past history of thyroid cancer increases the risk for the development 
of a breast malignancy (118). 
 Clinical classification of breast cancer is primarily based upon the expression of 
ERα, PR, and the epidermal growth factor receptor HER2, also known as ERBB2 
(119). Expression of ERα and PR are linked to a more differentiated disease whereas 
highly aggressive breast cancers exhibit loss of these three receptors. These receptors 
are also druggable and are commonly targeted in clinical practice to reduce tumor 
burden. Molecular analysis has increased understanding of the differences between 
breast tumors resulting in the PAM50 algorithm. A set of 50 genes are now used to 
define the intrinsic subtypes of breast cancer and classify breast tumors (120,121). 
These subtypes include hormone receptor positive luminal A and luminal B, HER2 
positive, normal-breast like, and basal-like breast cancers. In the United States, 
Surveillance, Epidemiology, and Endpoints Results classifications includes both 
luminal subtypes, HER2 positive, and basal-like subtypes, but not Normal-like. 
Luminal A breast cancer is the most commonly diagnosed and HER2 positive is the 
rarest (Figure 3) (122). Luminal A exhibits the greatest survival odds, whereas basal-
like breast cancer patients have the worst outcomes (Figure 3) (122). 
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Figure 3: Breast Cancer Subtypes Vary in Prevalence and Prognosis. A) Prevalence of Breast 
Cancer Subtypes in the United States of America (2012-2016). B) Relative 5-year Survival of 
Breast Cancer Subtypes in the United States of America (2010-2015). 
1.3.1. Luminal Breast Cancer 
 Luminal breast tumors are defined as ERα positive tumors. Luminal subtypes 
are distinguished from each other by expression of the proliferation marker Ki-67 and 
PR; luminal B breast cancer exhibits either increased Ki-67 or reduced PR whereas 
luminal A tumors express comparatively high PR and low Ki-67 (123). Luminal B 
tumors may also have increased expression of HER2 (124). Luminal subtypes are less 
likely to present with distal metastases, with the least likely being luminal A, consistent 
with the observed heightened survival of this subtype (125).  
 The most prominent genetic feature in luminal breast cancers is the heightened 
expression and activity of ERα, however it is not the sole genetic driver of the disease. 
Mutations to PIK3CA are relatively common; present in approximately 45% of luminal 
A cancers and in approximately 30% of luminal B tumors (126,127). GATA3 is mutated 
in approximately 15% of luminal breast cancers and mutually exclusive to PIK3CA 
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alterations. Mutations to MAP3K1 are most prevalent in luminal A, however TP53 
mutations are more common in luminal B (126,127). 
 The primary treatment for luminal breast cancer is surgical intervention with 
adjuvant chemotherapy (128). Due to the high expression and activity of ERα in 
luminal breast cancers, it is relatively common to treat them with a selective estrogen 
receptor modulator (SERM) (128,129). SERMS act on ERα in a tissue selective manner 
to reduce estrogenic signaling in the breast while maintaining a degree of estrogenic 
function in other body tissues (130). This specificity arises, in part, due to the tissue 
specific expression of ERα and ERβ, the dimerization partner for ERα on a response 
element, and subtle differences in protein conformation that results from a SERM or 
endogenous estrogen binding and resultant co-factor binding (130). This results in an 
antagonistic effect in some tissues and an agonistic effect in others. For example, the 
prototypical SERM tamoxifen is anti-estrogenic in breast, but pro-estrogenic in uterine 
tissue (130). Aromatase inhibitors (AI) are also commonly used as they inhibit the 
ability of the enzyme aromatase to synthesize bioactive estrogen (131). AI therapy may 
be prescribed separately, or in conjunction with a SERM. Both AIs and SERMs are 
used to reduce the odds of recurrence and to control the spread of metastatic nodules. 
However, treatment resistance is a relatively common occurrence and limits the utility 
of AIs and SERMs. Alterations to multiple pathways can contribute to resistance. 
Tamoxifen resistance can arise from upregulation of HER2 and/or PI3K activity (132). 
SERM resistance can also arise from a truncated ERα, dubbed ERα-36, which acts 
along with HER2 to drive tumor growth (133,134). Mutations to the ligand binding 
domain of ERα are associated with AI resistance (135) and have been shown in cell 
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models to be transcriptionally active in absence of cognate ligand (136). These 
mechanisms of resistance ultimately limit the utility of anti-estrogen therapies, but also 
provide alternate approaches for the treatment of luminal breast tumors. 
1.3.2. HER2 Positive Breast Cancer 
 The HER2 positive subtype of breast cancer is defined by high expression of 
HER2 and low expression of the hormone receptors ERα and PR. Increased HER2 
expression is associated with an increase in tumor grade (137). A primary or secondary 
metastasis occurs within HER2 positive breast cancer approximately 30% of the time, 
more often than in any other subtype of breast cancer (125). 
 HER2 itself is a member of the epidermal growth factor receptor family of 
RTKs, however it has no known ligand (138). HER2 can homodimerize and also 
heterodimerize with related RTKs, most prominently EGFR and HER3, in order to 
initiate a phosphorylation cascade (139). Following dimerization, HER2 stimulates the 
previously described PI3K and MAPK pathways. Additionally, HER2 will stimulate 
protein kinase c (PKC) though phospholipase c (PLC) (140) (Figure 4). PLC cleaves 
PIP2 to release the products diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
(IP3) (141). IP3 is important for calcium release, however DAG directly binds to PKC 
in order to stimulate kinase activity. These three pathways are all tumorigenic and 
promote proliferation via progression through the cell cycle, increase invasiveness, and 
stimulate pro-survival/anti-apoptotic activity (140). 
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Figure 4: HER2 stimulates PKC, MAPK, and PI3K pathways. 
 In addition to heightened expression of HER2, the HER2 positive subtype of 
breast cancer also exhibits significant mutational burdens. Alterations to PI3K effectors 
are common, PIK3CA is mutated approximately 40% of the time and PTEN is mutated or 
lost in approximately 20% of tumors (126,127). Additionally, TP53 is mutated in 75% of 
cases (126,127). HER2 positive breast cancers exhibit a greater overall mutational burden 
than other breast cancer subtypes (127).  
 Similar to luminal breast cancers, the standard of care for HER2 positive breast 
cancer is surgery with adjuvant chemotherapy (128). Additionally, the use of a 
monoclonal antibody that inhibits HER2 is recommended. The first approved anti-HER2 
agent is trastuzumab, which is still the front line therapy for HER2 positive breast cancer 
and substantially improved survival for patients (142). Other anti-HER2 agents have 
since been developed, including the monoclonal antibody pertuzumab and irreversible 
kinase inhibitors afatinib and neratinib (138). Unfortunately, cardiac side effects are 
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relatively common with trastuzumab, as high as 27% in initial studies however that has 
been reduced to less than 10% in more recent trials, likely a result of different patients 
populations exhibiting varying degrees of sensitivity to these side effects (143). The 
HER2 kinase inhibitors exhibit a more favorable cardiac profile than antibody therapy 
(143). As with other targeted therapies, resistance to trastuzumab is a problem. A variant 
known as p95HER2, which lacks the trastuzumab-binding extracellular domain, is one of 
the known mechanisms of resistance (144). Strikingly, this variant does exhibit kinase 
activity and stimulates canonical HER2 downstream effectors (145). Loss of PTEN 
expression (146) and PIK3CA mutations (147) also inhibit the anti-tumor activity of 
trastuzumab. 
1.3.3. Basal-like Breast Cancer 
 Basal-like breast tumors exhibit a triple-negative phenotype, that is, they do not 
express ER, PR, or HER2. As a result of this, treatment options are more limited than the 
other breast cancer subtypes. Accordingly, outcomes are worse with basal-like breast 
cancer exhibiting the lowest 5-year survival rate of the breast cancer subtypes (Figure 3). 
In addition, basal-like breast tumors have a high propensity to metastasize, only HER2 
positive breast cancer exhibits a greater capacity to develop metastatic lesions (125). 
 In addition to the defined lack of ER, PR, and HER2, basal-like breast cancer 
exhibits a unique and complex molecular signature. TP53 is more likely to be mutated in 
basal-like breast cancers than any other breast cancer subtype (126). Additionally, genetic 
alterations to the PI3K pathways are common, with mutations to PIK3CA and deletion of 
PTEN being relatively common (126). BRCA-associated breast cancers are 
disproportionally basal-like (148). The basal-like subtype also has a unique 
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transcriptomic profile, exhibiting increased expression of EGFR and basal cytokeratins 
(149). 
 A further division of basal-like breast cancer can be made based upon the 
expression levels of claudins. Claudins are a class of proteins which are responsible for 
maintaining the tight junctions between epithelial cells (150). Basal breast tumors that 
express low levels of claudins are more mesenchymal than claudin-high breast cancer, 
also, claudin-low breast cancer exhibits increased levels of stem-cell markers (151). Both 
of these features promote the ability of the tumor cells to survival disaggregation and 
colonize a new tumor elsewhere in the body. 
 Similar to other breast cancers, the standard of care for non-metastatic basal-like 
breast cancer is surgical, with supplemental radiation (152). Broad spectrum 
chemotherapy is also appropriate for invasive cases and for patients with metastatic 
disease. Additionally, combinational approaches are being attempted in order to induce 
synthetic lethality. Poly (ADP-Ribose) polymerase (PARP) inhibitors are used to impair 
the ability of the cells to repair damaged DNA. PARP inhibitors have been shown in 
multiple trials to slow tumor progression, with enhanced efficacy when paired with 
another anti-tumor agent (153), and are now approved for use clinically. The RTKs 
VEGFR and EGFR are also being actively investigated as potential targets for inhibition 
with promising results in clinical trials (154). 
BRCA mutations lead to basal-like breast cancer more often than any other 
subtype and represent 25% of basal-like tumors (155). Due to BRCA proteins acting to 
repair DNA, platinum-based compounds that work by damaging DNA have been 
investigated to determine if these cells are more sensitive to this treatment modality. The 
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data so far trends towards BRCA mutant breast cancer being more sensitive to platinum-
based drugs, although recent meta-analysis suggests that the advantage of this therapeutic 
approach is relatively minor (156-158).  
 The androgen receptor (AR) is emerging as another important molecular target 
in basal-like breast cancer. Although AR is expressed in luminal breast cancer, there is a 
lack of druggable targets in basal-like breast cancer, making it more significant in this 
subtype (159). AR functions in a similar function to other nuclear NRs, including ERs. In 
the cytoplasm, AR is bound to heat shock proteins (HSP) until a ligand binds, at which 
point it translocates into the nucleus. In the nucleus, AR binds to response elements to 
recruit a protein complex which regulates transcriptional activity of the gene (159). A 
recent phase II trial demonstrated that a subset of breast cancer patients responded 
positively to the AR antagonist enzalutamide (160). As the molecular signaling driving 
basal-like breast tumors becomes better understood, other new therapeutic strategies are 
emerging. 
 
1.4. Scope of Dissertation 
 TRβ exhibits profound anti-tumorigenic activity in multiple tissue types, most 
prominently thyroid and breast. There are effective treatment options for the more 
differentiated subtypes of these diseases, however the more aggressive variants present a 
challenge. The PI3K-AKT pathway is commonly mutated in both thyroid and breast 
tumors, and this is a pathway upon which TRβ has a profound suppressive role. However, 
TRβ primarily acts as a transcription factor and the transcriptional activity of TRβ in 
cancer cells is not well-delineated, a gap that this dissertation attempts to fill. 
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 In chapter 2, the ATC cell line SW1736 to characterize how TRβ alters cellular 
pathways and phenotypic characteristics that underly the tumor suppressive response. 
This work expands upon the prior study from the Carr lab that detailed the discovery of 
the TRβ-RUNX2 pathway (63). In addition to describing how TRβ acts to repress pro-
malignant cellular characteristics, the discovery of novel TRβ-induced re-differentiation 
and induction of STAT1 activity are delineated. 
 Chapter 3 was also the result of expanding on the discovery of the TRβ-RUNX2 
pathway in thyroid cancer. In this chapter, the evidence showing this pathway is also 
active in breast cells is presented. Additionally, this chapter is a demonstration that the 
T3-mediated repression of RUNX2 is a TRβ-specific pathway by highlighting that TRα is 
unable to regulate RUNX2 expression. 
 In chapter 4, TRβ signaling in breast cancer was further investigated by 
performing a similar analysis to what is detailed in chapter 2. To determine the effect 
TRβ and T3 have on the breast cancer transcriptome, TRβ was overexpressed and RNA-
sequencing was conducted. Novel regulation of genes involved in EMT are described. 
Additionally, the differentially expressed genes are compared to the results in thyroid 
cancer to reveal common TRβ signaling in thyroid and breast cancer.   
Chapter 5 of this dissertation is a further review of the scientific literature, and 
the result of serendipitously learning of an epidemiological link between thyroid and 
breast cancers. The evidence for the link is discussed as well as putative etiological 
factors, including thyroid hormone receptor signaling. This work reframes the results of 
the experimental approaches used in prior chapters. 
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 This dissertation focuses on the molecular events that the tumor suppressor TRβ 
regulates in thyroid and breast cancer. This has revealed novel signaling mechanisms, 
potential druggable targets, and demonstrates the importance of cellular identity on the 
pathways TRβ regulates. 
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CHAPTER 2: Thyroid Hormone Receptor Beta Induces a Tumor Suppressive 
Program in Anaplastic Thyroid Cancer. 
 
2.1. Abstract 
The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and 
differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is 
noted in thyroid, breast, and other solid tumors and is correlated with more aggressive 
disease. Restoration of TRβ levels decreased tumor growth supporting the concept that 
TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome 
is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid 
cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC 
cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem-
cell populations and induces cell death in a T3-dependent manner. Transcriptomic 
analysis of SW-TRβ cells via RNA-sequencing revealed distinctive expression patterns 
induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, 
liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of 
thyroid differentiation markers, and promoted pro-apoptotic pathways. Our results further 
revealed the JAK1-STAT1 pathway as a novel, T3-mediated, anti-tumorigenic pathway 
that can be activated in additional ATC lines. These findings elucidate a TRβ-driven 
tumor suppression transcriptomic signature, highlight unexplored therapeutic options for 
ATC, and support TRβ activation as a promising therapeutic option in cancers.  
Implications: TRβ-T3 induced a less aggressive phenotype and tumor suppression 
program in anaplastic thyroid cancer cells revealing new potential therapeutic targets. 
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2.2. Introduction 
The non-steroidal nuclear hormone receptor thyroid hormone receptor beta 
(TRβ) has been characterized as a tumor suppressor in multiple tumor types, primarily 
thyroid, breast, and hepatocellular carcinomas (1,2). Expression of TRβ is typically 
reduced in aggressive tumors. Epigenetic silencing of THRB is frequent, while mutations 
in the gene are relatively rare. As a nuclear hormone receptor, the canonical function of 
TRβ is to regulate gene expression in response to its ligand triiodothyronine (T3). It is 
also known that TRβ exerts ligand-independent genomic signaling and has non-genomic 
functions that are ligand regulated (3).  
Multiple lines of evidence demonstrate the tumor suppressive activity of TRβ in 
thyroid cancer. Re-expression of silenced TRβ using demethylating agents delays thyroid 
tumor progression in vivo (4), mice expressing a c-terminal frameshift of TRβ (ThrbPV) 
spontaneously develop follicular thyroid cancer (5), and ThrbPV/PV KrasG12D mice develop 
thyroid tumors with features of dedifferentiated thyroid cancer (6). 
TRβ has previously been shown to modulate anti-tumorigenic signaling in 
thyroid cancer in part through repression of driver pathways such as PI3K/AKT (7) and 
NF-κβ (8); modulation of inflammatory processes (8); and repression of the oncogenes β-
Catenin (9,10) and RUNX2 (11,12). These signaling nodes are important contributors to 
the tumor suppressive activity of TRβ, but they likely do not constitute the entire tumor 
suppression program.  
The current understanding of TRβ tumor suppressive activity has been described 
primarily in differentiated thyroid cancers, but there is a need to determine TRβ-mediated 
tumor suppressive actions in dedifferentiated anaplastic thyroid cancer (ATC). Although 
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this tumor subtype is rare, ATC is responsible for nearly 40% of thyroid cancer deaths 
with most patients exhibiting a median survival time of less than six months (13). This is 
mainly due to a lack of effective targeted therapeutic options. Characterization of the 
activity of tumor suppressors can provide important insights into the development of 
rationally designed treatment interventions. 
These studies aimed to understand the systemic impact of TRβ and its ligand 
thyroid hormone (T3) on ATC cancer cell characteristics. We performed transcriptomic 
analysis of TRβ in ATC cells to provide a comprehensive network of cellular signaling 
events altered by TRβ and T3. We have paired this transcriptomic data with functional 
studies to characterize the TRβ-mediated changes to ATC cell characteristics. Lastly, this 
analysis has revealed that activation of a STAT1-dependent anti-proliferative pathway is 
a vulnerability in ATC that can be exploited pharmacologically. 
 
2.3. Materials and Methods 
Culture of thyroid cell lines.  
Anaplastic thyroid cancer cell lines (SW1736, 8505C, OCUT-2, and KTC-2) 
were cultured in RPMI 1640 growth media with L-glutamine (300 mg/L), sodium 
pyruvate and nonessential amino acids (1%) (Corning Inc, Corning, NY, USA), 
supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, 
USA) and penicillin-streptomycin (200 IU/L) (Corning) at 37°C, 5% CO2, and 100% 
humidity. Lentivirally modified SW1736 cells were generated as recently described (12) 
with either an empty vector (SW-EV) or to overexpress TRβ (SW-TRβ). SW-EV and 
SW-TRβ were grown in the above conditions with the addition of 1 µg/ml puromycin 
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(Gold Bio, St Louis, MO, USA). SW1736 and KTC-2 were authenticated by the Vermont 
Integrative Genomics Resource at the University of Vermont using short tandem repeat 
profiles and Promega GenePrint10 System (SW1736, May 2019; KTC-2, October 2019). 
8505C and OCUT-2 were authenticated by University of Colorado by short tandem 
repeat profiles (8505C, June 2013; OCUT-2, June 2018). 
RNA-seq Library Construction and Quality Control.  
80% confluent monolayers of SW-EV and SW-TRβ cells were hormone starved 
for 24 hours in phenol red free RPMI with charcoal-stripped fetal bovine serum. 10-8 M 
T3 was added and incubated for 24 hours prior to sample collection. Total RNA was 
extracted and purified using RNeasy Plus Kit (Qiagen, Venlo, Netherlands) according to 
manufacturer’s protocol. Purity of the total RNA samples was assessed via BioAnalyzer 
(Agilent Technologies, Santa Clara, CA, USA) and samples with a RIN score >7 were 
used for library construction. rRNA was depleted using 1 μg of total RNA with the 
RiboErase kit (Roche, Basel, Switzerland). Strand-specific Illumina cDNA libraries were 
prepared using the KAPA Stranded RNA-Seq library preparation kit with 10 cycles of 
PCR (Roche). Library quality was assessed by BioAnalyzer (Agilent Technologies) to 
ensure an average library size of 300 bp and the absence of excess adaptors in each 
sample. RNA-Seq libraries were pooled and sequenced on the Illumina HiSeq 1500 with 
50 bp single-end reads. Quality scores across sequenced reads were assessed using 
FASTQC. All samples were high quality. For alignment and transcript assembly, the 
sequencing reads were mapped to hg38 using STAR. Sorted reads were counted using 
HTSeq and differential expression analysis was performed using DESeq2. Genes with a 
p-value of <0.05 and a fold change of >2 were considered differentially expressed and 
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were used for further analysis through Ingenuity Pathway Analysis (IPA) (Qiagen) and 
Gene Set Enrichment Analysis (GSEA). 
Immunoblot Analysis.  
Proteins were isolated from whole cells in lysis buffer (20mM Tris-HCl [pH 8], 
137mM NaCl, 10% glycerol, 1% Triton X-100, and 2mM EDTA) containing Protease 
Inhibitor Cocktail 78410 (Thermo Fisher Scientific). Proteins were resolved by 
polyacrylamide gel electrophoresis on 10% sodium dodecyl sulfate gels EC60752 
(Thermo Fisher Scientific) and immobilized onto nitrocellulose membranes (GE 
Healthcare, Chicago, IL, USA) by electroblot (Bio-Rad Laboratories, Hercules, CA, 
USA). Specific proteins were detected by immunoblotting with the indicated antibodies 
(Appendix A-1); immunoreactive proteins were detected by enhanced 
chemiluminescence (Thermo Scientific) on a ChemiDoc XRS+ (Bio-Rad Laboratories). 
Growth Assays.  
Cell growth was measured either through live cell imaging or by cell counting at 
discrete points. Live cell imaging was used to assess the growth kinetics of SW-EV and 
SW-TRβ. To perform live cell imaging, 5000 cells were plated per well in 24 well plates. 
After 24 hours in phenol red free, charcoal stripped media, media was supplemented with 
either 10-8 M T3 or equivolume vehicle (NaOH). Every two hours cells were imaged with 
a Lionheart automated microscope (Agilent Technologies) and quantified with Gen5 
software (Agilent Technologies). The cells entered the log phase of growth at 
approximately 48 hours, and we used the portion of the curve following this point to 
calculate the doubling time of the cells. 
Sulforhodamine B Cell Cytotoxicity Assay Kit (Abcam, Cambridge, UK) was 
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used to stain cell protein as a readout for cell viability. ATC cells were plated in 96-well 
clear flat-bottom plates at a density of 5,000 cells/well. Cells were treated with serial 
dilutions of the STAT1 activator 2-(1,8-Naphthyridin-2-ly)phenol (2-NP) (Abcam) or 
vehicle (DMSO). Plates were then incubated for 72 hours. Cells were fixed, stained, and 
then imaged using a plate reader according to manufacturer’s instructions.  
Soft Agar Colony Formation Assay.  
Soft agar colony forming assays were used to assess anchorage-independent 
growth. A layer 0.50% agar in thyroid media (as described) was solidified in 6-well cell 
culture plates. SW-EV or SW-TRβ cells were plated in a second layer of 0.25% agar in 
thyroid media. 200uL of thyroid media was maintained at the top of each well to prevent 
the agar from drying. Where indicated, 10-8 M T3 or vehicle (NaOH) was added to the 
media in all layers to evaluate the effects of liganded TRβ on anchorage-independent 
growth. Colonies were allowed to grow for 14 days. Live SW-EV and SW-TRβ colonies 
were detected via GFP expression using a ChemiDoc XRS+ (Bio-Rad Laboratories). 
Colonies were then counted with ImageJ using the Colony Counter plugin. 
Tumorsphere Assay.  
Tumorsphere-forming assays were used to assess self-renewal and sphere-
forming efficiency. For generating thyrospheres, adherent SW-EV and SW-TRβ 
monolayer cells were dissociated with Trypsin-EDTA, and single cells were moved to 
round-bottom ultra-low attachment 96-well plates at a density of 1000 cells/well 
(Corning). Thyrospheres were cultured in RPMI 1640 growth media supplemented with 
20ng/mL each of epidermal growth factor (EGF) and fibroblastic growth factor (FGF) 
(Gold Bio). Where indicated, 10-8 M T3 or vehicle (NaOH) was added to the media to 
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evaluate the effects of liganded TRβ on thyrosphere growth. Thyrospheres grew for seven 
days and were then counted with an inverted microscope.  
Migration Assay.  
Cell migration was determined by wound healing assay. Cells were plated and 
allowed to grow to 100% confluency. Two hours prior to scratching, cells were treated 
with 10 mg/ml Mitomycin C. A scratch was performed with a P1000 pipette tip and 
debris was washed away with PBS. Migration media was supplemented with 10-8 M T3. 
Images were obtained at 0, 24, 48, and 72 hours. Wound closure was measured using 
ImageJ macro “Wound Healing Tool” (http://dev.mri.cnrs.fr/projects/imagej-
macros/wiki/Wound_Healing_Tool). Values were normalized so that the initial scratch 
was 0% closure. 
Apoptosis Assay.  
Cells were plated at a density of 50,000 cells/well and treated with vehicle (1 N 
NaOH) or 10-8 M T3. After 5 days the cells were lysed for analysis, poly (ADP-ribose) 
polymerase 1 (PARP1) and Caspase 3 cleavage were assessed by immunoblot to measure 
apoptotic signaling. 
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR).  
Total RNA was extracted using RNeasy Plus Kit (Qiagen) according to 
manufacturer’s protocol. cDNA was then generated using the 5X RT Mastermix (ABM, 
Vancouver, Canada). Gene expression to validate RNASeq analysis was quantified by 
qRT-PCR using 2X SuperGreen Mastermix (Thermo Fisher Scientific) on a QuantStudio 
3 real-time PCR system (Thermo Fisher Scientific). Fold change in gene expression 
compared to endogenous controls was calculated using the ddCT method. Primer 
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sequences are indicated in Appendix A-2.   
Statistics.  
All statistical analyses were performed using GraphPad Prism software. Paired 
comparisons were by T-test and group comparisons were made by a 2-way ANOVA 
followed by a Tukey multiple comparisons test (p<0.05). Data are represented as mean  
standard deviation, or when stated otherwise mean  standard error of the mean. Area 
under the curve (AUC) at the 95th confidence interval was used to evaluate statistical 
differences in growth and migration assays. 
 
2.4. Results 
2.4.1. Expression of TRβ inhibits pro-tumorigenic characteristics of human anaplastic 
thyroid cells. 
Anti-tumorigenic signaling from the tumor suppressor TRβ has not been 
comprehensively defined in ATC. We utilized the human ATC cell line SW1736, 
modified to overexpress TRβ (previously used in (12)), to examine the effect of both T3 
and TRβ on the cellular growth. T3 modestly decreased the growth rate of SW-EV (Figure 
5A). Vehicle treated SW-EV also grew faster than vehicle treated SW-TRβ. Importantly, 
the combination of TRβ overexpression and T3 treatment profoundly reduced cellular 
growth. T3 treated SW-TRβ also exhibited the greatest doubling time (Figure 5B). TRβ 




Figure 5: Liganded TRβ Repressed Growth and Migration of ATC Cells. A) The combination of TRβ 
expression and T3 treatment repressed the growth of the ATC cells (n=8). Variability is represented by the 
standard error of the mean; significance was determined by calculating the 95th confident interval of AUC 
measurements. B) TRβ and T3 acted to increase doubling time of the cells (n=8, * p<0.01). C) SW-TRβ 
treated with T3 exhibited significantly reduced scratch closure at the 95th confidence interval by AUC (n=9) 
and D) representative images. 
 
In addition to inducing anti-proliferative activity, TRβ is known to block 
metastasis in vivo (14). As metastasis and invasiveness require heightened cellular 
motility, we also assessed the impact of T3 and TRβ on ATC cell migration by wound 
healing assay. Ligand treated SW-TRβ showed reduced migratory potential compared to 
ligand treated SW-EV (Figure 5C-D). These data indicate that TRβ in the presence of T3 
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ligand exerts tumor suppressor activity in ATC cells. 
2.4.2. TRβ reprograms the anaplastic thyroid cancer cell transcriptome. 
Given that T3 significantly reduced ATC cell growth and migration, we then 
interrogated the gene expression patterns elicited by TRβ with T3 treatment by RNA-seq. 
The expression patterns of differentially expressed genes (DEGs) across each condition 
was visualized using a clustered heatmap (Figure 6A). This analysis resulted in 5 
distinctive clusters of DEGs. Clusters 1 and 5 are DEGs regulated by T3 in the absence of 
TRβ overexpression. Clusters 2 and 3 are DEGs that are T3-regulated only when TRβ is 
overexpressed. Cluster 4 includes the DEGs that are repressed by T3 in the absence of 
TRβ and induced by T3 in cells that overexpress TRβ.  
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Figure 6: TRβ-T3 Altered the Transcriptome of ATC Cells. A) Thresholds for differentially regulated 
genes (DEGs) were set at p<0.05 and an absolute log2foldchange of at least 1, upregulated transcripts in 
red and repressed transcripts in blue. Genes were clustered according to patterns of expression. Clusters 1 
and 5 are genes that are T3 regulated independent of TRβ overexpression. Clusters 2-4 require TRβ for T3 to 
exert a regulatory effect. B) Ingenuity Pathway Analysis (IPA) software was utilized to determine pathways 
altered within each cluster. Notable cancer-related pathways are highlighted. C) IPA software was used to 
ascertain upstream regulators within each cluster. Exogenous chemicals were excluded, however 
endogenous chemicals were retained. 
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Enriched pathways within these five clusters of DEGs were determined using 
IPA software (Figure 6B). Highly enriched processes include Integrin-linked kinase 
(ILK) signaling (cluster 1), interferon signaling (cluster 2), endoplasmic reticulum (ER) 
stress (cluster 2), nucleotide excision repair (NER) (cluster 3), DNA methylation and 
transcriptional repression (cluster 3), and protein ubiquitination (cluster 4). Of these 
pathways highlighted in the cluster analysis, TRβ has previously been shown to regulate 
ILK (hereafter PI3K/ILK) and interferon signaling (hereafter interferon/JAK1/STAT1) 
(7,15). 
Following PI3K phosphorylation of PIP2, ILK catalyzes phosphorylation AKT 
and activates proliferative and invasive cellular processes (16). A pairwise comparison 
between T3-treated SW-EV and SW-TRβ cells demonstrates that expression of TRβ 
further represses genes within the PI3K/ILK pathway (Appendix A-3 A-I). Therefore, 
changes to the PI3K/ILK pathway are likely a reflection of the known repressive effect 
TRβ has on PI3K in cancer cells (7). TRβ repression of PI3K signaling was confirmed by 
assessing pAKT/AKT by immunoblot (Appendix A-3 J). 
TRβ has recently been shown to alter a set of genes in the 
interferon/JAK1/STAT1 pathway in breast cancer cells (15). This pathway was also 
significantly upregulated by TRβ in our ATC cell line model as predicted by IPA (Figure 
6B, Appendix A-4) and GSEA (Appendix A-5). Since the transcriptomic profiling of 
SW1736 was performed in vitro, the observed interferon response is likely intrinsic 
signaling (17). In the intrinsic interferon pathway, stimulation of the interferon receptor 
in cells drives phosphorylation of JAK proteins, which in turn phosphorylate STAT1 to 
initiate a transcriptional response. STAT1 signaling has been reported to promote 
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apoptosis and differentiation of tumor cells, as well as inhibit growth (17).  
The upstream regulators of each cluster were determined using IPA (Figure 6C). 
This analysis further confirmed alteration of the PI3K/ILK and interferon/JAK1/STAT1 
pathways. Suppression of PI3K/ILK signaling was consistent with repression of the PI3K 
family and the receptor tyrosine kinases FGF2 and EGFR (cluster 1). There was 
predicted activation of multiple effectors within the interferon/JAK1/STAT1 signaling 
network, including IFNG, IRF1, IFNA2, and STAT1 in cluster 2 as well as IRF7 in 
clusters 2 and 5.  
Analysis of the upstream regulators highlighted other genes known to be 
important in tumorigenesis. Notable upstream regulators were NF-κβ (cluster 1), MAPK1 
(cluster 2), CCND1 (cluster 4), ATF4 (clusters 1 and 3), and SMARCB1 (cluster 5). NF-
κβ and MAPK1 are well recognized to be oncogenic (18,19) and were predicted to be 
repressed by TRβ and T3. CCND1 encodes the protein cyclin D1, a cell cycle regulator 
which is regulated by T3 and TRβ in other cell types (20), and was predicted to be 
repressed in this analysis. The ER stress regulator ATF4 was repressed, itself a gene that 
is typically upregulated in malignancy and a potential drug target for ATC (21). Genes 
positively regulated by SMARCB1, a component of the SWI/SNF chromatin remodeling 
complex, were induced by T3. SWI/SNF components are more commonly mutated in 
ATC than in other thyroid cancer subtypes (22).  
These gene clusters were also used for chromatin immunoprecipitation 
enrichment analysis (ChEA) (23) in order to determine which transcription factors have 
overrepresented binding sites (Appendix A-6). Of these transcription factors, GATA2, 
IRF1, NELFE, VDR, and ZMIZ1 exhibited altered expression and are therefore possible 
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drivers of TRβ-mediated signaling.  
The majority of the DEGs in this analysis belong to clusters that were only 
significantly altered in the TRβ-T3 condition. Therefore, a pairwise comparison between 
SW-EV-T3 and SW-TRβ-T3 was performed (Appendix A-7). The long noncoding RNAs 
(lncRNA) were pulled from the set of genes due to their emerging role in tumor biology 
(24). lncRNAs upregulated included C1QTNF1-AS1, MIR210HG, TBILA, GAS6-AS1, 
LUCAT1, DRAIC, KIAA0125, MIR22HG, and UCA1. Conversely, LINC01133 was 
repressed. These lncRNAs have all been found to have a role in tumorigenesis (25-33). 
In addition to the pathways and key regulators uncovered by the use of 
bioinformatics software, we decided to directly examine cell cycle regulators that may 
aid in explaining the anti-proliferative phenotype we observed in the SW-TRβ-T3 group. 
CDKN1A is a known TRβ-T3 regulated gene in hepatocellular carcinoma, where 
CDKN1A mediates the anti-proliferative activity of TRβ (34). Expression of the oncogene 
MYC is induced by TRβ-PV in the development of thyroid tumors (6). In SW1736 cells, 
TRβ increased expression of CDKN1A and repressed MYC expression (Appendix A-8). 
Analysis of the transcriptomic profile induced by overexpression of TRβ and T3 
shows that many pathways and key regulators in cancer biology are altered. These 
signaling nodes relate to survival signaling, invasiveness, cellular maintenance, 
differentiation, and chromatin organization. Thus, T3 treatment of SW-TRβ induces 
transcriptomic changes associated with reduced cell growth, migration, cell cycle, and 
cell survival. 
2.4.3. Liganded TRβ reduces ATC stem-cell characteristics. 
Recently, it was demonstrated that TRβ reduces cancer stem cell renewal in 
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luminal breast cancer cell lines (15). We therefore examined whether TRβ expression and 
T3 treatment could attenuate the stem-like properties of SW1736 cells. Soft agar colony 
formation assays were used to measure changes in anchorage independent growth in the 
presence and absence of TRβ and T3. Treatment with T3 reduced anchorage-independent 
colony growth in SW-EV cells, and nearly ablated colony growth in SW-TRβ cells 
(Figure 7A-B). Tumorsphere assays were used to assess self-renewal and estimate the 
size of the cancer stem cell population within our heterogenous cultures. T3 had no effect 
on the number of tumorspheres formed from SW-EV cells. Expression of TRβ alone 
reduced tumorsphere formation, however the addition of T3 blocked almost all 
tumorsphere growth (Figure 7C).  
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Figure 7: TRβ Reduced Stem Cell Characteristics in ATC Cells. A) Treatment of SW1736 cells with T3 
was sufficient to decrease anchorage-independent growth; the most pronounced effect was observed in the 
SW-TRβ cells (n=4, * p<0.05). B) T3 significantly repressed tumorsphere formation in SW-TRβ, but not 
SW-EV (n=4, * p<0.05). D) Thyroid cancer-specific stem cell marker mRNA transcript levels were 
significantly repressed by TRβ and T3 by RNA-seq (n=3, * p<0.05). E) Reintroduction of TRβ and 
treatment with T3 resulted in a significantly increased thyroid differentiation score (TDS) (n=3, * p<0.05). 
 
Expression of key stem cell markers was also altered. Although the markers for 
thyroid cancer stem cells have not been studied with the same rigor as other aggressive 
cancer types, a recent review compiled a list of proposed cancer stem cell markers that 
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have been characterized in the thyroid (35). The combination of TRβ overexpression and 
T3 significantly reduced expression of the thyroid-specific cancer stem cell genes ALDH, 
POU5F1 (encodes OCT3/4), CD44, FUT4 (encodes SSEA-1), and PROM1 (encodes 
CD133) (Figure 7D). We also examined the EMT markers CHD1 (E-cadherin), VIM 
(Vimentin) (Appendix A-9). The epithelial marker CDH1 exhibited increased expression 
in SW1736-TRβ T3 treated cells, whereas expression of the mesenchymal marker VIM 
was decreased. Together with the phenotypic assays, these results demonstrate that TRβ 
in association with ligand decreases the stem cell population of ATC cells.  
To further explore the impact of T3 treatment in this ATC model, the thyroid 
differentiation score (TDS) was calculated for the SW1736 cells under each condition to 
evaluate whether the transcriptomic data indicates a change in thyroid-specific 
differentiation. The TDS has been demonstrated to have utility in predicting the 
aggressiveness of a thyroid tumor (36,37). Ten out of the thirteen genes which constitute 
the TDS are expressed in at least one condition in this dataset. DIO2, DUOX1, TPO, and 
TG, were highly responsive to TRβ expression and the addition of T3 (Appendix A-10). 
SW-TRβ cells treated with T3 have a significantly higher TDS, indicating that they have 
the most thyroid-like gene expression (Figure 7E). These results suggest that the tumor 
suppressive activity of TRβ observed in SW1736 cells may involve cellular 
differentiation and a consequential reduction in the cancer stem cell properties. 
2.4.4. TRβ stimulates apoptotic signaling. 
As a tumor suppressor, TRβ promotes apoptosis in other cancer cell types, 
however this has never been described in ATC (6,38). A targeted pathway enrichment 
analysis between SW-TRβ treated with vehicle or T3 revealed alterations in pathways that 
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suggested apoptotic programming was occurring (Figure 8A). Additionally, GSEA 
analysis using Hallmark gene sets highlighted enrichment of apoptotic signaling (Figure 
8B). We further investigated the ability of T3 to stimulate apoptosis in our model. SW-EV 
and SW-TRβ cells were cultured in media supplemented with T3 continuously for five 
days. Caspase 3 and PARP1 cleavage were detected by immunoblot to assess apoptotic 
activity. T3 induced cleavage of these apoptotic effectors only in SW-TRβ (Figure 8C). 
Neither T3 nor TRβ alone was sufficient to elicit this response. These data demonstrate 
heightened activity of TRβ promotes an apoptotic response in aggressive cancer cells, 
further confirming tumor suppressive activity. 
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Figure 8: Re-expression of TRβ Increased Apoptotic Signaling. A) In a comparison of DEGs between 
SW-EV and SW-TRβ, both T3 treated, IPA predicted changes in pathways important to apoptotic signaling, 
and B) GSEA predicted activation of apoptosis. C) Representative immunoblot demonstrates that 5 days of 
T3 treatment induces apoptosis in SW-TR cells assessed by cleavage of PARP1 and caspase 3 (n=6). 
 
2.4.5. TRβ stimulates anti-proliferative interferon/JAK1/STAT1 signaling. 
Of the pathways altered by TRβ, the interferon/JAK1/STAT1 pathway was 
among the most prominent within our transcriptomic analysis (Figure 6, Appendix A-4). 
We therefore decided to investigate the activity of this pathway in ATC and whether it 
could be modulated to slow tumor growth. Interferon/JAK1/STAT1 signaling is known to 
have potent anti-tumor and anti-proliferative activity (17,39). The primary effector of the 
interferon response is the transcription factor STAT1.  
Expression of the kinase effectors JAK1 and STAT1 were significantly 
increased in SW-TRβ cells following treatment with T3 (Figure 9A and Appendix A-11 
A-C). Additionally, transcriptional targets of STAT1 were significantly increased in T3 
treated SW-TRβ cells T3 also increased the expression of STAT1 target genes IRF1 and 
TAP1, and IRF1 target genes APOL6 and TNFSF10 (Figure 9B). TRβ-T3 mediated 
induction of these genes was confirmed by qRT-PCR (Appendix A-11 D). 
 69 
 
Figure 9: The Interferon-JAK1-STAT1 Pathway is Activated by TRβ. A) Interferon pathway effector 
proteins JAK1 and STAT1 are expressed at higher levels in SW-TRβ cells following T3 treatment 
(*p<0.05, n=3). B) STAT1 and IRF1 upregulated genes were repressed upon overexpression of TRβ and T3 
treatment. (n=3, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). C) Stimulation of STAT1 
transcriptional activity with the agonist 2-NP repressed growth of ATC cell lines (n=8, * p<0.05, ** 
p<0.01, *** p<0.001). 
 
STAT1 has anti-proliferative activity, raising the question whether it can be 
exploited pharmacologically to reduce ATC growth. To identify the effects of STAT1 
stimulation the ATC lines SW1736, 8505C, OCUT-2, and KTC-2 were treated for 72 
hours with various concentrations of 2-NP, a small molecule activator of STAT1 (40) 
(Figure 9C). SW1736 and 8505C were most sensitive to 2-NP, and growth of both KTC-
2 and OCUT-2 were repressed by the compound at 50 µM. Together, these results 
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demonstrate that liganded TRβ stimulates STAT1 signaling, which in turn can repress 
growth in ATC cell lines. 
 
2.5. Discussion 
While TRβ is a recognized tumor suppressor in thyroid cancer and is known to 
be silenced in ATC (11), TRβ-mediated signaling and phenotypic effects are not well 
characterized in ATC. Our data in ATC cells demonstrates that TRβ, in conjunction with 
T3, acts to regulate pathways important for the process of tumorigenesis and reduces the 
aggressive phenotypic characteristics. This change was demonstrated via multiple 
measures including reduced growth, migration, and stemness. In addition, the 
combination of TRβ and T3 induced the expression of thyroid differentiation markers in 
ATC cells, and after 5 days resulted in apoptosis. Indeed, T3 was essential for the 
profound anti-tumorigenic molecular signaling and phenotypic remodeling observed in 
this study. The major findings of our analysis are represented in Figure 10. 
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Figure 10: TRβ Activates Alternate Apoptotic Pathway. TRβ stimulates activity of STAT1, a transducer 
of anti-proliferative signaling. Stemness of the cells is reduced, while thyroid differentiation markers are 
increased. Additionally, apoptosis was increased in the cells. 
 
Our transcriptomic results reveal new details about TRβ-mediated regulation of 
critical cancer-related pathways in ATC. The prominent pathways from our analysis were 
repression of PI3K and activation of STAT1. TRβ-mediated repression of PI3K has been 
demonstrated in breast cancer and differentiated thyroid tumors (7,38), suggestive that 
this signaling is active in a variety of tumor types. Additionally, we highlight the 
interferon/JAK1/STAT1 pathway, previously unknown to be modulated by T3 in thyroid 
cells, although STAT1 was recently shown to be activated upon overexpression of TRβ 
in estrogen receptor positive breast cancer (15). Evidence of MAPK repression was also 
observed, another pathway previously shown to be regulated by TRβ in breast cancer 
cells (41). Along with alterations to PI3K and interferon activity, there were changes to 
cellular repair processes driven by TRβ overexpression. TRβ and T3 altered expression of 
genes involved ER stress. This is consistent with alteration of protein ubiquitination, 
which may indicate a greater turnover rate of misfolded proteins, an important 
component of ER stress. Additionally, alteration of transcriptional repression and NER 
are consistent with observed reduction of cell growth. These pathways can initiate an 
apoptotic response, such as through an accumulation of misfolded proteins in the ER 
(42), or a failure of DNA repair pathways to repair damaged DNA (43). Thus, these 
results indicate that these cells are primed for apoptosis to occur after multiple days of 
hormone treatment. 
The pathways in this analysis overlap substantially with known drivers of ATC. 
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ATC commonly exhibits mutations to the MAPK and PI3K pathways, the SWI/SNF 
complex, and DNA repair processes (22,44). These are also shown to be altered by TRβ 
in our analysis. The TRβ driven transcriptomic reprogramming is indicative of a reversal 
of the process of malignancy. Indeed, these changes in gene expression suggest that TRβ 
is promoting a differentiating effect in the cells, which was demonstrated by the TDS and 
multiple stemness assays, indicating that TRβ expression may be predictive in 
determining the aggressiveness of a tumor. Our results indicate that TRβ reduces the 
aggressive malignant phenotype of ATC cells.  
A significant finding here is that TRβ stimulates the activity of STAT1 in ATC. 
STAT1 is stimulated by interferons, which have been reported to be tumor suppressive in 
multiple cancer types (17). Interestingly, cytokine-cytokine receptor pathway was 
predicted to be changed in the thyroids of THRBPV/PV PTEN+/- mice (8), a class of 
interactions that includes interferon-interferon receptor. STAT1 itself may be a clinically 
important drug target as stimulation of STAT1 activity was sufficient to reduce growth in 
multiple ATC cell lines. Treatment strategies that focus on activating STAT1-directed 
signaling may have value for prolonging the lifespan of ATC patients. Several studies 
have examined the utility of treating thyroid cancer with interferon. Interferon γ reduces 
proliferation and migration in papillary thyroid cancer (45), and interferon α suppresses 
growth in thyroid cancer cells, including in ATC lines (46). Additionally, a phase II trial 
combined interferon α with doxorubicin and observed a modest response in advanced 
thyroid cancer patients, however toxicity was high (47). Modulation of STAT1 directly to 
suppress tumor growth may be better tolerated. In general, targeting multiple effectors in 
the same pathway reduces undesirable side effects in cancer patients (48). 
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We have used our investigation into TRβ signaling to elucidate ATC 
vulnerabilities and uncover a novel regulatory effect of TRβ in ATC by stimulating 
STAT1. Only recently have targeted therapies in ATC shown success in managing 
disease burden and progression (49). These treatment modalities focus primarily upon the 
mutational landscape of ATC, however epigenetic alterations, including silencing of the 
tumor suppressor TRβ, have an unrealized potential to inform drug development. 
Additionally, reversing the epigenetic silencing of TRβ may itself be beneficial. Our 
work on TRβ signaling reveals novel functions of TRβ in ATC and the need to 
investigate STAT signaling in aggressive thyroid cancers.  
Finally, our data demonstrates that there is value to maintaining euthyroid status 
in ATC patients. Hypothyroidism is a known consequence of certain treatment regimens 
(50) and treating chemotherapy-induced hypothyroidism may improve clinical outcomes 
due to stimulation of the tumor suppressive activity of TRβ, illustrating the potential for 
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CHAPTER 3: The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor 
Suppressive Pathway in Breast Cancer. 
 
3.1. Abstract 
Metastatic breast cancer is refractory to conventional therapies and an end stage 
disease. RUNX2 is a transcription factor that becomes oncogenic when aberrantly 
expressed in multiple tumor types, including breast cancer, supporting tumor progression 
and metastases. Our previous work demonstrated that the thyroid hormone receptor beta 
(TRβ) inhibits RUNX2 expression and tumorigenic characteristics in thyroid cells. As 
TRβ is a tumor suppressor, we investigated the compelling question whether TRβ also 
regulates RUNX2 in breast cancer. The Cancer Genome Atlas indicates that TRβ 
expression is decreased in the most aggressive basal-like subtype of breast cancer. We 
established that modulated levels of TRβ results in corresponding changes in the high 
levels of RUNX2 expression in metastatic, basal-like breast cells. The MDA-MB-231 
triple negative breast cancer cell line exhibit low expression of TRβ and high levels of 
RUNX2. Increased expression of TRβ decreased RUNX2 levels. The thyroid hormone 
mediated suppression of RUNX2 is TRβ specific as TRα overexpression failed to alter 
RUNX2 expression. Consistent with these findings, knock-down of TRβ in non-tumor 
MCF10A mammary epithelial-like cells results in an increase in RUNX2 and RUNX2 
target genes. Mechanistically, TRβ directly interacts with the proximal promoter of 
RUNX2 through a thyroid hormone response element to reduce promoter activity. The 
TRβ suppression of the oncogene RUNX2 is a signaling pathway shared by thyroid and 
breast cancers. 
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Implications: Our findings provide a novel mechanism for TRβ-mediated tumor 
suppression in breast cancers. This pathway may be common to many solid tumors and 
impact treatment for metastatic cancers. 
 
3.2. Introduction 
Breast cancer is the most commonly diagnosed malignancy in women worldwide 
[1]. In the United States, one in eight women are expected to develop the disease over the 
course of their lives [2]. Endocrine therapies that target the estrogen receptor (ERα) are a 
cornerstone of breast cancer treatment for most patients. Yet, these therapies often fail, as 
a consequence of distinct resistance pathways. Non-steroid nuclear hormone receptors 
have emerged as diagnostic and therapeutic targets in breast cancer, yet the functional 
mechanistic and clinically relevant roles of most of this family are minimally understood 
[3]. Notably, several lines of evidence from gain of function experiments indicate that 
thyroid hormone receptor beta (TRβ) exhibits tumor suppressor activity in breast cancer. 
In luminal A MCF7 cells, re-expression of TRβ reduced xenograft tumor mass and pro-
oncogenic STAT3 signaling [4]. Similar results were observed in triple negative MDA-
MB-468 cells. TRβ expression reduced metastases and angiogenesis [5]; further, 
expression of TRβ repressed of PI3K signaling and induced apoptosis [6]. Additionally, 
TRβ is correlated with improved disease-free survival in both BRCA associated tumors 
and in triple negative breast cancer [7, 8]. This may be in part due to increased 
sensitization to chemotherapeutics [8], necessitating a thorough understanding of the 
mechanisms by which TRβ suppresses tumor growth. 
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TRβ also exhibits tumor suppressor activity in thyroid cancer [9], a disease with a 
link to breast cancer. Women who develop thyroid cancer are more likely to develop 
breast cancer as a second primary tumor and patients with breast cancer are at increased 
risk of developing thyroid cancer [10-13]. Further understanding of either of these tumor 
types may reveal important insights into the predisposition for the other disease as well as 
insights into how both tumor types develop. Reciprocal synergies between these tumors 
may be highly informative. Intriguingly, bone is one of the most common distal sites of 
metastases in breast cancer [14] and is the second most common site in thyroid 
metastases [15]. We recently established a novel tumor suppression pathway by which 
the master regulator of osteoblast development, RUNX2, which functions oncogenically 
in cancer and promotes invasion and metastasis in thyroid cancer [16, 17], is repressed by 
TRβ in thyroid cells [18, 19]. Addition of the ligand, triiodothyronine (T3), enhances the 
TRβ mediated transcriptional events, reinforcing this novel pathway. In breast cancer, 
RUNX2 drives tumor progression, promoting proliferation and distal metastasis [20, 21] 
in part through the upregulation of genes critical to the process of invasion, including 
VEGF, OPN, and matrix metalloproteases (MMPs) [17, 22-26]. These findings indicate 
that the T3-TRβ-RUNX2 pathway could be active in breast cancer as well as in thyroid 
cancer.  
Unlike in thyroid cells where the dominant thyroid hormone receptor is TRβ, in 
breast cells TRα expression is robust. Although not yet well-defined, TR, in contrast to 
TRβ, may be associated with breast tumorigenesis. High TRα expression in BRCA1-
associated breast tumors correlates with a poor prognosis [7]. It has been reported that 
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elevated levels of the splice variant TRα1 of TRα are associated with a poor prognosis 
and decreased patient survival [27].  
A compelling question is whether the TRβ-RUNX2 signaling is active in breast as 
well as thyroid cancer. Given that T3 activates both TRβ and TRα, and that TRα 
expression is robust in breast cancer cells our experimental strategy was to determine 
whether one or both TRs are responsible for repression of RUNX2 in breast cancer cells. 
Our results establish that TRβ suppresses the oncogenic RUNX2 activity in breast cancer 
cells. These findings demonstrate that the suppressive action of T3 is mediated through 
TRβ but not TRα and support mechanistic linkage of thyroid hormone control with breast 
cancer activation and repression as well as provide potential therapeutic targets that are 
based on selective modifications in thyroid hormone receptor relationships. 
 
3.3. Materials and Methods 
Cell Culture and Treatments.  
MCF10A cells were grown in DMEM/F-12 (1:1) (Hyclone), supplemented with 
5% horse serum (Gibco), human insulin (10 µg/ml), human EGF (20 ng/ml), cholera 
toxin (100 ng/ml), hydrocortisone (0.5 µg/ml), and L-glutamine (2 mM) (Millipore 
Sigma). MDA-MB-231 were maintained in αMEM supplemented with 10% fetal bovine 
serum (Life Technologies), and L-glutamine (2 mM). Both cell lines were grown in the 
presence of penicillin-streptomycin (200 IU/L) (Cellgro/Mediatech). Cells were 
maintained at 37°C, 5% CO2, and 100% humidity. For hormone and drug treatments, 
cells were maintained in charcoal stripped serum (Sigma). MCF10A and MDA-MB-231 
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cells were purchased from American Type Culture Collection and authenticated via Short 
Tandem Repeat analysis in January 2018. 
Transient Transfections and Cloning Transfections were performed using 
Lipofectamine 3000 (Thermo Scientific) following manufacturer’s directions. The 
pDEST515-FLAG-THRB plasmid is the same used in prior work, as was the negative 
control vector [18]. We cloned pDEST515-FLAG-THRA using MCF10A cDNA 
(Appendix A-1). The amplicon was purified from an agarose gel with the Monarch® Gel 
Extraction Kit (New England Biolabs) and both the pDEST515-FLAG-THRB backbone 
vector and the THRA amplicon were digested with HindIII and BamHI (New England 
Biolabs). The THRB cds dropped out from the backbone and the THRA cds 
corresponding to the TRα1 variant was ligated into the vector. The identity of 
pDEST515-FLAG-THRA was confirmed by Sanger sequencing. 
Immunoblot.  
Proteins were isolated from whole cells in lysis buffer (20mM Tris-HCl, pH 8, 
137mM NaCl, 10% glycerol, 1% Triton X-100, and 2mM EDTA) containing Halt 
Protease Inhibitor Cocktail (Thermo Scientific 78410) as previously described [19]. 
Nuclear proteins were prepared with NE-PER Nuclear and Cytoplasmic extraction 
reagents (Thermo Scientific 78833) per manufacturer’s protocol. Proteins were resolved 
by polyacrylamide gel electrophoresis on Novex 10% Tris-glycine gels (Invitrogen) and 
immobilized onto Protran nitrocellulose membranes (GE Healthcare) by electroblot (Bio-
Rad Laboratories). Specific proteins were detected by immunoblotting with the indicated 
antibodies (Appendix A-2). Immunoreactive proteins were detected by enhanced 
chemiluminescence (GE Healthcare), visualized by VersaDoc MP3000 (Bio-Rad 
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Laboratories), and intensities were quantified by Image Lab (Bio-Rad Laboratories). 
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR).  
Total RNA was extracted using RNeasy Plus Kit (Qiagen) according to 
manufacturer’s protocol. cDNA was then generated using 5X RT Mastermix (ABM). 
Gene expression was quantified by qRT-PCR using 2X BrightGreen Mastermix (ABM) 
on a QuantStudio 3 real-time PCR system (Applied Biosystems). Primers are indicated in 
Appendix B-1. Fold change in gene expression compared to endogenous control GAPDH 
was calculated using the ddCT method.   
siRNA Transfection.  
Loss of function was assayed by siRNA using On Target Plus siRNAs targeting 
human TRβ (L-003447-00) with non-targeting siRNA (D-001810-10-20; GE Healthcare 
Dharmacon) as control. Cells were plated at a density of 2.5 x 105 per well and 
transfected with 50nM–200nM siRNA with Oligofectamine per manufacturer’s protocol 
(Invitrogen/Life Technologies). The effect of knockdown of TRβ on endogenous RUNX2 
and metastatic markers was determined after 24 hours 
Chromatin Immunoprecipitation (ChIP).  
Binding to RUNX2 chromatin was determined by ChIP-PCR. Cultured human 
breast cells were cross-linked with 1% formaldehyde for 10 minutes, neutralized with 
125mM glycine, rinsed twice with PBS, pelleted, and frozen. Cells were lysed in the 
presence of protease inhibitors (Roche) and chromatin was extracted and sonicated to 
200–500 bp in size using a Covaris S220 Focused-ultrasonicator. Sonicated cell lysate 
was incubated with 2 g of indicated antibody (Appendix B-2) and rotated overnight at 
4°C. Twenty microliters of Protein G Dynabeads (Invitrogen) were blocked in 0.5% BSA 
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and resuspended in lysis buffer, added to the lysate/antibody mix, and rotated at 4°C for 3 
hours. Complexes were washed extensively, eluted, and incubated at 65°C overnight to 
reverse cross-links. Samples were treated with ribonuclease A, incubated with Proteinase 
K, phenol/chloroform extracted, and ethanol precipitated. Pellets were resuspended in 70-
L 10mM Tris-HCl, pH 8. Fold binding over IgG was determined by qRT-PCR. 
Reporter Assay.  
Constructs were described in a prior publication [19]. We co-transfected the -763 
to -16 pGL3 luciferase reporter plasmid with pDEST515-FLAG-THRB in MCF10A and 
MDA-MB-231 cells and recorded luminescence after 48 hours as previously described. 
SV40 renilla construct was omitted due to reports of functional thyroid hormone response 
elements (TRE) [28]. 
DNA Pulldown Assay.  
The assay performed was as described in a published protocol with the following 
optimizations [29]. MyOne T1 Streptavidin beads (Invitrogen) were rinsed twice with 
binding buffer (20 mM HEPES, 30 mM KCl, 1 mM EDTA, 10 mM (NH4)2SO4, 1 mM 
DTT, 0.2% (v/v) Tween-20, pH 7.6), incubated with 5 ng of biotinylated probe at 4°C for 
1 hour, and then washed twice with binding buffer. 350 µg of nuclear protein extract was 
precleared with beads and 8 µg of sheared herring sperm DNA (Promega) for 15 minutes 
at room temperature. The lysate was combined with the probe-bound beads. Volume was 
brought to 0.75 ml with wash buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 
0.5% (v/v) NP-40, pH 7.5) and KCl was added to a final concentration of 300 mM for 
incubation at 4°C for 1.5 hours. The beads were then washed three times with wash 
buffer, once with water, and proteins were eluted for immunoblot. 
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Statistics.  
All statistical analyses were performed using GraphPad Prism software. Unless 
otherwise indicated an unpaired T-test (p < 0.05) was used for comparisons between two 
sets, a 2-way ANOVA followed by a multiple comparisons test (p < 0.05) was used to 
compare groups, and data are represented as means  standard deviation. 
 
3.4. Results 
3.4.1 TR expression is reduced in aggressive breast cancer 
Basal-like breast tumors exhibit elevated expression of RUNX2 [30]. We have 
previously reported an inverse relationship between TRβ and RUNX2 in thyroid cancer, 
providing a basis for the compelling question if a similar dynamic relationship is present 
in breast cancer. Both TRα and TRβ are both expressed in normal breast tissue [31], 
necessitating examination of the expression levels for the THRA and THRB genes. We 
interrogated RNA expression data from The Cancer Genome Atlas PanCancer Atlas 
using the cBioPortal interface [32, 33] (Fig 11). THRB was significantly repressed in the 
most aggressive basal-like tumors compared to other molecular subtypes. THRA 
expression was strikingly reduced in the basal-like breast tumors, although there was also 
increased expression of THRA in HER2 positive tumors. Similar to THRB, THRA 
expression does not vary significantly in the differentiated normal-like, luminal A, and 
luminal B cancers. In conclusion, the most aggressive basal-like breast cancers exhibit 
the lowest expression of both TRs.  
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Figure 11: Baseline expression of thyroid hormone receptors and RUNX2 in breast cells. A) 
THRB RNA expression is significantly reduced in basal-like breast tumors in comparison to all other 
subtypes. B) THRA RNA expression is significantly repressed in Basal-like breast cancers and greatest in 
HER2 expressing tumors. Other significant differences are indicated in the figure. C) MCF10A expresses 
higher levels of THRB mRNA than MDA-MB-231 (n=4, p<0.05). Both MCF10A and MDA-MB-231 
express comparable THRA mRNA (n=4, p>0.05). D) MCF10A express greater levels of TRβ protein than 
MDA-MB-231, while MDA-MB-231 express greater levels of TRα protein than MCF10A cells as 
measured by immunoblot (n=6, p<0.05). * p<0.05, *** p<0.001, **** p<0.0001, n.s. not significant 
 
3.4.2 Thyroid hormone repression of RUNX2 is driven by TRβ. 
MCF10A mammary epithelial-like cells and MDA-MB-231 triple negative breast 
cancer cells were examined to determine whether treatment with T3 can modify RUNX2 
expression. Following 24 hours of treatment with 10-8 M of T3 to model euthyroid serum 
conditions, RNA was isolated from the cells for analysis by qPCR and protein for 
immunoblot analysis. T3 treatment significantly decreased RUNX2 mRNA and protein 
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levels in both cell lines after 24 hours (Fig 12 and Appendix B-3).  
 
Figure 12: RUNX2 expression is reduced by Thyroid Hormone Treatment. MCF10A and 
MDA-MB-231 were treated with T3 at 10-8 M for 24 hours. A) Expression of RUNX2 was measured by RT-
qPCR (MCF10A: n=6, p<0.001. MDA-MB-231: n=6, p<0.01). B) RUNX2 protein levels were determined 
by immunoblot (MCF10A: n=9, p<0.01. MDA-MB-231: n=9, p<0.05). * p <0.05, ** p<0.01, *** p<0.001 
 
Unlike in the thyroid cells where we previously characterized the action of T3 on 
expression of the RUNX2 gene, breast cells express both TRα and TRβ. The DNA 
binding domain of TRs is highly conserved with significant homology between both TRs 
resulting in competency for both receptors to bind the same canonical response element 
on chromatin [34], however there are genes that are selectively regulated by a single TR 
[35-37]. To evaluate whether one or both TRs can repress RUNX2 expression MDA-MB-
231 cells were transiently transfected with vectors that overexpress either TRα or TRβ. 
When RUNX2 protein was quantitated by immunoblot analysis, TRβ expression was 
observed to reduce RUNX2 levels. However, when cells were transfected with a TRα 
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vector, RUNX2 expression did not change (Fig 13). To determine whether TRα could act 
as a negative regulator of TRβ, TRα was also overexpressed in MCF10A cells, which 
robustly express TRβ. No change to RUNX2 was observed, showing that increased levels 
of TRα did not inhibit the suppressive activity of TRβ. These results provide a functional 
indication of the specificity for TRβ regulation of RUNX2 in breast cancer. 
 
Figure 13: TRβ, and not TRα, Represses RUNX2. A) Transient transfection into MDA-MB-231 
cells of a plasmid encoding TRβ significantly reduced RUNX2 levels (n=6, p<0.01), however transfection 
with a TRα vector did not significantly alter RUNX2 protein expression (n=6, p>0.05) with B) 
representative immunoblots. Transient transfection of TRα did not alter RUNX2 mRNA levels in C) and 
MCF10A D) MDA-MB-231 cells. ** p <0.01, n.s. not significant 
 
To confirm that TRβ can repress RUNX2, TRβ expression was knocked down by 
siRNA in the normal breast cell line MCF10A (Fig 14). Decreased levels of TRβ 
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increased RUNX2 expression, and we also observed a significant increase in expression 
of the RUNX2 upregulated genes CCND1 [38], MMP9 [22], and VEGFA [24, 25] were 
also observed after siRNA knockdown of TRβ. Importantly, each of these have a 
demonstrated role in the process of tumorigenesis. These results reinforce the TRβ 
repression of RUNX2 expression with the functional consequence of repressing RUNX2 
driven pro-tumorigenic activity. 
 
Figure 14: Knockdown of THRB in MCF10A enhances RUNX2 and RUNX2 activity. A) 
Treatment of MCF10A with siRNA against TRβ repressed its expression in the cells as confirmed by 
immunoblot. B) Loss of TRβ mRNA correlated with significantly increased RUNX2 expression as 
measured by RT-qPCR (n=6, P<0.05). There was also an observed increase in the RUNX2 upregulated 
genes CCND1 (n=4), MMP9 (n=4) and VEGFA (n=4). * p<0.05 
 
3.4.3 TRβ binds to the RUNX2 promoter 
We previously mapped TREs in the P1 promoter of the RUNX2 gene and 
demonstrated that TRβ directly interacts with these regions in thyroid cells [19]. 
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Following ChIP from MCF10A cells there was significant enrichment of the RUNX2 
promoter utilizing a TRβ antibody as compared to IgG control (Fig 15A). This was 
further validated by a DNA pulldown assay utilizing biotinylated oligonucleotides 
containing a previously characterized TRE. Incubation of this oligonucleotide with 
MCF10A lysate revealed TRβ binding, which was ablated when the TRE was mutated 
(Fig 15B). Additionally, a luciferase reporter vector was co-transfected with a TRβ 
expression vector. Nominal, but insignificant repression was observed in MCF10A, in 
contrast to the MDA-MB-231 cells that express very low levels of endogenous TRβ 
where there was significant repression (Fig 15C). Taken together, these data provide 
evidence for direct interaction between TRβ and the RUNX2 gene to alter gene 
expression. 
 
Figure 15: TRβ Binds to the RUNX2 Promoter. A) Chromatin immunoprecipitation-PCR of 
RUNX2 in MCF10A cells (n=3, p<0.05). B) Biotinylated RUNX2 proximal promoter successfully pulls 
down TRβ from MCF10A lysate as shown by immunoblot. Mutation of the TRE ablated this interaction. C) 
Cotransfection of an expression vector and luciferase reporter vector in breast cell lines. Nominal 
repression of the promoter due to TRβ overexpression was observed in MCF10A (n=2, P>0.05) and MDA-





These results demonstrate that T3 mediated RUNX2 repression in breast cancer is 
facilitated by TRβ and not via TRα. Importantly, we have identified a gene that is 
preferentially regulated by TRβ and not TRα. This specificity provides a mechanistic 
insight into the observed TRβ tumor suppressor role and the putative oncogenic role of 
TRα [7]. We have also demonstrated a common pathway in breast and thyroid cancers, 
which demonstrates the value of this pathway for further understanding the observed 
epidemiological link between both diseases [10-13]. 
To understand the etiology of the link between breast and thyroid tumors, it is 
vital to understand the actions of shared tumor suppressors and oncogenes. The 
mechanisms by which TRβ represses tumorigenesis is an important question in tumor 
biology and pathology but minimally understood. Previously characterized mechanisms 
of TRβ-mediated tumor suppression in breast cancer focused on regulation of the 
PI3K/Akt [39], Ras/MAPK [40], and JAK2-STAT3 [4] pathways, and induction of 
mesenchymal-to-epithelial transitions [41]. In thyroid cancer, TRβ suppresses 
tumorigenesis through PI3K/Akt [42] and RUNX2 [19]. Our work here demonstrates that 
in addition to shared tumor suppression by PI3K/Akt, TRβ acts to repress RUNX2 
expression in both cell types. The Ras/MAPK and JAK2-STAT3 pathways and epithelial 
characteristics are all features regulated by TRβ in breast cancer that merit further 
investigation in thyroid cancer. Revealing common features can aid in understanding the 
metachronous nature of the two diseases. 
The T3-TRβ-RUNX2 axis could be a common signaling pathway in a variety of 
cancers. In addition to the role of RUNX2 in breast and thyroid tumorigenesis, RUNX2 
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has been proposed to contribute to the development of prostate cancer [43], liver 
carcinoma [44], colon cancer [45], and melanoma [46]. TRβ and/or T3 has been shown to 
have anti-tumor roles in these cancers as well. Overexpression of TRβ reduces cellular 
proliferation in vivo in hepatocellular carcinoma [5]. Thyroid hormone also induces 
differentiation of colon cancer stem cells [47]. In melanoma, a loss of heterozygosity of 
the THRB gene has been observed [48], consistent with functioning as a tumor suppressor 
gene, and T3 stimulation of dendritic cells represses melanoma tumor size in a xenograft 
[49]. These findings suggest that the T3-TRβ-RUNX2 signaling program may be 
operational in a spectrum of tissues.  
This work expands the understanding for involvement of the TRs in 
tumorigenesis and are consistent with the potential for TRs to improve diagnostic or 
prognostic capabilities for cancer diagnosis and treatment responsiveness. Aside from the 
treatment of existing thyroid disorders or to alleviate side effects from therapeutics, direct 
modulation of thyroid hormone levels is undesirably as potential confounding effects 
must be considered. TRα1 is associated with more advanced breast tumors [7, 27] and 
potential side effects for the cardiovascular system, that includes tachycardia and 
hypertension which result from TRα signaling in the heart [50]. Additionally, the αVβ3 
integrin is responsive to thyroid hormones, primarily thyroxine, promoting pro-oncogenic 
activity through the MAPK pathway [51, 52] and, through studies utilizing prostate 
cancer cells and osteoblasts, it was shown that αVβ3 induces an increase in expression 
and transcriptional activity of RUNX2 [53, 54]. However, it is not clear whether αVβ3 
can regulate RUNX2 in response to thyroid hormones. Encouragingly, thyromimetic 
compounds have been developed as selective agonists to TRβ [55, 56] and may stimulate 
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TRβ tumor suppressor activity in cancer. There is encouraging evidence that 
thyromimetics can enhance the sensitivity of aggressive breast cancer cells to certain 
chemotherapies [8]. Our work demonstrates another mechanism by which TRβ 
pharmacological stimulation may be beneficial. 
In closing, our findings demonstrate a tumor suppressive function of TRβ shared 
by multiple tissue types. The T3-TRβ-RUNX2 pathway is active in a variety of cancers. 
Understanding the role of this signaling in tumorigenesis may be leveraged for 
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CHAPTER 4: Common Tumor Suppressive Signaling of Thyroid Hormone 
Receptor Beta in Breast and Thyroid Cancer Cells. 
 
4.1. Abstract 
An epidemiological link between breast cancer and thyroid cancer has been 
established. Both of these diseases primarily impact women and prior history of one of 
these tumors increases the chance of an individual developing the other cancer in the 
future. Although the link has been established, the cause of the association is still 
unknown. The thyroid hormone receptor beta (TRβ) is a tumor suppressor in both breast 
and thyroid cancer and further understanding of the molecular mechanisms by which TRβ 
abrogates tumorigenesis could aid in understanding the link between both malignancies. 
Here, we introduce TRβ into the MDA-MB-468 basal-like breast cancer cell line and 
perform RNA-sequencing to determine changes in transcriptomic signaling. The TRβ 
expressing MDA-MB-468 cells exhibit a more epithelial character as determined by 
PCA-PAM50 score and through repression of mesenchymal cytokeratins. The epithelial 
to mesenchymal transition pathway is also significantly reduced. The MDA-MB-468 
dataset was also compared to RNA sequencing results from the thyroid cancer line 
SW1736 to determine which genes are TRβ regulated across both tissue types. Stearate 
biosynthesis was revealed as upregulated from the shared gene set, a lipid which is 
known to repress breast tumorigenesis. These data provide novel insights into the 
molecular mechanism by which TRβ suppresses breast tumorigenesis and suggests a 
common metabolic role in breast and thyroid cancer as well a role for TRβ in the 
maintenance of epithelial cellular identity.  
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4.2. Introduction 
A link has been established between breast cancer and thyroid cancer. 
International studies show that patients with breast cancer are at an increased risk of 
developing a future thyroid tumor and thyroid cancer increases the risk of breast cancer 
(1-7). Both diseases are among the most diagnosed cancers in women, making 
understanding this association an important public health concern. Breast cancer is the 
most commonly diagnosed cancer in women and thyroid cancer is projected to be the 4th 
most common cancer in the United States by 2030 and the 2nd most commonly 
diagnosed cancer in women, after breast (8). Strikingly, there are no good explanations 
available for the etiology of this association. 
A common factor in both diseases is loss of expression of the thyroid hormone 
receptor beta (TRβ) (9,10). TRβ is a nuclear hormone that is responsive to levels of 
triiodothyronine (T3). It is capable of binding to thyroid hormone response elements 
(TRE) both in the presence and absence of ligand in order to regulate transcription. The 
tumor suppression activity of TRβ has been validated through in vitro and in vivo studies. 
In xenograft experiments, restoration of TRβ expression limits tumor growth in follicular 
thyroid cancer cell lines (11), in a luminal A breast cancer cell line (12), and in a basal-
like breast cancer cell line (13). Loss or mutation of TRβ also leads to the development of 
tumors in mice (14,15). Notably, TRβ regulates pathways that are drivers of both breast 
and thyroid cancer. This includes repression of PI3K signaling and repression of RUNX2 
expression (9-11,16,17). 
Our laboratory has recently performed an analysis of the TRβ transcriptome in an 
anaplastic thyroid cancer (ATC) cell line. In this study, we combine that analysis with a 
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similar experiment performed in a basal-like breast cancer cell line, MDA-MB-468. TRβ 
has previously been demonstrated to exert a strong anti-tumor effect in these cells by 
independent laboratories (13,16,18). Briefly, the MDA-MB-468 cell line expresses very 
low endogenous TRβ and through viral transduction multiple laboratories have been able 
to restore TRβ expression exogenously. Increased expression of TRβ reduced the tumor 
burden in vivo. Importantly, this anti-tumor activity included repression of growth 
markers and increased anti-metastatic potential; mice with tumors expressing TRβ 
exhibited fewer metastatic lesions than control animals (13,18). Additionally, when the 
animals were rendered hypothyroid, the number of metastatic lesions in the animals 
increased (18). These data are suggestive of a vital role for T3 in TRβ-mediated tumor 
suppression. Transcriptomic analysis of the MDA-MB-468 cells demonstrated TRβ 
regulates breast differentiation, invasive genes, and metabolic signaling in these cells. 
When this analysis was compared to our prior analysis of ATC line SW1736 we were 





MDA-MB-468 cells were maintained at 37°C, 5% CO2, and 100% humidity. The 
cells were grown in αMEM supplemented with 10% fetal bovine serum (Life 
Technologies), and L-glutamine (2 mM) as well as the addition of penicillin-streptomycin 
(200 IU/L) (Cellgro/Mediatech). Identify of the cells was confirmed by short tandem 
repeats via the Promega GenePrint10 System in the Advanced Genome Technologies 
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Core at the University of Vermont (May 2019). The cells were tested for mycoplasma by 
PCR using 10 µM of each primer (May 2019) (Appendix C-1).  
The MDA-MB-468 cells were transduced as previously described (19). Briefly, 
viral particles containing pCDH-MSCV-EF1-GFP-Puro and pCDH-MSCV-EF1-GFP-
Puro-TRβ were generated in human embryo kidney 293 cells and the particles were used 
to transduce the cells to express either the empty vector (468-EV) or overexpress TRβ 
(468-TRβ). Following lentiviral transduction, the media was further supplemented with 1 
µg/ml puromycin (Gold Bio). 
Immunoblot 
Protein was extracted from the cells by treatment with lysis buffer (20mM Tris-
HCl [pH 8], 137mM NaCl, 10% glycerol, 1% Triton X-100, and 2mM EDTA) containing 
Protease Inhibitor Cocktail 78410 (Thermo Scientific). Following quantification by 
Bradford assay, the resulting lysate was resolved by polyacrylamide gel electrophoresis 
with 10% sodium dodecyl sulfate gels EC60752 (Life Technologies) and immobilized 
onto nitrocellulose membranes (GE Healthcare) by electroblot (Bio-Rad Laboratories). 
Membranes were probed for TRβ with the antibody MA1-216 (Thermo Scientific) and 
for β-actin with MA5-15739 (Thermo Scientific). Blots were imaged using enhanced 
chemiluminescence (Thermo Scientific) on a ChemiDoc XRS+ (Bio-Rad Laboratories). 
RNA Extraction and Library Generation 
468-EV and 468-TRβ cells were plated at 80% confluency and hormone starved 
for 24 hours in phenol red free αMEM with charcoal-stripped fetal bovine serum. 10-8 M 
T3 was added and incubated for 24 hours prior to sample collection. Total RNA was 
extracted and purified using RNeasy Plus Kit (Qiagen) according to manufacturer’s 
 107 
protocol. Purity of the total RNA samples was assessed via BioAnalyzer (Agilent) and 
samples with a RIN score >7 were used for library construction. rRNA was depleted 
using 1 μg of total RNA and strand-specific Illumina cDNA libraries were prepared using 
the NEBNext Ultra II RNA library kit with 7 cycles of PCR (New England Biolabs). 
Library quality was assessed by BioAnalyzer (Agilent) to ensure an average library size 
of 300 bp and the absence of excess adaptors in each sample. RNA-Seq libraries were 
pooled and sequenced with 50 bp single-end reads on the Illumina HiSeq 1500. Quality 
scores across sequenced reads were assessed using FASTQC. All samples were high 
quality. For alignment and transcript assembly, the sequencing reads were mapped to 
hg38 using STAR. Sorted reads were counted using HTSeq and differential expression 
analysis was performed using DESeq2. Genes with a p-value of <0.05 and a fold change 
of >2 were considered differentially expressed and were used for further analysis through 
Ingenuity Pathway Analysis (IPA) (Qiagen), Gene Set Enrichment Analysis (GSEA), and 




One of the major effects observed in the SW1736 cells was a TRβ-mediated 
increase in differentiation markers (as discussed in chapter 3). TRβ has also been 
demonstrated to reduce stemness in luminal breast cancer cell lines, further suggestive of 
TRβ having a role in tumor differentiation (21). Following confirmation of TRβ 
overexpression in the MDA-MB-468 cells we performed RNA sequencing in order to 
determine the transcriptomic profile (Appendix C-2). Of interest to the question of 
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differentiation is expression of the PAM50 genes, which are used to determine breast 
cancer intrinsic subtypes (22,23). We used the Principle Component Analysis-based 
iterative PAM50 subtyping (PCA-PAM50) algorithm on our sequencing data to 
quantitatively assess subtype scores for the different experimental conditions (Fig 16) 
(24). The scores for the luminal A and luminal B subtype were greatest in the 468-TRβ 
cells, particularly following T3 treatment. Additionally, there was a significant reduction 
in the basal-like breast cancer score in the 468-TRβ cells treated with T3. Notably, there 
was a 60% increase in expression of ESR1, a gene which expression effectively defines 
the luminal subtypes of breast cancer. These results are suggestive of a decrease in the 
aggressive, basal-like phenotype.  
 
Figure 16: Thyroid Hormone Receptor Beta Alters Genes that Determine Breast Intrinsic Subtype. 
Each sample of cells was evaluated to determine scoring for the different intrinsic subtypes of breast 
cancer. A and B) TRβ increased the luminal subtype scores. C) The combination of TRβ and cognate ligand 
reduced the basal-like score of these cells. D) Expression of ESR1 increased following T3 treatment in the 
468-TRβ cells. 
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The changes in gene expression were further delineated by cluster analysis 
(Figure 17). Using k-means clustering we separated the MDA-MB-468 differentially 
expressed genes (DEGs) into 7 clusters representing different patterns of gene expression. 
Analysis using IPA revealed alterations in cancer relevant pathways including interferon 
signaling, glioblastoma multiforme signaling, and stearate biosynthesis. Interferon 
induces anti-tumor activity through the stimulation of JAK1-STAT1 activity, which 
upregulates genes that reduce proliferation and induce apoptosis (25). The IPA 
glioblastoma multiforme signaling network incorporates multiple pro-tumor pathways 
including MAPK, PI3K, and WNT signaling. Stearate biosynthesis results in increased 
levels of the fatty acid stearic acid. Stearic acid has been shown to slow the growth of 
breast tumors and induce apoptosis (26-29). Notable upstream regulators derived from 
the IPA clusters include effectors within the interferon-JAK1-STAT1 pathway, primarily 




Figure 17: Expression of Thyroid Hormone Receptor Beta Induced Alterations to the Transcriptome 
and Signaling Networks. A) Cluster analysis of DEGs (p-value < 0.05 and an absolute log2FoldChange ≥ 
1) reveals distinct patterns of gene regulation. Clusters 1 and 3 are genes that can be repressed or induced 
by TRβ in absence of ligand. Clusters 2, 5, and 6 showcase genes that are T3 regulated in absence of 
exogenous TRβ, however genes in clusters 5 and 6 are more strongly regulated when TRβ expression is 
increased. The genes in clusters 4 and 7 are dependent upon both TRβ and T3 for differential expression. B) 
Ingenuity Pathway Analysis (IPA) was utilized to determine which signaling networks were altered. Up to 
two pathways form each cluster are represented, at p-value < 0.05 and absolute z-score >0. C) IPA was also 
used to predict upstream regulators, up to 10 were selected for each cluster as determined by p-value with a 
threshold of p-value < 0.05. 
The effects that TRβ overexpression had on the transcriptome included both direct 
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regulation of genes (primary regulation) and, due to allowing 24 hours of signaling 
following hormone treatment, for the directly regulated genes to exert additional changes 
in gene signaling through downstream transcription factors (secondary regulation). In 
order to determine putative secondary regulators the clusters were subjected to ChEA 
(Figure 18) (20). None of the transcription factors overrepresented in the analysis were 
induced or repressed at a level necessary to make the threshold to be considered a DEG, 
however ESR1 expression was significantly altered as shown in Figure 16. Additionally, 
SUZ12, SMAD4, GATA2, NELFE, and TRIM28 were uncovered from the equivalent 
analysis performed in SW1736 cells (Appendix B-6). Of these, NELFE was found to be 
repressed by TRβ in the thyroid cells (Appendix A-6), and is a transcription factor that 
aids in the induction of epithelial-to-mesenchymal transition (EMT) in pancreatic cancer 
(30). Additionally, GATA2 is known to interact with TRβ2 to repress thyroid stimulating 
hormone β (31). TRIM28 is known to interact with the SWI/SNF complex, a chromatin 
remodeling complex TRβ interacts with (19), and promotes mammosphere formation 
(32), which TRβ inhibits (21). 
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Figure 18: Chromatin Immunoprecipitation Enrichment Analysis Reveals Putative Secondary 
Regulators. The DEGs from each cluster were input into the ChEA webapplet at 
https://amp.pharm.mssm.edu/Enrichr/. Transcription factors from the ENCODE and ChEA Consensus TFs 
dataset was used to assign statistical values to each factor. 
In order to further investigate the pathways that TRβ regulates in breast cancer the 
DEGs from 468-EV and 468-TRβ cells, both T3 treated, were directly compared to each 
other via GSEA using the Gene Ontology and Hallmarks datasets (Appendix C-3). The 
top three pathways, by significance and effect size, were all processes that were driven by 
a change in cytokeratin expression (Figure 19). The set of cytokeratins that TRβ 
repressed includes markers of breast cancer aggressiveness that included in diagnostic 
assays, including the PAM50 gene set (33,34). Additionally, there are studies which 
highlight the importance of some of these genes for invasiveness. Notably, expression of 
KRT14 correlates with tumor stage and a basal-like phenotype (35). KRT5, KRT14, and 
KRT80 are also drivers of an invasiveness in breast tumors (35,36). Lastly, KRT16 is a 
prognostic marker as expression correlates with reduced survival (37). Consistent with 
the pro-invasive role of these cytokeratins, there was also a significant reduction in the 
expression of EMT drivers. 
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Figure 19: Thyroid Hormone Receptor Beta Represses Invasive Pathways. A) A pairwise comparison 
between EV-T3 and TRβ-T3 revealed multiple Gene Ontology pathways that are driven by expression of 
cytokeratins were repressed. B) KRT genes were significantly repressed in MDA-MB-468 cells that express 
exogenous TRβ following T3 treatment. C) Pairwise comparison between EV-T3 and TRβ-T3 showed 
repression of epithelial to mesenchymal transition. 
We have recently revealed the TRβ transcriptome within the anaplastic thyroid 
cancer cell line SW1736 and so we performed pairwise comparisons between SW1736-
EV-T3 and SW1736-TRβ-T3 and between 468-EV-T3 and 468-TRβ-T3 in order to 
determine which genes are differentially expressed independent of cell type. The majority 
of DEGs were regulated by TRβ-T3 in only one of the two cell types, however a subset of 
genes were regulated by TRβ-T3 in both. A total of 255 genes were induced by T3 in both 
cell lines and 70 genes were repressed (Figure 20). These genes were used for pathway 
analysis using the IPA algorithm and the top predicted pathways were examined to 
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determine cancer relevance. An important shared pathway uncovered was stearate 
biosynthesis. Four genes which encode biosynthetic enzymes were T3-induced in both 
SW1736 and MDA-MB-468 cells. Additionally, the shared gene set was used for GSEA 
using the Gene Ontology dataset (Appendix C-3 and C-4), which revealed repression of 
chromatin organization processes and induction of stress responses, including proteolytic 
signaling (Appendix C-5). 
 
Figure 20: A Subset of Genes are Regulated by TRβ in Breast and Thyroid Cancer Cells. A) Pairwise 
comparisons of 468-EV-T3 and 468-TRβ-T3 along with SW1736-EV-T3 and SW1736-TRβ-T3 were used to 
determine which genes were regulated in a tissue agnostic manner. 255 genes were upregulated and 70 
genes were repressed independent of cell type. B) IPA was used to predict pathways of these 325 genes and 
C-D) stearate biosynthesis was examined in closer detail, demonstrating induction of enzymes necessary 
for the conversion of palmitate to stearate. 
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4.5. Discussion 
Restored expression of the tumor suppressor TRβ in the breast cancer cell line 
MDA-MB-468 profoundly altered the transcriptome of the cells. Existing data from the 
cell line shows that TRβ acts to repress proliferation and migration in vitro as well as 
tumor growth and metastasis in vivo (13,16,18). Our work here adds to that understanding 
by providing evidence of the signaling events that result from TRβ activity. Importantly, 
there was a change in the set of genes that are used to define breast cancer subtypes and a 
change in EMT markers, revealing that the mesenchymal-like MDA-MB-468 cells were 
shifting to be more epithelial, and thus differentiated, in character. This is further 
supported by the observed reduction of pro-invasion and pro-metastatic cytokeratins. An 
induction of cellular differentiation could also explain why loss of TRβ has been found to 
decrease the efficacy of chemotherapeutics in basal-like breast cancer cells (38). 
Through comparison of a tumor suppressor in both a thyroid and breast cancer 
cell line we have revealed common signaling between both cell types. Notably, enzymes 
involved in the biosynthesis of stearic acid were revealed, a lipid that has a profound anti-
tumor role in breast cancer apoptosis (26-29). Not only does the data in this study suggest 
that TRβ induces expression of stearate synthetic enzymes, but also that stearate could 
have unrealized anti-tumor activity in thyroid cancer. Importantly, the anti-tumor 
properties of stearate are similar to that which has been observed to be performed by 
TRβ. This includes anti-proliferative, anti-metastatic, and pro-apoptotic effects. 
Stearic acid has also been found to have a relationship with obesity, a risk factor 
for the development of both breast cancer and thyroid cancer (39-42). Levels of stearic 
acid in women with larger adipocytes are reduced (43), and stored stearic acid is 
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inversely correlated with BMI (44). Additionally, stearate is a poor substrate for the 
synthesis of triglycerides, which further suggest an anti-adiposity effect (45). Stearic acid 
levels may be a connection between obesity and risk of malignancy in both breast and 
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Breast and thyroid cancers are two malignancies with highest incidence in 
women. These cancers often occur metachronously. Women with thyroid cancer are at 
increased risk for subsequent breast cancer; women with breast cancer have an increased 
incidence of later development of thyroid cancer suggesting a common etiology. This 
bidirectional relationship is reported worldwide, however the underlying reasons for this 
co-occurrence is unknown. In this review, we summarize the current epidemiological 
evidence and putative mechanisms of these metachronous or synchronous cancers. Key 
potential causative factors are chemotherapy and radiotherapy of the primary tumor, 
genetic variants linking the two diseases, hormonal signaling both from the thyroid gland 
and from estrogens, lifestyle and environmental factors. There is a critical need for 
additional epidemiological studies focused on gender and regional incidence together 
with molecular investigations on common tumorigenic pathways in these endocrine 
cancers. Understanding the putative mechanisms will aid in the diagnosis and clinical 
management of both diseases. 
 
5.2. Introduction 
Breast cancer is the most common cancer diagnosed in women in the United 
States (U.S.) with over 250,000 cases per year (1). Survivors of breast cancer are at 
increased risk of a second cancer, frequently thyroid cancer (2-4). Thyroid cancer, which 
also predominantly affects women, is of great concern as the incidence in the U.S. has 
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more than tripled over the past decades, including the aggressive variants (5,6). The 
higher incidence is not due to enhanced surveillance and advances in diagnostics; 
increases in tumors of all sizes as well as indolent and aggressive tumors are reported (7). 
Male thyroid cancer rates have doubled since 1975 whereas female rates have tripled (6). 
As 5-year survival rates after thyroid cancer are in excess of 90% (1) and the incidence of 
the disease is increasing, there are now more survivors of thyroid cancer than in the past. 
The risk of a subsequent second primary cancer, most often breast cancer, is increased for 
thyroid cancer survivors (3,4,8). Understanding health risks following treatment is critical 
for improving public health. 
Due to the rising incidence of thyroid cancer in the U.S., and globally (9), it is 
critical to understand the risk factors for thyroid cancer and long-term risks associated 
with the disease. Intriguingly, the increase in incidence can vary dramatically depending 
upon location (9). An increase in thyroid cancer incidence is most pronounced in Asia, 
particularly in South Korea, as compared to other regions. Contributing factors likely 
include improved health care networks and surveillance, environmental influences, 
hereditary factors, radiation exposure, and lifestyle factors. Iodine deficiency is an 
important public health problem in several Asian countries (10), and has been linked to 
an increased chance of developing thyroid cancer, in addition to increased risk of 
thyroidal disorders (reviewed in (11)).  
In contrast to the global increase in thyroid cancer incidence, changes in breast 
cancer incidence vary globally. U.S. incidence has been stable for the past few decades. 
Strikingly, in the 1980s, there was a 30% increase in female total breast cancer diagnoses, 
which is attributed to heightened surveillance (12). In China, breast cancer incidence has 
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also increased, however it is difficult to determine a precise figure due to the varying 
quality of studies (13). This may be a pattern similar to what was observed in the U.S. 
during the 1980s; the rise of breast cancer rates may be a result of China’s rapid growth 
in recent decades and improvements to health care technology and access. Low- and 
middle-income nations, such as South American nations, have exhibited the greatest 
increase in incidence of breast cancer (12). This may also be due to changes in 
surveillance and a result of improvements in health care access and technology. 
Regardless, a myriad of factors may underlie the observed increase in breast cancer rates 
in some regions of the world and the cause is not yet clear. 
Over the last 40 years, studies reveal compelling evidence of a bidirectional, and 
potentially causative, relationship between breast cancer and thyroid cancer. Women with 
breast cancer are at increased risk for developing thyroid cancer; survivors of thyroid 
cancer are more likely to develop breast cancer suggesting common etiological features 
in the development of both tumor types (14). A metachronous relationship between 
thyroid and breast cancers has significant implications for clinical surveillance and 
management of both diseases. Additionally, understanding the etiology of the second 
primary tumor is vital for the development of new preventive strategies, diagnostics, and 
therapeutics.  
 
5.3. What is the Epidemiological Evidence of the Relationship Between Breast and 
Thyroid Cancer? 
In the past few years alone, population studies in Asia, Europe, and the U.S. 
reveal increased incidence of breast cancer among women previously diagnosed with 
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thyroid cancer (15-21). Of note, aggressive follicular thyroid cancer is detected in 
patients with a history of breast cancer more often than the more common papillary 
thyroid cancer (18). Further, and importantly for determining etiology, non-malignant 
thyroid nodules are more common in women with breast cancer than those without breast 
tumors (19). There is an increased risk of developing thyroid cancer following breast 
cancer (16,20). Women with prior benign breast disease also are reported to be at a 
greater risk of thyroid cancer (21). The increased risk of thyroid cancer following breast 
cancer and breast cancer following thyroid cancer is reported in both women and men 
(22). Women with breast cancer are two-fold more likely to develop future thyroid cancer 
and women with thyroid cancer have a 67% greater chance of developing breast cancer 
than the general population. These recent studies are summarized in Table 1. Importantly, 
the metachronous relationship was evaluated in nations with widespread cancer screening 
and nations where screening is becoming more common. In particular, Zhang and 
colleagues evaluated cancer patients between 2001 and 2010 in China, which 
corresponded with investments into cancer registries (17,23). 
 
Table 1: Summary of Studies linking Breast and Thyroid Cancer Incidence. Only the studies 
published in the last 5 years (since 2013) are presented, organized by which cancer was the initial disease. 
Some studies explored the bidirectional relationship and are listed twice. Luo et al (marked with a *) 
examined benign breast disease rather than a breast malignancy, and Shi et al (marked with a **) studied 
thyroid nodules, rather than thyroid cancer. Fold refers to the fold change of risk for the second tumor as 
compared to people who do not have a history of the initial cancer. The sample size classifies patients 
based upon the site of the earlier cancer. Abbreviations used are OR (Odds Ratio), SIR (Standard Incidence  




The clinical characteristics of the initial and metachronous tumors exhibit 
distinctive features compared to non-metachronous cancer patients. The metachronous 
breast tumors following thyroid cancer are more likely to be hormone receptor positive 
than breast cancer patients without this history (16). The metachronous thyroid tumors 
following breast cancer are smaller but more aggressive than the control population of 
females with thyroid cancer without a history of breast cancer. Metachronous thyroid 
cancer is also more common when the initial breast tumor was HER2 positive (24). 
Analysis of Surveillance, Epidemiology, and End Results data revealed patients who 
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developed metachronous breast cancer following a thyroid tumor typically were 
diagnosed with breast cancer at a younger age than average and exhibited histological 
features associated with hormone replacement therapy, implicating a potential role for 
estrogen (18).  
These recent studies highlight the trends observed in prior research and meta-
analyses (25,26). Studies to date have primarily focused on metachronous cancer 
incidence in women as both cancers occur primarily in women (100:1 for breast and 4:1 
for thyroid, female:male). Remarkably, the co-occurrence of these diseases is even 
greater in men. Men with a prior history of breast cancer are 19 times more likely to 
develop thyroid cancer. This link is bidirectional; men with prior thyroid cancer are 29 
times more likely to develop breast cancer (22). Independent confirmation of the 
metachronous risk in male cases is needed. The epidemiological linkage between thyroid 
cancer and breast cancer is bidirectional and data from patients collected globally has 
consistently demonstrated the metachronous relationship. However, larger studies are 
needed to increase confidence as to how much greater a risk there is of a second primary 
tumor as the various studies presented in this review do not report increased risk using 
the same parameters. Further research is needed to determine if certain demographics are 
at greater risk, the role of socioeconomic factors, or if there are geographic hotspots at 
greater risk of metachronous disease.  
 
5.4. What Genetic Factors Link the Diseases? 
There is a strong familial component in the development of cancer. A recent, 
large study examining twins in the Nordic nations estimated hereditability to be 
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approximately 33% of cancer risk (27). There does appear to be some familial link 
between thyroid and breast cancer; a study on Swedish patients found that first-degree 
relatives of women diagnosed with breast cancer are at an increased risk of developing 
thyroid cancer (28). Similar results were observed in a U.S. population (29). Among 
other factors that could drive a familial association, genetics has potentially the greatest 
explanatory power in the link between breast tumors and thyroid tumors as many driver 
mutations are similar in both cancers. Cowden Syndrome is an already recognized 
genetic disorder, arising from mutations to the tumor suppressor PTEN, which increases 
the risk of both breast and thyroid cancer, among other cancers including endometrial and 
gastrointestinal (30,31). PTEN encodes for phosphatase and tensin homolog (PTEN), 
which inhibits the catalytic activity of the enzyme phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase (PI3K) (32). PI3K upregulates the downstream effector 
AKT, which then phosphorylates an array of proteins, ultimately changing gene 
expression. The PI3K-AKT pathway promotes survival, proliferation, and migration to 
drive tumorigenesis. Cowden Syndrome can also be worsened by co-mutations to KLLN 
and genes that make up the succinate dehydrogenase complex (SDHx) (25). KLLN is a 
transcription factor that shares the PTEN promoter and upregulates TP53 to promote 
apoptosis (33). SDHx mutations also dysregulate TP53 through enhanced proteasomal 
degradation of p53 (34). Other genes that feed into the PI3K pathway and apoptosis may 
be involved in the link between thyroid and breast cancers. 
Additionally, germline mutations in PARP4 were identified in women treated for 
both cancers (35). Heightened expression of PARP4 also correlated with longer disease-
free survival and overall survival in breast cancer patients. PARP4 belongs to a family of 
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genes, poly-ADP-ribose polymerases (PARPs) that encode enzymes to catalyze synthesis 
of poly-ADP-ribose (36). Levels of poly-ADP-ribose increase in response to genetic 
insults and is a critical component of DNA repair. PARP inhibitors are used clinically to 
treat ovarian tumors and are in clinical trials for breast cancer (37). However, existing 
drugs do not target PARP4. PARP4 is unique in that it can also be found in the 
cytoplasm, unlike the other members of the PARP family (36). Unfortunately, PARP4 is 
not well characterized and more research is needed to determine the biochemical and 
physiological processes it regulates. 
To date, no other mutations have been demonstrated to be causal agents linking 
metachronous breast and thyroid tumors. More studies to examine patients with histories 
of both diseases are needed to uncover new gene variants. Further, epigenetic changes 
including altered expression of microRNAs and long-noncoding RNAs (lncRNA), 
covalent modification of DNA, and mutations to regulatory elements in the genome could 
be critical. Recently, the lncRNA MANCR, has been demonstrated to be upregulated and 
a driver of aggressive breast cancer (38). MANCR is also upregulated in thyroid cancers 
(39). Such information from these two studies exemplifies common transcriptional 
regulation in both diseases. 
 
5.5. What is the Impact of Cancer Treatment on Future Risk? 
Radiation, despite being a treatment option for breast cancer, is a well-
documented risk factor in the development of cancer and is a major risk factor for thyroid 
cancer (40-42). Multiple recent clinical studies demonstrate alteration of the ability of the 
thyroid to produce hormones following radiotherapy (43-45). Despite this evidence that 
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radiotherapy harms the thyroid, a very large study from Taiwan of over 55,000 patients 
did not report any association between treating breast cancer with radiation and 
subsequent thyroid cancer, nonetheless the results did corroborate the previously 
discussed relationship between thyroid and breast cancers (46). Another study revealed 
that although the use of radiation therapy to treat breast cancer was associated with an 
increased risk of certain tumors, including leukemia and lung cancer, there was not an 
observed increase in the risk of thyroid cancer (47). 
Childhood radiation therapy is documented to increase the chance of a women 
developing breast cancer later in life (48,49) Thyroid tumors are not typically treated with 
beam radiotherapy, but one of the most commonly prescribed treatments for thyroid 
cancer is to treat the patient with radioactive iodide (131I). 131I selectively targets the 
tumor via the sodium-iodide symporter (NIS) to kill the diseased thyroid tissue. However, 
breast tissue expresses NIS to transport iodide into milk and so could be impacted by 
radioactive 131I (50). There is also evidence that dietary iodide intake is protective against 
the development of breast cancer (51). Since the 1960s, numerous studies denote a 
concern for secondary tissue effects with the use 131I treatment for thyroid diseases (52). 
Although increased risk for development of leukemia was determined, no association 
with breast cancer was noted (53-55). Additionally, meta-analysis of studies specifically 
examining 131I treatment for thyroid cancer reveal no association between the use of 131I 
and subsequent development of breast cancer (56). A recent study found no difference in 
breast cancer risk between thyroid cancer patients treated with and without 131I, 
confirming prior observations (57).  
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While the impact of radiotherapy on thyroid function has been extensively 
studied, data on chemotherapy is sparse. Studies on breast cancer patients receiving 
different chemotherapeutic treatments reveal a reduction in serum T4 levels, but 
subsequent recovery of thyroid function and thyroid cancer risk was not assessed (58-60). 
Critically, the impact of chemotherapeutic agents on thyroid function and cancer risk 
needs further study.  
 
5.6. Are Thyroid Disease and Disruptions of Thyroid Hormone Signaling Risk 
Factors? 
Thyroidal status may be an important factor in second tumor development, 
although studies are limited. Clinical implications of thyroid hormone mediated effects 
altering initial tumor development are unclear, data on the impact of thyroid hormone 
levels on the likelihood of developing a tumor are inconsistent (61-63). Regardless, in a 
small clinical study utilizing patients with advanced cancers, including breast tumors, 
ablation of de novo thyroid hormone synthesis and supplementation with T3 prolonged 
patient survival (64). Strikingly, in a mouse xenograft study, more metastases were 
observed in hypothyroid than euthyroid animals, and hypothyroid mice developed 
smaller primary tumors, suggestive of an important role for thyroid hormones on 
tumorigenesis (65). Additionally, the impact of tyrosine kinase inhibitors (TKI) on 
thyroid function has predictive value in determining patient outcomes; patients with 
cancers other than thyroid cancer rendered hypothyroid after TKI treatment have a more 
favorable prognosis, as defined by overall survival (66). The subpopulation of patients 
who experienced drug-induced hypothyroidism and received supplemental T4 exhibited 
 133 
greater odds of overall survival than those with untreated hypothyroidism. The authors 
note that thyroidal dysfunction may be indicative of the effectiveness of the cancer 
treatment but the mechanisms are unknown (66). Overall, studies of drug-induced 
hypothyroidism indicate that thyroid hormone signaling may protect against advanced 
breast cancer. 
The canonical pathway for thyroid hormone action is through the nuclear 
hormone receptors thyroid hormone receptor alpha (TRα) and thyroid hormone receptor 
beta (TRβ). Of these receptors, TRβ is expressed in both breast and thyroid tissue (67). 
TRβ has also been implicated as a tumor suppressor (68). The pathways which TRβ 
regulates have not yet been thoroughly explored, however there is evidence that it 
represses PI3K in both breast and thyroid cancer cells (69,70). TRβ also represses 
transcription of the oncogene RUNX2 in thyroid cancer through an interaction with a 
chromatin-remodeling complex (71,72). RUNX2 is a driver of both breast and thyroid 
cancers and common thyroid hormone mediated mechanisms may be active in both 
tissues (73,74). There is also a non-classical thyroid hormone receptor, the integrin αVβ3, 
which responds to T4 rather than T3, and activates the pro-oncogenic MAPK pathway 
(75). It is probable that the response a tumor has to thyroidal status depends upon the 
genes expressed in the cells due to the multiple receptors that feed into many different 
pathways. 
 
5.7. Does Hormonal Disruption alter Metachronous Cancer Susceptibility? 
Breast cancer is often hormonally driven through upregulation of estrogen and 
progesterone receptors and mimetics of these compounds can be carcinogenic (reviewed 
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in (76)). This relationship has been extensively studied, and although there are still many 
unanswered questions regarding the mechanistic details, there is little doubt concerning 
whether estrogenic signaling can promote breast tumorigenesis. Estrogen is also 
implicated in the development of thyroid cancer, and may explain why women develop 
the disease at roughly 4 times the rate as men (reviewed in (77)). Numerous studies have 
linked endocrine disrupting chemicals (EDCs) to obesity, developmental perturbations 
and hormone-dependent cancers (78). Exposure to EDCs at prenatal and early 
developmental stages are associated with later development of cancers (79), which could 
predisposition the same individual to developing both tumor types; potentially explaining 
why the same person develops both diseases in a short time frame and at a younger age. 
For example, EDCs may stimulate thyroid and breast cancer development through 
estrogenic signaling. Bisphenol A (80) and flame-retardants (81), mimetics of 
endogenous estrogen or xenoestrogens, have been implicated in the development of 
thyroid cancer as well as breast cancers (82). Bisphenol A binds to TRs and antagonizes 
thyroid hormone action (83,84). As TRβ is a tumor suppressor in both thyroid and breast 
cancers, this inhibition may be a common mechanism.  
Epidemiological analysis of hotspots for thyroid cancer development is consistent 
with the hypothesis that an increase in thyroid cancer may be linked to environmental as 
well as lifestyle factors (85). We performed an exploratory analysis in Vermont, 
comparing the breast and thyroid cancer incidence rates in different counties, and 
observed a weak correlation between the two cancer types (Fig 21). A linear trend line fit 
to the data indicated that an increase of breast cancer incidence by 10 per 100,000 women 
corresponded to an increase in thyroid cancer of 1.6 per 100,000 people. An investigation 
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into hotspots where breast and thyroid cancers co-occur could reveal environmental 
factors, including EDCs, that drive both tumor types.  
 
Figure 21: Thyroid Cancer and Breast Cancer Incidence are Positively Correlated among 
Vermont Counties. County-specific age-adjusted thyroid cancer and invasive breast cancer incidence for 
2010-2014 among Vermont females was obtained from the state of Vermont Environmental Public Health 
Tracking Data Explorer. A linear regression was performed to yield a slope of 0.1565 with an R-square 
value of 0.2102. The counties of Essex and Grand Isle were excluded due to insufficient numbers of thyroid 
cancer cases in these small population counties. 
 
Approximately 80% of breast tumors are hormone receptor positive. Endocrine 
therapies via selective estrogen receptor modulators (SERMs) that target estrogen 
receptor alpha are a cornerstone of breast cancer treatment for most patients (86,87). The 
prototypical SERM, Tamoxifen, has been reported to stimulate thyroid stimulating 
hormone (TSH) production (88) and, in a rat model, to induce thyroid tissue proliferation 
(89). In patients on both endocrine therapy and T4 replacement therapy for 
hypothyroidism there is an increase to levels of thyroxine-binding globin, total T4, and 
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TSH (90). What effect SERMs have on thyroid tumorigenesis has not been adequately 
investigated.  
 
5.8. Are Lifestyle Related Environmental Factors Common Between Breast and 
Thyroid Cancer? 
Behaviorally driven environmental factors, include obesity, sedentary lifestyle, 
alcohol consumption, and tobacco usage have been demonstrated to increase cancer risk 
(91). Breast cancer risk increases with weight gain, alcohol consumption, and from a lack 
of regular exercise (92,93). Shared risk factors with thyroid cancer are candidates to the 
etiology of metachronous tumors. Obesity is a risk factor to the development of 
epithelial-derived thyroid cancers, but not to tumors that arise from the thyroid’s c-cells 
(94,95). Despite the association with obesity, there does not appear to be strong evidence 
of physical activity altering thyroid cancer risk (96,97). Alcohol related mechanisms of 
tumorigenesis are also not shared between the two diseases. A meta-analysis pooled over 
7,000 thyroid cancer patients and demonstrated alcohol consumption does not contribute 
to a heightened risk of developing a thyroid tumor (98). For the patients that develop 
metachronous breast and thyroid tumors, specific studies are needed to determine 
whether lifestyle factors alter the risk of a second cancer. 
A factor addressed earlier in this review, thyroid hormones, do have an impact on 
obesity and metabolism. Changes in signaling resulting from activity of the tumor 
suppressor TRβ may be related to obesity as a risk factor. A high fat diet enhanced 
thyroid tumor growth by the leptin-mediated JAK2-STAT3 pathway in a mouse model 
exhibiting mutant variants of TRβ and PTEN (99). Increased STAT3 activity has been 
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demonstrated to promote breast cancer progression in animal xenograft models and 
detected at the invasive tumor front in breast biopsy specimens (100,101). STAT3 
activity may be important to the breast-thyroid cancer link. 
 
5.9. Concluding Remarks 
There is strong evidence of a relationship between breast and thyroid cancer as 
survivors of either cancer are at increased risk for development of thyroid or breast 
tumors compared with the general population. The etiology of these cancers and possible 
causative factors are at an infancy stage and just beginning to be studied. Further 
investigation into the genomics and epigenetics underlying both breast and thyroid cancer 
can yield clues into the specifics of tumorigenesis and identifying who are at greatest risk 
of a metachronous tumor. A greater understanding of the etiology of male cases of both 
breast and thyroid cancer also has the potential to uncover important etiological factors. 
Different subtypes of breast cancer are more common in men as compared to women 
(102) and the same in true for thyroid (103). These differences could account for the 
greater rate of metachronous occurrence and investigations into molecular differences 
could reveal novel insights. Additionally, although radiotherapy has been investigated 
and is unlikely to be a significant factor, there is a lack of convincing evidence in either 
metachronous direction as to a potential role for chemotherapy. Further studies are 
needed into the effects of chemotherapy and endocrine therapy on thyroid disease and 
cancer susceptibility. EDCs promote development of hormone-dependent cancers, 
however there is a lack of information on EDC exposure and the development of thyroid 
cancer, an area that merits further investigation. Further research into the role of obesity 
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and JAK-STAT signaling on breast and thyroid tumorigenesis may also provide insights 
into the metachronous relationship. The potential for the different possible etiologies in 
the breast-thyroid cancer relationship is summarized (Fig 22). 
 
Figure 22: Summary of Possible Etiological Factors in the Thyroid and Breast Cancer Link. 
Factors that have the potential to drive the relationship between thyroid and breast cancer are displayed 
here on an arbitrary scale to represent potential explanatory power. Factors at the top of the figure, darker, 
are more likely than agents at the bottom of the figure, lighter. Likely etiological factors include genes, 
obesity, and hormonal influences such as estrogen, thyroid hormone, and environmental endocrine 
disruptors. Chemotherapy is a possibility, however there are a lack of studies so the role it has is unclear. 
Radioactive iodide, or radiotherapy, is very unlikely to be etiological, and both alcohol use and a sedentary 
lifestyle are unlikely factors for the development of metachronous breast and thyroid tumors. 
 
Importantly, studies are needed to perform parallel observations in both tumor 
types to enhance understanding of which tumorigenic pathways are common to both 
breast and thyroid and narrow down risk factors for these metachronous neoplasms. The 
existing public databases for thyroid cancer characteristics need expansion to allow for 
extensive cross comparison between thyroid and breast cancers. There also needs to be a 
greater focus towards generating thyroid cancer public datasets for comparison to the 
many existing breast cancer datasets. With the increase in thyroid cancer incidence and 
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improved survivorship of breast and thyroid cancers, it is an important public health 
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CHAPTER 6: Discussion and Concluding Remarks 
 
6.1. Summary 
This dissertation provides insights into the mechanisms by which a tumor 
suppressor, TRβ, acts to repress the malignant character of both thyroid and breast 
cancer. Phenotypic and transcriptomic characterization of TRβ activity using an 
anaplastic thyroid cancer cell line, SW1736, was performed and discussed in chapter 2, 
demonstrating that TRβ broadly represses the aggressive malignant phenotype of the 
cells. Chapter 3 details the evidence that the TRβ-RUNX2 pathway is active in breast 
cancer. RUNX2, a transcription factor that is aberrantly overexpressed in dedifferentiated 
tumors and drives cancer progression, was already known to be regulated by TRβ in 
thyroid cancer. This provides an example of shared tumor suppressive signaling in breast 
and thyroid cells, suggestive that TRβ-mediated tumor suppressive mechanisms are 
active across different cell types. Additionally, transcriptomic profiling was performed on 
the breast cancer cell line MDA-MB-468 and discussed in chapter 4, where it was 
compared with the transcriptomic profiling of TRβ performed in chapter 2. These studies 
yielded insights both into how TRβ alters the gene expression program of both of these 
cancer cells lines, and also revealed a set of genes regulated by TRβ in both cell types. 
Intriguingly, there is a link between breast and thyroid cancer, discussed in chapter 5, and 
as a shared tumor suppressor, loss TRβ and TRβ-mediated tumor suppressive signaling 





The work presented in this dissertation reveals important mechanistic insights into 
TRβ-mediated tumor suppression. This work has uncovered novel signaling networks in 
both thyroid and breast cancer types. This includes the discovery that STAT1 signaling is 
upregulated by TRβ in thyroid cancer cells and that STAT1 is a potential therapeutic 
target. Importantly, TRβ expression and activity induced differentiation markers, and a 
decrease in the cancer stem cell subpopulation, in the thyroid cancers. Additionally, the 
degree to which TRβ activity in cancer is dependent upon cellular identity was examined. 
This includes demonstrating that the T3-TRβ-RUNX2 pathway is active in breast cancer 
in addition to thyroid cancer (1), as well as identifying the genes TRβ regulates in basal-
like breast cancer. In the MDA-MB-468 breast cancer cell line, TRβ also induced a more 
epithelial-like gene expression profile, evidenced by changes in the PAM50 score, 
expression of pro-invasive cytokeratins, and in repression in epithelial-to-mesenchymal 
transition (EMT) drivers. Importantly, TRβ induced a more differentiated gene 
expression profile in both breast and thyroid cells. Although different genes may be 
involved in determining cellular character, this result does suggest that robust TRβ 
expression and activity could aid in maintenance of cellular identify to prevent 
tumorigenesis. 
Additionally, this research allowed for pairing of the transcriptomic and the 
phenotypic effects of heightened TRβ expression in MDA-MB-468. Prior research has 
revealed that TRβ reduces in vivo growth of tumors arising from this cell line and reduces 
the metastatic capacity of the cells (2,3). Critically, T3 levels enhanced the anti-metastatic 
capacity of TRβ (3). This dissertation adds to that research by highlighting changes in 
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transcriptomic networks that drive metastasis including the aforementioned cytokeratins 
and EMT markers as well as novel induction of genes encoding stearate biosynthetic 
enzymes. TRβ-mediated induction of the stearate biosynthesis pathway was observed in 
both breast and thyroid cell lines. Although stearate is known to have an anti-tumor role 
in breast cancer, demonstrated in vitro (4) and in vivo (5), there are a lack of studies on 
the role of this lipid in thyroid cancer. The shared analysis also showed there were 
significant changes to gene sets involved in chromatin organization and protein 
degradation, consistent with the concept that TRβ acts to restore a homeostatic gene 
regulation to a cancer cell and blocks the aberrant transcriptional activity intrinsic to 
cancer cells (6). 
Interestingly, although the PI3K pathway is a driver of both breast and thyroid 
tumors and TRβ is known to directly modulate the activity of the PI3K enzyme complex, 
repression of the pathway was only predicted from the SW1736 transcriptomic results. 
Regardless, TRβ represses phosphorylation of effectors of the PI3K pathway in a breast 
cancer model (7) and TRβ induced a similar repression of AKT phosphorylation in 
SW1736 cells. The lack of a predicted PI3K pathway repression in the MDA-MB-468 
cells is likely a limitation of using a transcriptomic profile to model pathways that are 
largely mediated by post-translational modifications to effector kinases. Additionally, as 
a master regulatory pathway, the downstream response from altered PI3K activity is most 
likely dependent upon the cellular context, including the mutational profile of a cell, 




6.3. Future Directions 
These studies can be built upon by a deeper investigation into the consequences of 
the pathways revealed to be regulated by TRβ. There is not yet a study showing that 
overexpression of TRβ in ATC reduces tumor growth in vivo and the SW1736 ATC cell 
line I modified to overexpression TRβ would serve this purpose. The transcriptomic 
results can inform what pathways to examine in the resultant tumors, including STAT1-
regulated genes, PI3K effectors, thyroid differentiation markers, and epithelial markers. 
Another intriguing avenue of research is the aforementioned stearate biosynthetic 
pathway. Stearic acid levels of the cells overexpressing TRβ should be measured to 
confirm that the pathway is functionally stimulated. Stearate has been investigated as an 
anti-tumor agent in breast cancer, but the role of this lipid in thyroid cancer is unknown. 
An investigation into the pharmacological properties of stearate on thyroid cancer cells 
may provide a novel treatment strategy for advanced cases of thyroid cancer. This 
includes measuring proliferation, cellular migration, and apoptosis following stearate 
treatment of ATC cells. It would also be of value to test whether blocking stearate 
biosynthesis impairs TRβ-T3 mediated tumor suppression. Should there be an effect in 
vitro, a mouse model of advanced thyroid cancer should be given a stearate high diet to 
determine if the lipid represses tumorigenesis. 
TRβ itself may be a target of therapeutic intervention. Although the studies in this 
dissertation relied upon stimulation with T3, many TRβ-selective thyromimetics have 
been developed (8). Importantly, one of these agents, GC-1, elicited the same 
transcriptional response as T3 in a liver cell line that expressed TRβ, but lacked TRα (9). 
These agents may be able to stimulate endogenous TRβ and elicit an anti-tumor response. 
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As this analysis has revealed a multitude of pathways relevant to cancer progression, a 
rational approach can be taken where TRβ agonists can be combined with modulators of 
other pathways to enhance efficacy. Candidate pathways from the research presented in 
this dissertation include PI3K inhibitors, interferons, and STAT1 agonists. Additionally, 
as Gene Set Enrichment Analysis of the differentially expressed genes shared between 
both SW-TRβ and 468-TRβ revealed many chromatin organization pathways were 
altered, the efficacy of epigenetic modulators may also be increased with a TRβ agonist. 
For example, histone deacetylase and bromodomain inhibitors show promise in both 
anaplastic thyroid cancer (10) and breast cancer (11,12). 
 
6.4. Concluding Remarks 
The work presented in this dissertation adds to the fields of breast and thyroid 
cancer research by revealing novel insights into the molecular activity of a tumor 
suppressor. TRβ acts upon multiple pathways and regulates numerous cancer-relevant 
phenotypes including proliferation, migration, stemness, and apoptosis. Through the 
modulation of many cellular networks, including RUNX2, JAK/STAT, and PI3K, TRβ 
drives an anti-tumor gene expression program that blunts the aggressive nature of a 
tumor. These results support the potential of TRβ as not only a therapeutic target, but also 
a biomarker.  
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Appendix A-1: Antibody Table 
Antibody Manufacturer Protein Species 
SAB4300042 Millipore-Sigma pAKT (S142) Rabbit 
CST9167 
Cell Signaling 
Technology STAT1 Mouse 
CST9167 
Cell Signaling 
Technology JAK1 Mouse 
MA5-15739 
ThermoFisher 
Scientific β-Actin Mouse 
CST14220 
Cell Signaling 








Technology PARP Rabbit 
CST5625 
Cell Signaling 
Technology Cleaved PARP Rabbit 
 
 190 
Appendix A-2: Primer Table 
 
Gene Forward Oligo Reverse Oligo 
MYC AGCGACTCTGAGGAGGGAACAA GTGGGCTGTGAGGAGGTTTG 
CDKN1A GCAGACCAGCATGACAGATTT CTGGACTTCGAGCAAGAGATG 
TNFSF10 CCGTCAGCTCGTTAGAAAGATGAT TGTGTTGCTTCTTCCTCTGGT 
APOL6 CCTGTTCAAAGGCCACCCTA TCAAATGATTTTCTTCTCTCCACGG 
TAP1 GCCTTGTTCCGAGAGCTGAT AATGGCCATCTCCCCAAGAG 
IRF1 CTTCCAGGTGTCACCCATGC CCATCCACGTTTGTTGGCTG 
GAPDH ATGTTCGTCATGGGTGTGAA TGTGGTCATGAGTCCTTCCA 
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Appendix A-3: TRβ Repressed PI3K Signaling. 
 
 
Appendix A-3. A-I) Expression of cluster 1 differentially expressed genes in the ILK signaling IPA 
pathway. All genes were repressed by T3 and the level of most of these genes was repressed in the SW-
TRβ-T3 condition compared to SW-EV-T3. (n=3, * p<0.05, n.s. p>0.05) B) AKT phosphorylation was 
repressed upon overexpression of TRβ in SW1736 cells. (representative blot of 3 experiments)
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Appendix A-4: Significantly Altered Pathways between SW-EV-T3 and SW-TRβ-T3 as 
determined by Ingenuity Pathway Analysis. 
Ingenuity Canonical Pathways  -log(p-value) Ratio z-score 
LPS/IL-1 Mediated Inhibition of RXR Function 7.75E+00 1.25E-01 -1.265 
VDR/RXR Activation 3.88E+00 1.41E-01 0.378 
Prostanoid Biosynthesis 3.70E+00 4.44E-01 2 
Interferon Signaling 3.53E+00 1.94E-01 2.646 
Dopamine Degradation 3.16E+00 2.00E-01 0 
Aryl Hydrocarbon Receptor Signaling 3.08E+00 9.79E-02 -0.816 
Cardiac Hypertrophy Signaling (Enhanced) 2.91E+00 6.57E-02 0.365 
STAT3 Pathway 2.83E+00 9.63E-02 -0.333 
SPINK1 Pancreatic Cancer Pathway 2.81E+00 1.33E-01 -2.828 
Tryptophan Degradation X (Mammalian, via 
Tryptamine) 2.71E+00 2.00E-01 -1.342 
Inhibition of Matrix Metalloproteases 2.55E+00 1.54E-01 -1.342 
Sirtuin Signaling Pathway 2.54E+00 7.19E-02 -0.229 
Intrinsic Prothrombin Activation Pathway 2.38E+00 1.43E-01 1.633 
Oxidative Ethanol Degradation III 2.34E+00 2.11E-01 0 
Osteoarthritis Pathway 2.24E+00 7.51E-02 0.775 
Colorectal Cancer Metastasis Signaling 2.19E+00 7.09E-02 2.5 
Putrescine Degradation III 2.18E+00 1.90E-01 -1 
Dermatan Sulfate Biosynthesis (Late Stages) 2.18E+00 1.30E-01 0 
Ethanol Degradation IV 2.03E+00 1.74E-01 0 
p53 Signaling 1.99E+00 9.18E-02 0.378 
Neuroprotective Role of THOP1 in Alzheimer's 
Disease 1.97E+00 8.62E-02 3 
Wnt/β-catenin Signaling 1.92E+00 7.51E-02 0 
Sumoylation Pathway 1.86E+00 8.74E-02 0.333 
LXR/RXR Activation 1.85E+00 8.26E-02 0.707 
Leukocyte Extravasation Signaling 1.80E+00 7.04E-02 2.111 
Death Receptor Signaling 1.72E+00 8.79E-02 1.414 
Endocannabinoid Neuronal Synapse Pathway 1.69E+00 7.81E-02 1.667 
HMGB1 Signaling 1.69E+00 7.23E-02 0.632 
Dermatan Sulfate Biosynthesis 1.67E+00 1.02E-01 0 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 1.63E+00 6.88E-02 0.832 
PCP pathway 1.61E+00 9.84E-02 0.816 
ILK Signaling 1.59E+00 6.77E-02 -0.277 
Ethanol Degradation II 1.54E+00 1.25E-01 0 
Apelin Adipocyte Signaling Pathway 1.53E+00 8.64E-02 1.134 
Chondroitin Sulfate Biosynthesis (Late Stages) 1.51E+00 1.04E-01 0.447 
Superpathway of Melatonin Degradation 1.49E+00 9.23E-02 0 
IL-8 Signaling 1.46E+00 6.50E-02 1.941 
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FGF Signaling 1.43E+00 8.24E-02 -1.134 
Serotonin Degradation 1.43E+00 8.96E-02 0 
Noradrenaline and Adrenaline Degradation 1.41E+00 1.14E-01 -1 
Type II Diabetes Mellitus Signaling 1.41E+00 6.99E-02 -0.447 
B Cell Receptor Signaling 1.36E+00 6.45E-02 0.905 
IL-6 Signaling 1.36E+00 7.14E-02 0.707 
Glioblastoma Multiforme Signaling 1.36E+00 6.63E-02 0.302 
Opioid Signaling Pathway 1.35E+00 6.00E-02 0.258 
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Appendix A-5: Significantly Altered Hallmark and Gene Ontology Gene Set Enrichment 
Analysis Pathways between SW-EV-T3 and SW-TRβ-T3. 
 
PATHWAY NAME SIZE ES NES 
Nominal 
p-value 
HALLMARK IL2 STAT5 SIGNALING 34 0.549212 1.993116 0 
HALLMARK INTERFERON ALPHA RESPONSE 36 0.507281 1.866105 0 
HALLMARK INTERFERON GAMMA RESPONSE 62 0.457168 1.82303 0 
HALLMARK ANDROGEN RESPONSE 28 0.447349 1.576111 0.018626 
HALLMARK KRAS SIGNALING DN 26 0.445573 1.555294 0.030588 
HALLMARK APOPTOSIS 33 0.42514 1.528914 0.032768 
HALLMARK MYOGENESIS 33 0.424435 1.525912 0.037246 
HALLMARK KRAS SIGNALING UP 46 0.422374 1.647219 0.011892 
HALLMARK HYPOXIA 50 0.420136 1.633861 0.012876 
GO REGULATION OF ANION TRANSPORT 16 0.647537 1.961926 0 
GO ENSHEATHMENT OF NEURONS 15 0.63384 1.888172 0 
GO NEGATIVE REGULATION OF IMMUNE 
RESPONSE 18 0.623441 1.982653 0 
GO MATERNAL PROCESS INVOLVED IN FEMALE 
PREGNANCY 15 0.605408 1.842508 0.002528 
GO NEGATIVE REGULATION OF CELL 
MORPHOGENESIS INVOLVED IN 
DIFFERENTIATION 15 0.599959 1.807874 0.003802 
GO REGULATION OF G PROTEIN COUPLED 
RECEPTOR SIGNALING PATHWAY 17 0.589212 1.8504 0.001261 
GO NEGATIVE REGULATION OF NEURON 
PROJECTION DEVELOPMENT 22 0.585012 1.913372 0 
GO REGULATION OF AXONOGENESIS 23 0.58306 1.934126 0 
GO AXON EXTENSION 16 0.580806 1.76497 0.008706 
GO ANTIGEN PROCESSING AND PRESENTATION 
OF PEPTIDE ANTIGEN VIA MHC CLASS I 19 0.580567 1.84078 0.002421 
GO REGULATION OF NEUROLOGICAL SYSTEM 
PROCESS 15 0.578919 1.743862 0.007673 
GO POSITIVE REGULATION OF MULTI 
ORGANISM PROCESS 16 0.569209 1.734695 0.011598 
GO NEGATIVE REGULATION OF IMMUNE 
EFFECTOR PROCESS 16 0.568819 1.760847 0.002541 
GO POSITIVE REGULATION OF PEPTIDE 
SECRETION 29 0.565288 1.986042 0 
GO CHLORIDE TRANSPORT 18 0.563822 1.753195 0.005096 
GO REGULATION OF EXTENT OF CELL GROWTH 16 0.558058 1.694238 0.009792 
GO POSITIVE REGULATION OF PROTEIN KINASE 
B SIGNALING 19 0.553993 1.769344 0.008495 
GO NEGATIVE REGULATION OF VIRAL PROCESS 19 0.551946 1.739828 0.007194 
GO INORGANIC ANION TRANSPORT 23 0.547105 1.845404 0.002364 
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GO NEURON PROJECTION EXTENSION 17 0.545537 1.688651 0.007326 
GO RESPONSE TO TYPE I INTERFERON 23 0.541304 1.824775 0 
GO LONG CHAIN FATTY ACID METABOLIC 
PROCESS 19 0.540457 1.722342 0.008696 
GO POSITIVE REGULATION OF CHEMOTAXIS 15 0.536159 1.616078 0.019704 
GO REGULATION OF DNA TEMPLATED 
TRANSCRIPTION IN RESPONSE TO STRESS 16 0.53267 1.62916 0.018657 
GO TUMOR NECROSIS FACTOR SUPERFAMILY 
CYTOKINE PRODUCTION 18 0.532292 1.696899 0.01233 
GO PRODUCTION OF MOLECULAR MEDIATOR 
OF IMMUNE RESPONSE 19 0.52714 1.676789 0.008557 
GO NEGATIVE REGULATION OF CELL 
PROJECTION ORGANIZATION 26 0.526901 1.794707 0.001174 
GO NEGATIVE REGULATION OF VIRAL GENOME 
REPLICATION 15 0.526274 1.602835 0.022444 
GO RESPONSE TO HEAT 15 0.525898 1.560976 0.040973 
GO PRIMARY ACTIVE TRANSMEMBRANE 
TRANSPORTER ACTIVITY 18 0.525452 1.671375 0.012579 
GO ANCHORED COMPONENT OF MEMBRANE 23 0.52515 1.750417 0.004684 
GO POSITIVE REGULATION OF AUTOPHAGY 17 0.523293 1.648211 0.012469 
GO ATPASE ACTIVITY COUPLED TO MOVEMENT 
OF SUBSTANCES 20 0.522145 1.708004 0.004831 
GO ANTIGEN PROCESSING AND PRESENTATION 
OF PEPTIDE ANTIGEN 25 0.519054 1.806069 0.004684 
GO ENDOTHELIAL CELL PROLIFERATION 18 0.51824 1.630316 0.009721 
GO FATTY ACID BIOSYNTHETIC PROCESS 25 0.517154 1.790263 0.002326 
GO MEMBRANE FUSION 16 0.515827 1.560734 0.026895 
GO UNSATURATED FATTY ACID METABOLIC 
PROCESS 18 0.515356 1.620658 0.024297 
GO RESPONSE TO TEMPERATURE STIMULUS 23 0.514636 1.738781 0.010817 
GO POSITIVE REGULATION OF ERK1 AND ERK2 
CASCADE 18 0.509508 1.608124 0.021066 
GO RESPONSE TO FIBROBLAST GROWTH 
FACTOR 18 0.507422 1.586456 0.026087 
GO POST TRANSLATIONAL PROTEIN 
MODIFICATION 33 0.50568 1.819322 0.001143 
GO ICOSANOID METABOLIC PROCESS 17 0.503684 1.550899 0.036993 
GO NEGATIVE REGULATION OF NEURON 
DIFFERENTIATION 32 0.502984 1.815329 0.003417 
GO INORGANIC ANION TRANSMEMBRANE 
TRANSPORTER ACTIVITY 20 0.500421 1.617689 0.01444 
GO CYTOKINE METABOLIC PROCESS 19 0.499549 1.60804 0.027981 
GO POSITIVE REGULATION OF TRANSPORTER 
ACTIVITY 17 0.499204 1.551982 0.0425 
GO T CELL RECEPTOR SIGNALING PATHWAY 20 0.498825 1.617687 0.02457 
GO RESPONSE TO VITAMIN 16 0.497992 1.517769 0.042875 
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GO SERINE HYDROLASE ACTIVITY 25 0.496751 1.690443 0.008323 
GO NEGATIVE REGULATION OF DEFENSE 
RESPONSE 26 0.494931 1.70787 0.009456 
GO VESICLE LOCALIZATION 19 0.493067 1.580967 0.021546 
GO DEFENSE RESPONSE TO BACTERIUM 21 0.492649 1.62172 0.014493 
GO MACROAUTOPHAGY 25 0.491718 1.66188 0.015495 
GO REGULATION OF PRODUCTION OF 
MOLECULAR MEDIATOR OF IMMUNE RESPONSE 17 0.489345 1.544081 0.03198 
GO POSITIVE REGULATION OF LEUKOCYTE 
MIGRATION 19 0.488579 1.539014 0.043684 
GO METALLOPEPTIDASE ACTIVITY 20 0.488505 1.604386 0.021713 
GO POSITIVE REGULATION OF SECRETION 49 0.48764 1.910219 0 
GO RAB GTPASE BINDING 18 0.486209 1.535886 0.041872 
GO REGULATION OF LEUKOCYTE MIGRATION 28 0.485348 1.709499 0.006849 
GO REGULATION OF VIRAL LIFE CYCLE 26 0.484676 1.651607 0.012731 
GO IRON ION BINDING 20 0.48405 1.547183 0.034105 
GO ENDOPEPTIDASE REGULATOR ACTIVITY 28 0.483351 1.703125 0.009368 
GO REGULATION OF RESPONSE TO BIOTIC 
STIMULUS 19 0.482561 1.559634 0.027947 
GO TUMOR NECROSIS FACTOR MEDIATED 
SIGNALING PATHWAY 19 0.4806 1.538006 0.041463 
GO ANTIGEN PROCESSING AND PRESENTATION 28 0.479264 1.688396 0.00576 
GO NIK NF KAPPAB SIGNALING 22 0.478409 1.597187 0.02974 
GO NEGATIVE REGULATION OF CYTOKINE 
PRODUCTION 41 0.477304 1.81826 0.001098 
GO SITE OF POLARIZED GROWTH 19 0.476715 1.516823 0.039663 
GO PEPTIDASE REGULATOR ACTIVITY 32 0.475629 1.709681 0.007042 
GO REGULATION OF SYMBIOSIS 
ENCOMPASSING MUTUALISM THROUGH 
PARASITISM 27 0.474584 1.647228 0.008037 
GO TYPE I INTERFERON PRODUCTION 21 0.474526 1.553489 0.020581 
GO NEGATIVE REGULATION OF 
DEVELOPMENTAL GROWTH 21 0.474124 1.528637 0.031863 
GO DEVELOPMENTAL CELL GROWTH 23 0.473638 1.573811 0.026474 
GO DEVELOPMENTAL GROWTH INVOLVED IN 
MORPHOGENESIS 27 0.470821 1.643117 0.016 
GO ANTIGEN RECEPTOR MEDIATED SIGNALING 
PATHWAY 26 0.469483 1.61903 0.019883 
GO T CELL PROLIFERATION 23 0.468407 1.57022 0.02497 
GO SPROUTING ANGIOGENESIS 24 0.467069 1.546203 0.031616 
GO REGULATION OF BLOOD PRESSURE 33 0.466682 1.67405 0.005701 
GO SPECIFIC GRANULE 19 0.466117 1.510681 0.045056 
GO HEART PROCESS 25 0.463807 1.57181 0.029621 
GO AXON DEVELOPMENT 60 0.463489 1.876637 0 
GO VOLTAGE GATED ION CHANNEL ACTIVITY 22 0.463471 1.501311 0.045949 
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GO INTERFERON GAMMA PRODUCTION 23 0.463215 1.554114 0.019139 
GO NEGATIVE REGULATION OF NERVOUS 
SYSTEM DEVELOPMENT 39 0.463096 1.773813 0.005556 
GO ADHERENS JUNCTION ORGANIZATION 19 0.462314 1.505994 0.04896 
GO ESTABLISHMENT OF ORGANELLE 
LOCALIZATION 31 0.462252 1.644556 0.011338 
GO NEGATIVE REGULATION OF DNA BINDING 
TRANSCRIPTION FACTOR ACTIVITY 21 0.460942 1.493413 0.047847 
GO REGULATION OF MULTI ORGANISM 
PROCESS 49 0.458686 1.799577 0 
GO PEPTIDASE ACTIVITY 70 0.454856 1.874579 0 
GO T CELL DIFFERENTIATION 37 0.454637 1.690113 0.005537 
GO REGENERATION 38 0.453457 1.704756 0.005574 
GO CELL CHEMOTAXIS 33 0.453449 1.629858 0.01373 
GO CATION CHANNEL ACTIVITY 28 0.451402 1.560146 0.028802 
GO OXIDOREDUCTASE ACTIVITY ACTING ON 
PAIRED DONORS WITH INCORPORATION OR 
REDUCTION OF MOLECULAR OXYGEN 24 0.449344 1.516543 0.043728 
GO CYTOKINE RECEPTOR BINDING 27 0.448833 1.575743 0.021004 
GO REGULATION OF EXTRINSIC APOPTOTIC 
SIGNALING PATHWAY 23 0.447673 1.506763 0.040237 
GO NEGATIVE REGULATION OF APOPTOTIC 
SIGNALING PATHWAY 24 0.446991 1.531891 0.039673 
GO GOLGI VESICLE TRANSPORT 28 0.444335 1.548446 0.024166 
GO NEGATIVE REGULATION OF MULTI 
ORGANISM PROCESS 27 0.444207 1.5553 0.03169 
GO ORGANELLE LOCALIZATION 38 0.4434 1.631574 0.010297 
GO REGULATION OF LEUKOCYTE 
PROLIFERATION 27 0.440103 1.52778 0.036824 
GO REGULATION OF CHEMOTAXIS 28 0.439815 1.541717 0.030588 
GO REGULATION OF AUTOPHAGY 31 0.439697 1.583541 0.015784 
GO POSITIVE REGULATION OF I KAPPAB KINASE 
NF KAPPAB SIGNALING 28 0.439203 1.556501 0.020548 
GO LIPID MODIFICATION 31 0.438909 1.577764 0.017222 
GO FATTY ACID METABOLIC PROCESS 33 0.438108 1.592505 0.022497 
GO NEGATIVE REGULATION OF CELL 
DEVELOPMENT 40 0.438 1.662895 0.003371 
GO NEURON PROJECTION GUIDANCE 39 0.437973 1.648987 0.005701 
GO ATPASE ACTIVITY COUPLED 29 0.436629 1.551395 0.021378 
GO PROCESS UTILIZING AUTOPHAGIC 
MECHANISM 47 0.435348 1.682766 0.002155 
GO INTERFERON GAMMA MEDIATED 
SIGNALING PATHWAY 24 0.433353 1.47067 0.042755 
GO REGULATION OF RESPONSE TO CYTOKINE 
STIMULUS 28 0.433071 1.530637 0.027491 
GO CELLULAR RESPONSE TO OXYGEN LEVELS 33 0.432858 1.553396 0.031285 
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GO INTERACTION WITH HOST 26 0.432622 1.477209 0.0454 
GO NEGATIVE REGULATION OF PEPTIDASE 
ACTIVITY 37 0.431201 1.57793 0.016704 
GO DEFENSE RESPONSE TO VIRUS 45 0.430754 1.672151 0.006623 
GO REGULATION OF CELL MORPHOGENESIS 
INVOLVED IN DIFFERENTIATION 36 0.430047 1.589398 0.015801 
GO NEGATIVE REGULATION OF PROTEOLYSIS 42 0.429535 1.626882 0.007761 
GO REGULATION OF EPITHELIAL CELL 
MIGRATION 38 0.428413 1.601131 0.01 
GO CELL MORPHOGENESIS INVOLVED IN 
NEURON DIFFERENTIATION 62 0.42811 1.745418 0 
GO NEGATIVE REGULATION OF CELL GROWTH 29 0.427938 1.51795 0.030928 
GO SECRETORY GRANULE MEMBRANE 31 0.426612 1.521126 0.034091 
GO ENDOPEPTIDASE ACTIVITY 52 0.424232 1.670582 0.005405 
GO CIRCULATORY SYSTEM PROCESS 66 0.421578 1.711263 0.003188 
GO EXTRINSIC APOPTOTIC SIGNALING PATHWAY 32 0.421395 1.507483 0.036405 
GO SYNAPTIC MEMBRANE 34 0.420783 1.54822 0.029579 
GO I KAPPAB KINASE NF KAPPAB SIGNALING 36 0.420671 1.563163 0.025785 
GO VIRAL LIFE CYCLE 43 0.419689 1.603734 0.012876 
GO MONOCARBOXYLIC ACID BIOSYNTHETIC 
PROCESS 34 0.419144 1.544815 0.030405 
GO INFLAMMATORY RESPONSE 86 0.417094 1.754796 0 
GO HORMONE METABOLIC PROCESS 42 0.416015 1.573177 0.013115 
GO MULTI MULTICELLULAR ORGANISM 
PROCESS 43 0.415174 1.596705 0.01547 
GO ZINC ION BINDING 78 0.415007 1.733993 0 
GO DEVELOPMENTAL GROWTH 78 0.414935 1.74156 0.003128 
GO PROTEIN MATURATION 32 0.413693 1.491014 0.039773 
GO LEUKOCYTE MIGRATION 63 0.412795 1.662624 0.00106 
GO CELLULAR COMPONENT DISASSEMBLY 46 0.412364 1.603382 0.016234 
GO TRANSITION METAL ION BINDING 111 0.411783 1.795982 0 
GO LYMPHOCYTE DIFFERENTIATION 47 0.411123 1.590951 0.012088 
GO CELL PART MORPHOGENESIS 70 0.410375 1.690601 0.005247 
GO POSITIVE REGULATION OF ESTABLISHMENT 
OF PROTEIN LOCALIZATION 42 0.40872 1.566964 0.019956 
GO REGULATION OF PEPTIDASE ACTIVITY 56 0.404615 1.618099 0.007487 
GO GATED CHANNEL ACTIVITY 35 0.403899 1.477755 0.046083 
GO STEM CELL DIFFERENTIATION 39 0.403838 1.515103 0.030939 
GO ORGANIC CYCLIC COMPOUND CATABOLIC 
PROCESS 49 0.403782 1.566806 0.01652 
GO RESPONSE TO VIRUS 56 0.396453 1.587233 0.008538 
GO REGULATION OF INNATE IMMUNE 
RESPONSE 55 0.396233 1.572975 0.005342 
GO DEFENSE RESPONSE TO OTHER ORGANISM 64 0.395039 1.609834 0.007361 
GO REGULATION OF VASCULATURE 55 0.394666 1.563828 0.018182 
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DEVELOPMENT 
GO MEMBRANE ORGANIZATION 76 0.394447 1.660607 0.001041 
GO NEGATIVE REGULATION OF HYDROLASE 
ACTIVITY 54 0.393359 1.575005 0.012862 
GO REGULATION OF RESPONSE TO EXTERNAL 
STIMULUS 93 0.392555 1.662111 0.001037 
GO REGULATION OF CELL ACTIVATION 67 0.391265 1.605231 0.005236 
GO RESPONSE TO OXYGEN LEVELS 53 0.391191 1.54535 0.02063 
GO REGULATION OF PEPTIDE SECRETION 52 0.390138 1.522617 0.022508 
GO ACTIVE TRANSMEMBRANE TRANSPORTER 
ACTIVITY 53 0.389852 1.545007 0.021436 
GO RESPONSE TO INTERFERON GAMMA 39 0.388208 1.461169 0.048943 
GO PASSIVE TRANSMEMBRANE TRANSPORTER 
ACTIVITY 49 0.38816 1.52367 0.025527 
GO ENDOPLASMIC RETICULUM LUMEN 45 0.387492 1.482298 0.035676 
GO REGULATION OF LYMPHOCYTE ACTIVATION 52 0.385666 1.510442 0.019334 
GO REGULATION OF NEURON PROJECTION 
DEVELOPMENT 57 0.385644 1.552919 0.016895 
GO SYNAPTIC SIGNALING 57 0.385247 1.543757 0.015038 
GO NEGATIVE REGULATION OF MULTICELLULAR 
ORGANISMAL PROCESS 162 0.384751 1.715059 0.001008 
GO MONOCARBOXYLIC ACID METABOLIC 
PROCESS 67 0.383666 1.557665 0.005269 
GO RECEPTOR REGULATOR ACTIVITY 57 0.383656 1.540213 0.022532 
GO ORGANIC ACID BIOSYNTHETIC PROCESS 47 0.382345 1.500053 0.03337 
GO NEGATIVE REGULATION OF IMMUNE 
SYSTEM PROCESS 59 0.380784 1.518625 0.024758 
GO REGULATION OF SECRETION 89 0.380389 1.604804 0.005118 
GO RESPONSE TO BACTERIUM 75 0.379729 1.569967 0.011494 
GO NEGATIVE REGULATION OF CELL ADHESION 47 0.379591 1.46074 0.027927 
GO REGULATION OF NEURON DIFFERENTIATION 79 0.378575 1.585397 0.005171 
GO TISSUE MIGRATION 48 0.376939 1.460763 0.039258 
GO REGULATION OF CELL PROJECTION 
ORGANIZATION 75 0.376254 1.548828 0.011628 
GO REGULATION OF APOPTOTIC SIGNALING 
PATHWAY 47 0.375635 1.459788 0.033696 
GO CATION TRANSMEMBRANE TRANSPORTER 
ACTIVITY 63 0.373926 1.521393 0.020299 
GO NEURON DIFFERENTIATION 147 0.373014 1.688197 0 
GO TAXIS 77 0.370249 1.548929 0.015756 
GO T CELL ACTIVATION 63 0.370225 1.530367 0.023305 
GO NEGATIVE REGULATION OF CELL 
DIFFERENTIATION 91 0.369482 1.574338 0.004119 
GO SECRETORY GRANULE 95 0.369293 1.593146 0.003099 
GO INTERSPECIES INTERACTION BETWEEN 76 0.369035 1.549359 0.013528 
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ORGANISMS 
GO PROTEOLYSIS 174 0.368969 1.670815 0 
GO NEURON DEVELOPMENT 115 0.368273 1.622731 0.002041 
GO IMMUNE RESPONSE REGULATING 
SIGNALING PATHWAY 59 0.36504 1.45923 0.027572 
GO REGULATION OF CELL CELL ADHESION 61 0.361323 1.472242 0.02766 
GO REGULATION OF CELL MORPHOGENESIS 58 0.360867 1.441276 0.041314 
GO RESPONSE TO BIOTIC STIMULUS 123 0.359989 1.582911 0.002039 
GO ANION TRANSPORT 82 0.359777 1.533712 0.012422 
GO CALCIUM ION BINDING 76 0.35963 1.51665 0.017801 
GO DEFENSE RESPONSE 208 0.35824 1.642828 0.001001 
GO REGULATION OF SYSTEM PROCESS 67 0.357123 1.45438 0.02935 
GO PEPTIDE SECRETION 70 0.357055 1.472403 0.019895 
GO ENZYME INHIBITOR ACTIVITY 53 0.355563 1.418072 0.047468 
GO CYTOKINE MEDIATED SIGNALING PATHWAY 119 0.355429 1.565876 0.001017 
GO NEUROGENESIS 181 0.353864 1.606674 0 
GO CELL SURFACE 107 0.352718 1.535428 0.007172 
GO KINASE BINDING 71 0.352442 1.468891 0.025343 
GO REGULATION OF CELL DEVELOPMENT 106 0.352033 1.537332 0.012195 
GO AMEBOIDAL TYPE CELL MIGRATION 65 0.351985 1.448039 0.035789 
GO CELL BODY 65 0.3507 1.439895 0.043524 
GO LYMPHOCYTE ACTIVATION 83 0.349816 1.470141 0.028361 
GO REGULATION OF SIGNALING RECEPTOR 
ACTIVITY 70 0.349332 1.444291 0.034006 
GO RESPONSE TO WOUNDING 95 0.345693 1.503966 0.018462 
GO REGULATION OF IMMUNE RESPONSE 112 0.34521 1.489822 0.01433 
GO TRANSMEMBRANE TRANSPORTER ACTIVITY 132 0.34427 1.530914 0.003043 
GO IMMUNE EFFECTOR PROCESS 146 0.344127 1.542292 0.00304 
GO CYTOKINE PRODUCTION 102 0.343976 1.481774 0.013265 
GO INNATE IMMUNE RESPONSE 119 0.343949 1.502394 0.007202 
GO VACUOLE 86 0.343637 1.465123 0.014568 
GO REGULATION OF DEFENSE RESPONSE 91 0.343565 1.481777 0.015576 
GO CELL MORPHOGENESIS INVOLVED IN 
DIFFERENTIATION 86 0.343448 1.461047 0.028866 
GO NERVOUS SYSTEM PROCESS 110 0.341946 1.505712 0.008138 
GO GOLGI MEMBRANE 87 0.341716 1.469958 0.023958 
GO SECRETORY VESICLE 114 0.340686 1.474996 0.011202 
GO POSITIVE REGULATION OF CELL ADHESION 61 0.340118 1.403317 0.036765 
GO EXOCYTOSIS 103 0.339306 1.46334 0.019368 
GO POSITIVE REGULATION OF IMMUNE 
RESPONSE 88 0.33867 1.453083 0.022751 
GO NEGATIVE REGULATION OF RESPONSE TO 
STIMULUS 205 0.338208 1.549161 0.001002 
GO NEGATIVE REGULATION OF SIGNALING 173 0.337418 1.502875 0.002022 
GO NEGATIVE REGULATION OF 133 0.337235 1.486214 0.005071 
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DEVELOPMENTAL PROCESS 
GO RESPONSE TO CYTOKINE 169 0.337159 1.537006 0 
GO ION TRANSMEMBRANE TRANSPORTER 
ACTIVITY 99 0.336881 1.447841 0.023736 
GO TRANSPORTER ACTIVITY 154 0.335972 1.513632 0.003021 
GO GROWTH 113 0.335854 1.454196 0.020471 
GO REGULATION OF NERVOUS SYSTEM 
DEVELOPMENT 104 0.33569 1.446955 0.026694 
GO WOUND HEALING 73 0.335517 1.398873 0.049215 
GO ENDOPLASMIC RETICULUM PART 170 0.334757 1.527149 0.002016 
GO NEGATIVE REGULATION OF CATALYTIC 
ACTIVITY 91 0.332704 1.434678 0.028896 
GO HYDROLASE ACTIVITY ACTING ON ACID 
ANHYDRIDES 89 0.331295 1.408093 0.038342 
GO REGULATION OF CELLULAR COMPONENT 
MOVEMENT 135 0.330072 1.459029 0.014242 
GO REGULATION OF PROTEOLYSIS 82 0.32977 1.39046 0.046973 
GO NUCLEAR OUTER MEMBRANE 
ENDOPLASMIC RETICULUM MEMBRANE 
NETWORK 136 0.329528 1.452296 0.016113 
GO NEURON PART 156 0.328785 1.470799 0.008065 
GO RESPONSE TO ABIOTIC STIMULUS 133 0.3277 1.455192 0.007092 
GO POSITIVE REGULATION OF INTRACELLULAR 
SIGNAL TRANSDUCTION 118 0.325479 1.414209 0.021191 
GO POSITIVE REGULATION OF TRANSPORT 112 0.321815 1.408163 0.019527 
GO REGULATION OF CELL ADHESION 109 0.319826 1.389924 0.038815 
GO CELL PROJECTION ORGANIZATION 151 0.318468 1.451611 0.010091 
GO NEGATIVE REGULATION OF MOLECULAR 
FUNCTION 126 0.317113 1.39259 0.027356 
GO ORGANIC ACID METABOLIC PROCESS 121 0.316831 1.379301 0.029323 
GO CELL CELL ADHESION 99 0.315904 1.363538 0.045596 
GO NEURON PROJECTION 121 0.315453 1.374605 0.031568 
GO CARDIOVASCULAR SYSTEM DEVELOPMENT 113 0.314171 1.367531 0.033673 
GO CYTOPLASMIC VESICLE PART 162 0.313193 1.412517 0.014141 
GO GOLGI APPARATUS PART 115 0.313143 1.36674 0.0409 
GO TRANSMEMBRANE TRANSPORT 187 0.313142 1.411586 0.011078 
GO GOLGI APPARATUS 183 0.312356 1.418048 0.013078 
GO SIGNAL TRANSDUCTION BY PROTEIN 
PHOSPHORYLATION 111 0.311314 1.370082 0.037717 
GO REGULATION OF TRANSPORT 199 0.311207 1.423575 0.007021 
GO ORGANONITROGEN COMPOUND CATABOLIC 
PROCESS 123 0.309866 1.359883 0.039594 
GO SIGNALING RECEPTOR BINDING 184 0.308256 1.400347 0.019095 
GO SMALL MOLECULE METABOLIC PROCESS 222 0.308192 1.424631 0.007 
GO INTRINSIC COMPONENT OF PLASMA 182 0.307087 1.385017 0.01712 
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MEMBRANE 
GO SECRETION 200 0.306801 1.401896 0.009027 
GO REGULATION OF ANATOMICAL STRUCTURE 
MORPHOGENESIS 156 0.306351 1.367079 0.019173 
GO IDENTICAL PROTEIN BINDING 186 0.303694 1.394577 0.015091 
GO POSITIVE REGULATION OF SIGNALING 227 0.303549 1.409608 0.005015 
GO REGULATION OF RESPONSE TO STRESS 164 0.303474 1.37639 0.01506 
GO REGULATION OF CELL DIFFERENTIATION 229 0.298762 1.381317 0.009018 
GO ION TRANSPORT 191 0.298041 1.367587 0.022066 
GO ENDOPLASMIC RETICULUM 230 0.297184 1.379726 0.014042 
GO WHOLE MEMBRANE 186 0.297139 1.359234 0.03009 
GO BIOLOGICAL ADHESION 187 0.296793 1.349621 0.023023 
GO MOLECULAR FUNCTION REGULATOR 179 0.296147 1.356645 0.022133 
GO REGULATION OF INTRACELLULAR SIGNAL 
TRANSDUCTION 212 0.290747 1.322498 0.029146 
GO REGULATION OF IMMUNE SYSTEM PROCESS 187 0.289403 1.32808 0.037149 
GO APOPTOTIC PROCESS 221 0.286938 1.316483 0.031093 
GO POSITIVE REGULATION OF MULTICELLULAR 
ORGANISMAL PROCESS 230 0.285401 1.322074 0.02505 
GO PROTEIN PHOSPHORYLATION 228 0.281398 1.306697 0.023046 
GO CHROMOSOME 65 -0.24549 -1.48646 0 
GO PROTEIN HETERODIMERIZATION ACTIVITY 60 -0.25648 -1.59191 0 
GO CHROMOSOME ORGANIZATION 69 -0.26622 -1.70404 0.020833 
GO CHROMATIN 46 -0.28284 -1.61245 0.037975 
GO EPIDERMAL CELL DIFFERENTIATION 32 -0.3013 -1.51752 0.024793 
GO NUCLEAR CHROMOSOME 45 -0.31441 -1.86593 0 
GO DIGESTIVE SYSTEM DEVELOPMENT 20 -0.31951 -1.44865 0.045714 
GO ORGANIC ACID TRANSMEMBRANE 
TRANSPORT 23 -0.32554 -1.56623 0.029586 
GO REGULATION OF CHROMOSOME 
ORGANIZATION 20 -0.32851 -1.48071 0.031847 
GO RNA METABOLIC PROCESS 86 -0.34762 -2.40766 0 
GO REGULATION OF EPITHELIAL CELL 
DIFFERENTIATION 21 -0.34878 -1.54034 0.039773 
GO MALE GAMETE GENERATION 29 -0.35003 -1.70536 0.006993 
GO GENE SILENCING BY RNA 21 -0.36279 -1.58384 0.03352 
GO MESODERM DEVELOPMENT 19 -0.37763 -1.57562 0.041451 
GO REGULATION OF DNA METABOLIC PROCESS 16 -0.3806 -1.54878 0.032787 
GO POSITIVE REGULATION OF MYELOID CELL 
DIFFERENTIATION 16 -0.38795 -1.60227 0.033333 
GO OXIDOREDUCTASE ACTIVITY ACTING ON CH 
OH GROUP OF DONORS 19 -0.38807 -1.66139 0.012121 
GO CHROMATIN ASSEMBLY OR DISASSEMBLY 21 -0.39308 -1.72442 0.030303 
GO REGULATION OF NUCLEOBASE CONTAINING 
COMPOUND METABOLIC PROCESS 30 -0.41285 -2.09342 0 
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GO UBIQUITIN LIKE PROTEIN LIGASE ACTIVITY 15 -0.41406 -1.6046 0.027027 
GO CELLULAR RESPONSE TO REACTIVE OXYGEN 
SPECIES 16 -0.41808 -1.69832 0.009615 
GO AMINO ACID TRANSMEMBRANE 
TRANSPORT 18 -0.41848 -1.73785 0.015 
GO METHYLATION 25 -0.45065 -2.18152 0 
GO RIBONUCLEOPROTEIN COMPLEX 
BIOGENESIS 21 -0.46656 -2.02903 0 
GO MACROMOLECULE METHYLATION 17 -0.47267 -2.0032 0 
GO CHROMATIN ASSEMBLY 19 -0.48615 -2.09289 0 
GO DNA PACKAGING 19 -0.48615 -2.06391 0 
GO MEGAKARYOCYTE DIFFERENTIATION 18 -0.49739 -2.02943 0 
GO DNA CONFORMATION CHANGE 21 -0.50933 -2.28077 0 
GO CATALYTIC ACTIVITY ACTING ON RNA 27 -0.51663 -2.55498 0 
GO PROTEIN DNA COMPLEX SUBUNIT 
ORGANIZATION 23 -0.53245 -2.3819 0 
GO NUCLEOSOME ORGANIZATION 18 -0.55132 -2.40781 0 
GO PROTEIN DNA COMPLEX 28 -0.5582 -2.77188 0 
GO REGULATION OF GENE SILENCING 16 -0.56221 -2.29416 0 
GO NCRNA PROCESSING 18 -0.58002 -2.39072 0 
GO REGULATION OF MEGAKARYOCYTE 
DIFFERENTIATION 15 -0.59517 -2.32157 0 
GO NCRNA METABOLIC PROCESS 27 -0.62592 -3.11261 0 
GO DNA PACKAGING COMPLEX 24 -0.66429 -3.02316 0 
GO TELOMERE ORGANIZATION 16 -0.69624 -2.78713 0 
GO TRNA METABOLIC PROCESS 15 -0.70427 -2.7583 0 
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Appendix A-6: RNA-sequencing of the TRβ-Regulated Transcriptome Reveals a 
Transcription Factor Network. 
 
Appendix A-6. A) Chromatin Enrichment Analysis (ChEA) of differential expression clusters was 
performed to evaluate which transcription factor networks were overrepresented in each cluster. B) 
Multiple transcription factors elucidated by ChEA were also differentially expressed.
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Appendix A-7. A) A pairwise comparison between SW-EV-T3 and SW-TRβ-T3 revealed differential 
expression of both mRNAs and lncRNAs (log2(foldchange)>2 and p<0.05). A total of 350 mRNAs and 28 
lncRNAs were differentially expressed. B) Expression levels of the differentially expressed lncRNAs in 
transcripts per million reads. 
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Appendix A-8: TRβ Regulates Key Cell Cycle Regulators. 
 
 
Appendix A-8. RNA-sequencing data revealed statistically significant increase of the anti-proliferative 
gene CDKN1A and repression the pro-proliferative gene MYC. n=3, ** p<0.01, *** p<0.001 
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Appendix A-9: TRβ Induced a more Differentiated Phenotype. 
 
Appendix A-9. RNA-sequencing data revealed statistically significant increase of the epithelial marker 
CDH1 and repression of the mesenchymal marker VIM. Although SNAI1 was expressed, no significant 
changes in expression were observed. n=3, * p<0.05, ***** p<0.0001 
 
 208 
Appendix A-10: Reintroduction of TRβ altered Thyroid Differentiation Markers. 
 
Appendix A-10. Thyroid differentiation markers were significantly induced in SW-TRβ cells treated with 
T3 (n=3, * p<0.05). 
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Appendix A-11: Reintroduction of TRβ Increased Expression of interferon/JAK1/STAT1 
Pathway Effectors. 
 
Appendix A-11. A-C) Following 24 hours of treatment with T3 or vehicle, protein levels in SW-EV and 
SW-TRβ were assessed by western blot. TRβ induced expression of JAK1 and STAT1. Representative 
western blot depicted. (*p<0.05, n=6) D) STAT1 and IRF1 regulated genes were induced upon 
















































Appendix B-1: Primers and Oligonucleotides 
Oligonucleotide Sequence Purpose 
VEGFA Forward CCTTGCTGCTCTACCTCCAC qPCR 
VEGFA Reverse CCATGAACTTCACCACTTTCG qPCR 
THRA Forward AGGTCACCAGATGGAAGCG qPCR 
THRA Reverse AGTGATAACCAGTTGCCTTGTC qPCR 
GAPDH Forward ATGTTCGTCATGGGTGTGAA qPCR 
GAPDH Reverse TGTGGTCATGAGTCCTTCCA qPCR 
RUNX2 Forward CAGCCCCAACTTCCTGTG qPCR 
RUNX2 Reverse CCGGAGCTCAGCAGAATAAT qPCR 
MMP9 Forward CCTGGAGACCTGAGAACCATC qPCR 
MMP9 Reverse CCACCCGAGTGTAACCATAGC qPCR 
RUNX2 P1 Forward GGACAGCAAGAAGTCTCTGGTT qPCR 
RUNX2 P1 Reverse GATGCCATAGTCCCTCCTTTTT qPCR 
Cyclin D1 Forward GCTGCGAAGTGGAAACCATC qPCR 
Cyclin D1 Reverse CCTCCTTCTGCACACATTTGAA qPCR 
THRB Forward GGCGCAGCACGTTGAAAAAT qPCR 
THRB Reverse CACATCATCVATGGTCCAGATGG qPCR 
















THRA Cloning Forward ACAAAAGCTTATGGAACAGAAGCCAA
GCAAGG 
THRA Cloning 






Appendix B-2: Antibodies 
Antibody Manufacturer Target Purpose 
MA5-15739  Thermo Fisher Scientific β-Actin Immunoblot 
SC-390715 Santa Cruz 
Biotechnology 
RUNX2 Immunoblot 
PA1-211A Thermo Fisher Scientific TRα Immunoblot 
MA1-216 Thermo Fisher Scientific TRβ Immunoblot 
AB53170 Abcam TRβ Immunoblot 
PA5-29684 Thermo Fisher Scientific TRβ ChIP 
31887 Pierce Scientific N/A (IgG) ChIP 
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Appendix B-3: Repression of RUNX2 by Thyroid Hormone 
 
Appendix A-3. Breast cell lines MCF10A and MDA-MB-231 were treated for 24 hours with 10-8 M T3 
and RUNX2 expression was measured by immunoblot. T3 significantly repressed RUNX2 expression in 
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Appendix C-1: Mycoplasma PCR Primers. 











Appendix C-2: Reintroduction of TRβ to MDA-MB-468 cells. 
 
 
Appendix C-2. MDA-MB-468 cells were transfected with either an empty vector (EV) or a vector that 
expresses wild type TRβ. Overexpression of TRβ was confirmed by western blot. 
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Appendix C-3: Significantly Altered Hallmark and Gene Ontology Gene Set Enrichment 
Analysis Pathways between 468-EV-T3 and 468-TRβ-T3. 
 
PATHWAY NAME SIZE ES NES 
Nominal 
p-value 
HALLMARK INFLAMMATORY RESPONSE 22 -0.37732 -1.94494 0.003185 
HALLMARK EPITHELIAL MESENCHYMAL 
TRANSITION 28 -0.32683 -1.87006 0.003663 
HALLMARK TNFA SIGNALING VIA NFKB 21 -0.37503 -1.87435 0.00641 
HALLMARK UV RESPONSE DN 18 -0.38381 -1.82522 0.008427 
GO POSITIVE REGULATION OF ORGANELLE 
ORGANIZATION 26 0.41754 1.846908 0.006739 
GO CELLULAR LIPID METABOLIC PROCESS 47 0.334884 1.760693 0.009235 
GO POSITIVE REGULATION OF IMMUNE 
RESPONSE 35 0.358501 1.781869 0.009736 
GO MEMBRANE ORGANIZATION 32 0.371835 1.770413 0.010825 
GO REGULATION OF VESICLE MEDIATED 
TRANSPORT 33 0.352438 1.723024 0.012195 
GO PASSIVE TRANSMEMBRANE 
TRANSPORTER ACTIVITY 21 0.407297 1.720896 0.014793 
GO POSITIVE REGULATION OF RNA 
BIOSYNTHETIC PROCESS 47 0.312377 1.65367 0.016667 
GO REGULATION OF CELL MORPHOGENESIS 31 0.365325 1.745347 0.017931 
GO IMMUNE RESPONSE REGULATING 
SIGNALING PATHWAY 24 0.394224 1.697102 0.019971 
GO POSITIVE REGULATION OF DEFENSE 
RESPONSE 27 0.372784 1.67321 0.022472 
GO ENDOCYTOSIS 26 0.37337 1.651849 0.024793 
GO LIPID METABOLIC PROCESS 64 0.282495 1.667814 0.025063 
GO GATED CHANNEL ACTIVITY 15 0.456657 1.680443 0.025185 
GO ACTIVATION OF INNATE IMMUNE 
RESPONSE 19 0.425724 1.735362 0.0279 
GO REGULATION OF IMMUNE RESPONSE 48 0.304758 1.640261 0.030223 
GO ACTIVATION OF IMMUNE RESPONSE 25 0.367587 1.62691 0.036111 
GO REGULATION OF ANATOMICAL 
STRUCTURE MORPHOGENESIS 67 0.266734 1.595238 0.037783 
GO REGULATION OF INNATE IMMUNE 
RESPONSE 24 0.389231 1.66464 0.038407 
GO POSITIVE REGULATION OF CELLULAR 
COMPONENT ORGANIZATION 61 0.272602 1.56971 0.038557 
GO FATTY ACID METABOLIC PROCESS 16 0.41946 1.611667 0.047267 
GO MEMBRANE REGION 22 0.357972 1.539507 0.047955 
GO VASCULAR PROCESS IN CIRCULATORY 
SYSTEM 22 0.370112 1.566991 0.048023 
GO REGULATION OF CELL ADHESION 46 0.283399 1.518403 0.048969 
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GO IMPORT INTO CELL 34 0.314766 1.541387 0.049007 
GO SKIN DEVELOPMENT 34 -0.58441 -3.50755 0 
GO CORNIFICATION 19 -0.7207 -3.49877 0 
GO KERATINIZATION 20 -0.69499 -3.46765 0 
GO EPIDERMAL CELL DIFFERENTIATION 24 -0.66195 -3.43124 0 
GO INTERMEDIATE FILAMENT 
CYTOSKELETON 19 -0.69527 -3.3382 0 
GO EPIDERMIS DEVELOPMENT 33 -0.54663 -3.31345 0 
GO EPITHELIAL CELL DIFFERENTIATION 54 -0.44889 -3.14855 0 
GO CYTOSKELETAL PART 50 -0.41402 -2.89313 0 
GO SUPRAMOLECULAR COMPLEX 44 -0.40219 -2.85011 0 
GO EPITHELIUM DEVELOPMENT 79 -0.3363 -2.63464 0 
GO POLYMERIC CYTOSKELETAL FIBER 29 -0.46637 -2.58778 0 
GO STRUCTURAL MOLECULE ACTIVITY 56 -0.33447 -2.51667 0 
GO NEGATIVE REGULATION OF PEPTIDASE 
ACTIVITY 22 -0.44831 -2.29491 0 
GO NEGATIVE REGULATION OF HYDROLASE 
ACTIVITY 30 -0.37157 -2.14747 0 
GO ENDOPEPTIDASE REGULATOR ACTIVITY 16 -0.46235 -2.10286 0 
GO AGING 19 -0.42386 -2.10265 0.003205 
GO VIRAL LIFE CYCLE 18 -0.44284 -2.08896 0 
GO INTERSPECIES INTERACTION BETWEEN 
ORGANISMS 30 -0.37515 -2.07692 0 
GO REGULATION OF ENDOTHELIAL CELL 
MIGRATION 20 -0.40504 -2.0139 0.006536 
GO NEGATIVE REGULATION OF PROTEOLYSIS 26 -0.36542 -2.00984 0 
GO COAGULATION 20 -0.40744 -2.0017 0 
GO NEGATIVE REGULATION OF 
LOCOMOTION 23 -0.39279 -1.9916 0.010101 
GO RESPONSE TO BIOTIC STIMULUS 71 -0.25196 -1.97639 0 
GO NEGATIVE REGULATION OF CATALYTIC 
ACTIVITY 48 -0.28653 -1.97566 0.009091 
GO NEGATIVE REGULATION OF CELL 
MOTILITY 22 -0.37524 -1.91946 0.006711 
GO PEPTIDASE REGULATOR ACTIVITY 19 -0.39199 -1.90271 0.013514 
GO REGULATION OF NEUROTRANSMITTER 
LEVELS 17 -0.42162 -1.88871 0 
GO POSITIVE REGULATION OF VASCULATURE 
DEVELOPMENT 25 -0.34693 -1.85027 0.006431 
GO BLOOD VESSEL ENDOTHELIAL CELL 
MIGRATION 15 -0.42133 -1.84962 0.01791 
GO RESPONSE TO VIRUS 24 -0.35377 -1.84828 0.010563 
GO POSITIVE REGULATION OF ENDOTHELIAL 
CELL MIGRATION 17 -0.40436 -1.84612 0.031546 
GO CELL JUNCTION ASSEMBLY 23 -0.35777 -1.83409 0.006969 
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GO REGULATION OF SYMBIOSIS 
ENCOMPASSING MUTUALISM THROUGH 
PARASITISM 16 -0.41376 -1.81229 0.008746 
GO ENZYME INHIBITOR ACTIVITY 25 -0.33106 -1.80354 0.003344 
GO TISSUE MIGRATION 29 -0.31383 -1.80289 0.013201 
GO NEGATIVE REGULATION OF MOLECULAR 
FUNCTION 57 -0.24111 -1.80152 0.009434 
GO REGULATION OF EPITHELIAL CELL 
MIGRATION 24 -0.34598 -1.80133 0.022727 
GO ENDOTHELIAL CELL MIGRATION 23 -0.35127 -1.77876 0.014235 
GO DEFENSE RESPONSE TO VIRUS 17 -0.38976 -1.76128 0.018127 
GO NEGATIVE REGULATION OF 
TRANSCRIPTION BY RNA POLYMERASE II 29 -0.3079 -1.75908 0.016 
GO NEGATIVE REGULATION OF RESPONSE TO 
EXTERNAL STIMULUS 25 -0.32238 -1.75072 0.02807 
GO DEFENSE RESPONSE 104 -0.20076 -1.74875 0 
GO NEGATIVE REGULATION OF TRANSPORT 30 -0.29859 -1.72403 0.01581 
GO POSITIVE REGULATION OF EPITHELIAL 
CELL MIGRATION 18 -0.37175 -1.71627 0.024768 
GO REGULATION OF MULTI ORGANISM 
PROCESS 28 -0.30311 -1.69656 0.022951 
GO AXON 33 -0.28497 -1.69618 0.015385 
GO NEGATIVE REGULATION OF CELL 
DIFFERENTIATION 31 -0.28297 -1.68274 0.02214 
GO CELL JUNCTION ORGANIZATION 26 -0.31073 -1.68257 0.025926 
GO ENZYME REGULATOR ACTIVITY 51 -0.23892 -1.67848 0.018182 
GO REGULATION OF PEPTIDASE ACTIVITY 32 -0.27741 -1.67461 0.019531 
GO NEGATIVE REGULATION OF PROTEIN 
METABOLIC PROCESS 61 -0.22471 -1.6743 0.010753 
GO HEPARIN BINDING 17 -0.36739 -1.67375 0.027027 
GO REGULATION OF HYDROLASE ACTIVITY 66 -0.22101 -1.66495 0.010309 
GO REGULATION OF TRANSMEMBRANE 
RECEPTOR PROTEIN SERINE THREONINE 
KINASE SIGNALING PATHWAY 18 -0.34998 -1.64962 0.024316 
GO TRANSMEMBRANE RECEPTOR PROTEIN 
SERINE THREONINE KINASE SIGNALING 
PATHWAY 23 -0.31389 -1.61431 0.030612 
GO DEPHOSPHORYLATION 15 -0.37662 -1.61256 0.043478 
GO POSITIVE REGULATION OF 
DEVELOPMENTAL PROCESS 98 -0.1883 -1.60936 0.019481 
GO RESPONSE TO WOUNDING 42 -0.23897 -1.595 0.03861 
GO NEGATIVE REGULATION OF 
DEVELOPMENTAL PROCESS 47 -0.233 -1.56332 0.030172 
GO REGULATION OF BODY FLUID LEVELS 39 -0.24598 -1.55248 0.038911 
GO RESPONSE TO RADIATION 17 -0.33301 -1.54114 0.047945 
GO MOLECULAR FUNCTION REGULATOR 102 -0.17351 -1.52187 0.026316 
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GO RESPONSE TO DRUG 57 -0.21043 -1.48429 0.049774 
GO NEGATIVE REGULATION OF RESPONSE TO 
STIMULUS 90 -0.17652 -1.45039 0.041916 
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Appendix C-3: Significantly Altered Gene Ontology Gene Set Enrichment Analysis 
Pathways between 468-EV-T3 and 468-TRβ-T3 Using Shared Differentially Expressed 
Genes. 
PATHWAY NAME SIZE ES NES 
Nominal 
p-value 
GO PEPTIDASE ACTIVITY 18 0.573847 1.72028 0.009153 
GO RESPONSE TO GROWTH FACTOR 15 0.566824 1.630316 0.019608 
GO BEHAVIOR 18 0.532005 1.582079 0.020478 
GO REGULATION OF PROTEOLYSIS 15 0.529535 1.535544 0.034158 
GO REGULATION OF NEURON 
DIFFERENTIATION 18 0.522837 1.574351 0.017202 
GO RESPONSE TO BACTERIUM 18 0.517076 1.529227 0.030033 
GO CELL SURFACE 21 0.508689 1.578421 0.02718 
GO REGULATION OF SECRETION 22 0.508067 1.601615 0.023179 
GO POSITIVE REGULATION OF TRANSPORT 25 0.50146 1.598127 0.017699 
GO REGULATION OF RESPONSE TO STRESS 30 0.5014 1.665553 0.005348 
GO SECRETORY GRANULE 23 0.497511 1.55795 0.030668 
GO INFLAMMATORY RESPONSE 22 0.493079 1.534242 0.023077 
GO REGULATION OF PROTEIN LOCALIZATION 22 0.48783 1.513206 0.034483 
GO ENZYME LINKED RECEPTOR PROTEIN 
SIGNALING PATHWAY 19 0.487414 1.48511 0.045913 
GO PROTEOLYSIS 39 0.484836 1.680512 0.006336 
GO PLASMA MEMBRANE REGION 28 0.482214 1.610188 0.011879 
GO RESPONSE TO ABIOTIC STIMULUS 27 0.477453 1.563998 0.016287 
GO NERVOUS SYSTEM PROCESS 27 0.477135 1.552331 0.028078 
GO RESPONSE TO ENDOGENOUS STIMULUS 35 0.474273 1.598648 0.019792 
GO REGULATION OF NERVOUS SYSTEM 
DEVELOPMENT 24 0.47253 1.488514 0.044469 
GO SECRETORY VESICLE 27 0.471191 1.520926 0.025974 
GO RESPONSE TO HORMONE 23 0.467318 1.464294 0.043285 
GO RESPONSE TO DRUG 28 0.463248 1.521577 0.031049 
GO RESPONSE TO LIPID 32 0.44958 1.5278 0.02234 
GO REGULATION OF INTRACELLULAR SIGNAL 
TRANSDUCTION 45 0.429039 1.515355 0.024819 
GO REGULATION OF TRANSPORT 37 0.423213 1.465962 0.046561 
GO NEGATIVE REGULATION OF RESPONSE 
TO STIMULUS 42 0.415829 1.465677 0.039501 
GO NEURON DIFFERENTIATION 39 0.414326 1.463045 0.048168 
GO NEGATIVE REGULATION OF SIGNALING 33 0.411966 1.401268 0.049841 
GO SECRETION 47 0.409263 1.468127 0.031217 
GO PROTEIN HETERODIMERIZATION 
ACTIVITY 23 -0.33414 -1.56859 0 
GO CELLULAR PROTEIN CONTAINING 
COMPLEX ASSEMBLY 21 -0.3407 -1.61937 0.018349 
GO CHROMATIN ORGANIZATION 23 -0.51729 -2.46573 0 
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GO CHROMOSOME ORGANIZATION 24 -0.53515 -2.62044 0 
GO PROTEIN DNA COMPLEX 19 -0.78795 -3.67323 0 
GO DNA PACKAGING COMPLEX 18 -0.83713 -3.70015 0 
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Appendix C-4: Significantly Altered Gene Ontology Gene Set Enrichment Analysis 
Pathways between SW-EV-T3 and SW-TRβ-T3 Using Shared Differentially Expressed 
Genes. 
PATHWAY NAME SIZE ES NES 
Nominal 
p-value 
GO PEPTIDASE ACTIVITY 18 0.578812 2.075959 0.002304 
GO POSITIVE REGULATION OF CATABOLIC 
PROCESS 15 0.56707 1.950009 0 
GO INFLAMMATORY RESPONSE 22 0.531233 2.058922 0.001129 
GO CYTOKINE PRODUCTION 24 0.50329 1.965671 0.003275 
GO REGULATION OF IMMUNE RESPONSE 24 0.500027 1.966478 0 
GO REGULATION OF CELLULAR CATABOLIC 
PROCESS 18 0.482722 1.787873 0.01049 
GO RESPONSE TO BACTERIUM 18 0.478485 1.760672 0.008102 
GO ORGANOPHOSPHATE METABOLIC 
PROCESS 15 0.471951 1.619419 0.031991 
GO POSITIVE REGULATION OF SECRETION 15 0.471343 1.643262 0.028037 
GO REGULATION OF DEFENSE RESPONSE 16 0.46267 1.641106 0.027381 
GO INNATE IMMUNE RESPONSE 19 0.460688 1.715514 0.019653 
GO REGULATION OF CATABOLIC PROCESS 20 0.447717 1.70786 0.013857 
GO POSITIVE REGULATION OF IMMUNE 
RESPONSE 19 0.446869 1.676469 0.020833 
GO RESPONSE TO BIOTIC STIMULUS 22 0.437278 1.688847 0.022198 
GO DEFENSE RESPONSE 39 0.435436 1.921073 0.001063 
GO NEGATIVE REGULATION OF IMMUNE 
SYSTEM PROCESS 17 0.431539 1.567853 0.04 
GO REGULATION OF RESPONSE TO 
EXTERNAL STIMULUS 19 0.430565 1.603309 0.039306 
GO PROTEOLYSIS 39 0.426857 1.883387 0.002139 
GO IMMUNE EFFECTOR PROCESS 29 0.411864 1.688592 0.010834 
GO REGULATION OF RESPONSE TO STRESS 30 0.406382 1.715006 0.010823 
GO NEGATIVE REGULATION OF 
MULTICELLULAR ORGANISMAL PROCESS 38 0.402177 1.777883 0.005313 
GO POSITIVE REGULATION OF IMMUNE 
SYSTEM PROCESS 26 0.397518 1.569866 0.042999 
GO RESPONSE TO ABIOTIC STIMULUS 27 0.39345 1.599698 0.03352 
GO POSITIVE REGULATION OF TRANSPORT 25 0.387458 1.534851 0.045606 
GO ORGANONITROGEN COMPOUND 
CATABOLIC PROCESS 27 0.38228 1.570028 0.039735 
GO NEGATIVE REGULATION OF RNA 
BIOSYNTHETIC PROCESS 31 -0.22538 -1.55937 0.035294 
GO CATION TRANSMEMBRANE TRANSPORT 15 -0.34706 -1.65136 0.018405 
GO NUCLEAR CHROMATIN 21 -0.36151 -2.11366 0 
GO NUCLEAR CHROMOSOME 21 -0.36151 -2.02312 0.007692 
GO MYELOID CELL DIFFERENTIATION 17 -0.36896 -1.8677 0.019231 
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GO CHROMATIN 27 -0.37138 -2.3174 0 
GO RNA BINDING 16 -0.37834 -1.92114 0 
GO CHROMOSOME 30 -0.3803 -2.56913 0 
GO CELLULAR PROTEIN CONTAINING 
COMPLEX ASSEMBLY 21 -0.38587 -2.22366 0 
GO PROTEIN HETERODIMERIZATION 
ACTIVITY 23 -0.41697 -2.5619 0 
GO CHROMATIN ORGANIZATION 23 -0.53561 -3.03361 0 
GO PROTEIN DNA COMPLEX 19 -0.70431 -3.69231 0 






Appendix C-5: Gene Sets Regulating Chromatin Structure and Protein Degradation Are 
Regulated by TRβ in Breast and Thyroid Cancer Cells. 
 
Appendix C-5. Gene Ontology pathways altered by TRβ overexpression included chromatin remodeling 









3-Phosphoinositide Dependent Protein Kinase-1 (PDK1) 
Anaplastic Thyroid Cancer (ATC) 
Androgen Receptor (AR) 
Area Under the Curve (AUC) 
Aromatase Inhibitor (AI) 
Chromatin Immunoprecipitation (ChIP) 
Chromatin Immunoprecipitation Enrichment Analysis (ChEA) 
Diacylglycerol (DAG) 
Differentially Expressed Gene (DEG) 
DNA-Binding Domain (DBD) 
Endocrine Disrupting Chemical (EDC) 
Epidermal Growth Factor (EGF) 
Epithelial to Mesenchymal Transition (EMT) 
Estrogen Receptor (ER) 
Fibroblastic Growth Factor (FGF) 
Follicular Thyroid Cancer (FTC) 
Gene Set Enrichment Analysis (GSEA) 
Guanidine Diphosphate (GDP) 
Guanidine Triphosphate (GTP) 
Heat Shock Proteins (HSP) 
Hepatocellular Carcinoma (HCC) 
Inositol 1,4,5-Trisphosphate (IP3) 
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Integrin-Linked Kinase (ILK) 
Ligand-Binding Domain (LBD) 
Long-Noncoding RNA (LncRNA) 
Mammalian Target of Rapamycin Complex 2 (MTORC2) 
Matrix Metalloprotease (MMP) 
Mitogen Activated Protein Kinase (MAPK) 
Nuclear Export Signals (NES) 
Nuclear Hormone Receptor (NR) 
Nuclear Localization Signal (NLS) 
Nuclear Receptor Coactivator 1 (NCOA1) 
Nuclear Receptor Co-Repressor (NCOR) 
Nucleotide Excision Repair (NER) 
Papillary Thyroid Cancer (PTC) 
Phosphatase and Tensin Homolog (PTEN) 
Phosphatidylinositol (3,4,5)-Trisphosphate (PIP3) 
Phosphatidylinositol 4,5-Bisphosphate (PIP2) 
Phosphoinositide 3-Kinase (PI3K) 
Phospholipase C (PLC) 
Poly (ADP-Ribose) Polymerase (PARP) 
Poly (ADP-Ribose) Polymerase 1 (PARP1) 
Poorly Differentiated Thyroid Cancer (PDTC) 
Principle Component Analysis-Based Iterative PAM50 Subtyping (PCA-PAM50) 
Progesterone Receptor (PR) 
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Protein Kinase C (PKC) 
Quantitative Real-Time PCR (qRT-PCR) 
Radioactive Iodide (RAI) 
Receptor Tyrosine Kinase (RTK) 
Retinoid X Receptor (RXR) 
Selective Estrogen Receptor Modulator (SERM) 
Silencing Mediator for Retinoid or Thyroid-Hormone Receptors (SMRT) 
Small Ubiquitin-Like Modifier (SUMO) 
Sodium-Iodide Symporter (NIS) 
Succinate Dehydrogenase Complex (SDHx) 
Thyroid Differentiation Score (TDS) 
Thyroid Hormone Receptor (TR) 
Thyroid Hormone Receptor Alpha (TRα) 
Thyroid Hormone Receptor Beta (TRβ) 
Thyroid Hormone Response Element (TRE) 
Thyroid Stimulating Hormone (TSH) 
Thyroxine (T4) 
Triiodothyronine (T3) 
Vitamin D Receptor Interacting Protein/Thyroid Hormone Receptor-Associated Protein 
(DRIP/TRAP) 
